PROGRAM - Sbfte€¦ · Maria Christina W. de Avellar (Unifesp-EPM, Coordinator) Letícia V. Costa...

PROGRAM

49th Brazilian Congress of

Pharmacology and Experimental Therapeutics

Ribeirão Preto Convention Center 17-20 October 2017

49th Brazilian Congress of Pharmacology and Experimental Therapeutics 2

Sociedade Brasileira de Farmacologia e Terapêutica Experimental (SBFTE) Executive Secretary http://www.sbfte.org.br [email protected]


Message of the Congress Organizers

It is time now for our 49th Brazilian Congress of Pharmacology Experimental Therapeutics that will take place from 17-20 October 2017, in the Ribeirão Preto Convention Center, Ribeirão Preto, São Paulo, marking the 51st anniversary since the founding of our Society.

The scientific program was set up through the outstanding hard work of the Scientific Committee in assembling the final Congress Program, taking into strong consideration the suggestions received from SBFTE’s members. In our vision for new ways forward in pharmacology in Brazil, and looking ahead to future developments, we chose Systems Pharmacology as the central theme of this year’s scientific program. More than 70 speakers, among them 22 leading international researchers, will present keynote lectures, Lectures, courses and roundtable talks over the course of four days, covering cutting-edge presentations of new and original scientific research on the latest and most innovative topics in pharmacology and related areas. We also highlight the sessions dedicated to topics related to the research on alternative tests to the use of animals in pre-clinical studies and graduate education in pharmacology in Brazil, where we plan to discuss both the scientific background of research/teaching activities, as well as their political and economic context. English will be the official language of our meeting.

Twenty-four young researchers from different regions in Brazil and one from Chile, from a collaborative partnership with the Chilean Society of Pharmacology, were selected and included in the program to present Oral Communications. The Congress Sessions Meet the Pharmacologist and the Roundtable on Doutores na Indústria (Doctors in Industry), both organized by SBFTE Jovem, will also provide an important space for discussions on career and professional development for young trainees and investigators. Furthermore, SBFTE Merit Awards for the best scientific abstracts presented by young investigator attendees during the poster sessions (categories: undergraduate, graduate student and post-doc) will be announced at the Congress closing ceremony session. Also at that time, the awards sponsored by SBFTE’s corporate partner Biolab Sanus Farmacêutica (José Ribeiro do Valle Award) will be presented as well. We are also pleased to announce that this year (2017) marks the initial presentation of the Senior Pharmacologist Award. This award has been established as a joint project of the partnership between SBFTE and Aché Laboratórios Farmacêuticos S.A., and will be presented during the Opening Ceremony of our Congress.

Finally, we are proud to announce the latest developments in our ongoing SBFTE Education Initiatives. We will be joined this year by the General Secretary of IUPHAR to initiate discussions and other activities to further develop postsecondary and professional pharmacology education, training and research in Brazil for future generations of pharmacologists. The closing lecture this year will be the Sergio Ferreira Memorial Lecture, to be followed by our farewell celebration.

The Congress Convention Center will offer attendees a unique environment for networking, the exchange of scientific ideas, and meaningful social interactions. Two 2-day poster sessions will be on display during the Congress, near the areas appointed for coffee-breaks and sponsoring Exhibitors. The SBFTE Board of Directors, Executive Council and the SBFTE Jovem will meet and welcome students, young investigators and junior faculty members on the first day of the Congress.

We truly appreciate all SBFTE members, Colleagues and Collaborators for all of their hard and exceptional work in assembling this Congress. Also noteworthy is the strong presence of our Commercial Exhibitors, who bring to the participants the latest worldwide technologies in terms of equipment, methodologies, materials, protocols and services in the field. We are very thankful for their participation in our Congress.

We look forward to welcoming all of you, long time members and first timers alike, to Ribeirão Preto. We are counting on each of you to make this Congress a fantastic success! Thank you in advance for bringing your energy and your enthusiasm to this year’s congress.

Maria Christina Avellar Congress President

4 49th Brazilian Congress of Pharmacology and Experimental Therapeutics



Index

Message of the Congress Organizers 3 SBFTE Board of Directors (2015-2017) 6 Past SBFTE Board of Directors 6 Congress' Committees 7 SBFTE Support 9 Useful information 10 E-Book Launch – SBFTE Education Initiatives 11 Satellite Meeting 11 Keynote Speaker:: Opening Lecture 13 Keynote Speaker: Sergio Ferreira Memorial Lecture/Closing Lecture 13 José Ribeiro do Valle Award – First Place Winner History 13 José Ribeiro do Valle Award – 2017 Finalists 15 Prize Awards – Inaugural Senior Pharmacologist Award 16 About SBFTE Jovem 17 Program at a Glance 19

Oct 17, 2017 (Tuesday) 19 Oct 18, 2017 (Wednesday) 20 Oct 19, 2017 (Thursday) 21 Oct 20, 2017 (Friday) 22

Scientific program 23 Oct 17, 2017 (Tuesday) 23 Oct 18, 2017 (Wednesday) 24 Oct 19, 2017 (Thursday) 29 Oct 20, 2017 (Friday) 33

Lecture abstracts 35 Poster Session 1 (Oct 18, 2017) 35

01. Cellular and Molecular Pharmacology 55 02. Neuropharmacology 56 03. Psychopharmacology 57 04. Inflammation and Immunopharmacology 58 05 Pain and Nociception Pharmacology 60 06. Cardiovascular and Renal Pharmacology 60 07. Endocrine, Reproductive and Urinary Pharmacology 62 08. Respiratory and Gastrointestinal Pharmacology 63 09. Natural Products and Toxinology 64 10. Cancer Pharmacology 65 11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Toxicology 66 12. Drug Discovery and Development 67 13. Systems Pharmacology 67 14. Pharmacology Education and Technology 68 15. Pharmacology: Other 68

Poster Session 2 (Oct 20, 2017) 69 01. Cellular and Molecular Pharmacology 69 02. Neuropharmacology 69 03. Psychopharmacology 70 04. Inflammation and Immunopharmacology 70 05. Pain and Nociception Pharmacology 71 06. Cardiovascular and Renal Pharmacology 72 07. Endocrine, Reproductive and Urinary Pharmacology 74 08. Respiratory and Gastrointestinal Pharmacology 74 09. Natural Products and Toxinology 75 10. Cancer Pharmacology 76 11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Toxicology 77 12. Drug Discovery and Development 77 14. Pharmacology Education and Technology 77

Index of Authors 78


SBFTE Board of Directors (2015-2017)

President: Maria Christina W. Avellar (Unifesp-EPM) Vice President: Letícia V. Costa Lotufo (USP)

Executive Director: Fernando de Q. Cunha (FMRP-USP) Administrative Director: Patrícia Machado Rodrigues e Silva (Fiocruz)

Financial Director: Rosely Oliveira Godinho (UNIFESP/EPM)

Deliberative Council Carlos Fernando de Mello (UFSM) Emiliano de Oliveira Barreto (UFAL) François G. Noël (UFRJ) Mauro M. Teixeira (UFMG) (Past President) Teresa Cristina T. Dalla Costa (UFRGS) Thereza Christina Barja-Fidalgo (UERJ) Thiago Mattar Cunha (USP)

Financial Council Emer Suavinho Ferro (ICB-USP) Roberto Cesar P. Lima Junior (UFC) Vinicius de Frias Carvalho (Fiocruz) Substitute Members: Daniele da Gloria de Souza (UFMG) Juliana Geremias Chichorro (UFPR) Bagnólia Araújo da Silva (UFPB)

Past Board of Directors

1966-1981

President: Maurício Rocha e Silva Vice-President: José Ribeiro do Valle General Secretary: Alexandre Pinto Corrado First Secretary: Lauro Sollero Treasurer: Hanna A. Rothschild

1982-1983

President: Alexandre Pinto Corrado Vice-President: Aron Jurkiewicz General Secretary: Sergio H. Ferreira First Secretary: Roberto Soares de Moura Treasurer: Adolfo M. Rothschild

1984-1985

President: Aron Jurkiewicz Vice-President: Roberto Soares de Moura General Secretary: Sergio H. Ferreira First Secretary: João Palermo Neto Treasurer: Therezinha Bandieira Paiva

1986-1987

President: Sergio H. Ferreira Vice-President: Guilherme Suarez-Kurtz General Secretary: João Garcia Leme First Secretary: Fernando Morgan de A. Correa Treasurer: William A. do Prado

1988-1989

President: Sergio H. Ferreira Vice-President: Guilherme Suarez-Kurtz General Secretary: João Garcia Leme First Secretary: Fernando Morgan de A. Correa Treasurer: William A. do Prado

1990-1991

President: Renato S. B. Cordeiro Vice-President: João B. Calixto General Secretary: Regina P. Markus First Secretary: Krishnamurti M. Carvalho Treasurer: Patrícia Machado Rodrigues e Silva

1992-1993

President: Renato S. B. Cordeiro Vice-President: João B. Calixto General Secretary: Giles A. Rae Secretary: Manoel Odorico de Moraes Filho Treasurer: Patrícia Machado Rodrigues e Silva

1994-1995

President: João B Calixto Vice-President: William A. do Prado General Secretary: Giles A. Rae Secretary: Manoel Odorico de Moraes Filho Treasurer: Jamil Assreuy Filho

1996-1997

President: João B Calixto Vice-President: Maria Cristina O. Salgado General Secretary: Jamil Assreuy Secretary: Giles A. Rae Treasurer: Carlos A. Flores

1998-1999

President: Maria Cristina O. Salgado Vice-President: Regina P. Markus General Secretary: Gustavo Ballejo Secretary: José Geraldo Mill Treasurer: Jamil Assreuy

2000-2001

President: Antonio José Lapa Vice-President: Roberto Soares de Moura General Secretary: Caden Souccar Secretary: Francisco Ruy Capaz Treasurer: Thereza C. M. de Lima

2002-2003

President: Giles A. Rae Vice-President: Manassés C. Fonteles General Secretary: Edson Antunes Secretary: François G. Noël Treasurer: Mauro M. Teixeira

2004-2005

President: Giles A. Rae (UFSC) Vice-President: Regina P. Markus (USP) General Secretary: François G. Noël (UFRJ) Secretary: Isac A. Medeiros (UFAL) Treasurer: Mauro M. Teixeira (UFMG)

2006-2008

President: Regina P. Markus (USP) Vice-President: Jamil Assreuy (UFSC) General Secretary: Marco Aurélio Martins (Fiocruz) Secretary: Mauro M. Teixeira (UFMG) Treasurer: Maria Elisabeth A. de Moraes (UFC)

2009-2011

President: Jamil Assreuy (UFSC) Vice-President: Mauro M. Teixeira (UFMG) General Secretary: Rosely O. Godinho (UNIFESP-EPM) Primeiro-Secretary: Teresa Cristina T. Dalla Costa (UFRGS) Treasurer: Ronaldo de A. Ribeiro (UFC)

2012-2014

President: Mauro M. Teixeira (UFMG) Vice-President: Fernando de Q. Cunha (USP) Executive Director: Letícia Costa Lotufo (UFC) Adminsitrative Director: Yara Cury (Instituto Butantan) Financial Director: Maria Christina W. de Avellar (Unifesp-EPM)


2017 Congress’ Committees

Organizing Committee Maria Christina W. de Avellar (Unifesp-EPM, Coordinator) Letícia V. Costa Lotufo (USP) Fernando de Q. Cunha (USP) Patrícia M. R. Silva Martins (Fiocruz) Rosely O. Godinho (Unifesp-EPM)

Scientific Committee Emiliano Barreto (UFAL, Coordinator) André S. Pupo (Unesp) Maria Christina W. Avellar (Unifesp-EPM) Teresa Dalla Costa (UFRGS) Thiago Mattar Cunha (USP)

Fundraising Committee

Thiago Mattar Cunha USP, (Coordinator) Leticia Veras Costa Lotufo (USP)

José Ribeiro do Valle Award Committee Maria Christina W. de Avellar (Unifesp-EPM, Chair) Edson Antunes (Unicamp) Concepción Peiró Vallejo (Universidad Autónoma de Madrid, Spain) Sharon Prince (University of Cape Town, South Africa)

Abstract Evaluation Committee Patrícia Machado Rodrigues e Silva (Coordinator, Fiocruz) Roberto César Pereira Lima Júnior (Co-Coordinator, UFC) Adair Roberto Soares dos Santos (UFSC) Daniele da Glória de Souza (UFMG) Gisele Zapata Sudo (UFRJ) José Carlos Alves Filho (USP) Ana Lucia de Aguiar Pires (Secretary, Fiocruz)

Poster Evaluation Committee Patrícia Machado Rodrigues e Silva (Coordinator, Fiocruz) Adair Roberto Soares dos Santos (UFSC) Daniele da Glória de Souza (UFMG) Gisele Zapata Sudo (UFRJ) José Carlos Alves Filho (USP) Ana Lucia de Aguiar Pires (Secretary, Fiocruz)

SBFTE Young Trainee Committee (SBFTE Jovem) Sanseray da Silveira Cruz Machado (Coordinator, USP) Ana Maria Orellana (USP) Enio Setsuo Arakaki Pacini (Unifesp-EPM) Fabio Cardoso Cruz (Unifesp-EPM) Juliano Quintella Dantas Rodrigues (Unifesp-EPM)

Promoting Pharmacology in Primary Public Schools in Ribeirão Preto Committee Coordinators: Maria Christina W. Avellar (Unifesp-EPM) and François G. Noel (UFRJ)

SBFTE Young Team Members: (SBFTE Jovem) Enio Pacini (Unifesp-EPM) Fábio Cardoso Cruz (Unifesp-EPM) Juliano Quintella Dantas Rodrigues (Unifesp-EPM) Lucas Garcia Alves Ferreira (Unifesp-EPM)


2017 Congress’ Committees

Abstract Reviewers Adair Roberto Soares Santos Albetiza Lobo Araújo Aldeídia Pereira Oliveira Ana Luisa Palhares Miranda André Sampaio Pupo Angela Castro Resende Aurea Elizabeth Linder Bagnólia Araújo Silva Caden Souccar Candida Aparecida Leite Kassuya Carlos Alberto Manssur Fraga Carlos Fernandes De Melo Célia Aparecida Paulino Ciomar A Bersani-Amado Claudia Lucia Martins Silva Claudia Ó Pessoa Cristoforo Scavone Danielle Da Glória De Souza Edson Antunes Eduardo Koji Tamura Eduardo Vera Tibiriça

Fernando Mauricio Francis Abdalla Flavio Aimbire Soares De Carvalho Francisco Guimarães Francois Noel Giles Rae Gisele Zapata Sudo Giselle Zenker Justo Helena Serra Azul Monteiro Heloisa Helena Araujo Ferreira Hugo Caire De Catro Faria Neto Isac A De Medeiros Jamil Assreuy João Estáquio Antunes Joilson O Martins José Carlos Farias Alves Filho José Eduardo Da Silva Santos José Eduardo Tanus-Santos Marco Aurelio Martins Maria das Graças Henriques Patrícia Dias Fernandes Patrícia Macedo Rieken Rocco

Patrícia Machado R. E Silva Martins Paulo De Assis Melo Paulo Ricardo Nazario Viecili Rafael Roesler Regina Pekelmann Markus Renato Sérgio Balão Cordeiro Ricardo Tabach Richardt Gama Landgraf Roberto César Pereira Lima-Junior Roberto Takashi Sudo Soraia Katia Pereira Costa Stela Maris Kuze Rates Stella Regina Zamuner Stephen F. De Paula Rodrigues Tereza Cristina Tavares Dalla Costa Thereza Christina Barja-Fidalgo Thereza Christina Monteiro Lima Thiago Mattar Cunha Valber Frutuoso Da Silva Yara Cury

Poster Reviewers Agnaldo Bruno Chies Alice Cristina Rodrigues Ana Maria Marques Orellana Andre Sampaio Pupo Andressa Bernardi Arthur da Silveira Prudente Bibiana Verlindo de Araújo Bruna Priscilla Vasconcelos Dantas Caden Souccar Carlos Renato Tirapelli Cássia Regina Silva Celia Regina Ambiel Christianne Brêtas Vieira Scaramello Claudia Lucia Martins Silva Cristina Antoniali Silva Cristóforo Scavone Daniela Dal Secco Abbud Daniele Maria-Ferreira Daniella Bonaventura Darizy Flavia S. A. de Vasconcelos

Edson Antunes Elen Rizzi Elisabeth Marostica Enilton Aparecido Camargo Erick Jose Ramo Silva Fabio Cardoso Cruz Fernanda Carla F. Brito Francois Noel Guilherme Carneiro Montes Guilherme Rabelo de Souza Jamil Assreuy Jaqueline Soares da Silva Joao Alfredo de Moraes João Eustáquio Antunes Katharinne Ingrid Moraes de Carvalho Luis Eduardo Menezes Quintas Luisa Mota da Silva Magda Fráguas Serra Marcelo Abrahão Strauch Marcelo Nicolás Muscará

Marcia Maria de Souza Marco Aurélio Martins Mariana Renovato-Martins Maximiliano Ruben Ferrero Nilson Carlos Ferreira Júnior Paulo César Ghendini Paulo de Assis Melo Priscila de Souza Regina Pekelmann Markus Rosane Gomez Sandra Helena Penha de Oliveira Simone Regina Potje Soraia Katia Pereira Costa Talita Perdigão Domiciano Tereza Cristina Tavares Dalla Costa Thereza Cristina Barja-Fidalgo Thiago Mattar Cunha Vinícius Frias Carvalho Waldiceu Aparecido Verri Junior Zulma Silva Ferreira


SBFTE thanks the following organizations for supporting the

49th Brazilian Congress of Pharmacology and Experimental Therapeutics

Coordination for the Improvement of Higher Education Personnel (CAPES) Financial Support

National Council for Scientific and Tecnological Development Financial Support

State of Rio de Janeiro Research Foundation Financial Support

State of São Paulo Research Foundation Financial Support

Aché Senior Pharmacologist Award

Biolab-Sanus-Farmacêutica Financial support José Ribeiro do Valle Award

International Union of Basic & Clinical Pharmacology

Centro de Inovação e Ensaios Pré-Clínicos Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos Exhibitor

CRID Centro de Pesquisa em Doenças Inflamatórias

Alesco Ind e Com Exhibitor

BD Life Sciences Exhibitor and Lecture

Biozeus Meeting Bags Folders

Bonther Equipamentos para Ensino e Pesquisa Exhibitor

Exxtend Exhibitor

Greiner Bio-One Brasil Produtos Médicos Hospitalares Ltda Exhibitor

Leica Microsystems Brasil Exhibitor

Pensabio Instrumentos de Biotecnologia Exhibitor

Safelab Meeting Bags Folders

Sarstedt Ltda Exhibitor

World Courier Meeting Bags Folders

Eventus Planejamento e Organização Meeting Secretariat http://www.eventus.com.br

http://www.leica-microsystems.com/?nlc=20150701-DEWE-9XZQ2Z&utm_source=LMSSignature



















Useful information

Secretariat Congress Secretariat will be open from 08h00 to 18h00 Posters

All posters should be on display until the end of your poster presentation, when they should be taken off.

Poster presenters must attend the Session scheduled by the scientific committee (Oct 18 from 18h50 to 20h20 and Oct 20 from 10h00 to 11h30) when posters will be viewed by Poster Evaluators. o Poster Session 1: You should fix your poster at the time you arrive at the Convention Center on Oct

17 and take it off at the end of the session on Oct 18 (20h00). o Poster Session 2: You should fix your poster on Oct 19 (morning), and take it off at the end of the

session on Oct 20, at 11h30. Certificates The Certificates will be sent by email to the participants and lecturers in pdf. Courses The course certification will be given for the participants with at least 2 classes attendance. Media Desk Media desk will be open from 08h00 to 18h00. All speakers are requested to leave the material at Media Desk at least two hours before presentations. All rooms have data show. If you need any other equipment, please inform Media Desk as soon as possible. Lecturers presenting talks at 08h00 should leave their material at the Media Desk the day before the presentation. Badges The use of badge is mandatory for all activities and circulation areas in the Convention Center, Hotel Rafain. Abstracts Abstracts presented at the poster session will be available at SBFTE website (http://www.sbfte.org.br) and SBFTE 2017 Congress APP. Parties

Dinner Oct 18, 2017 20h30-23h00 Restaurante Epicurista Rua Dr. Francisco Junqueira, 3280 (Purchase ticket at the Congresss Secretariat)

Social Event: Dinner/dance party (to all attendee Oct 19, 2017 19h30 Cervejaria Invicta Av. do Café, 1881

https://maps.google.com/?q=Rua+Dr.+Francisco+Junqueira,+3280%0D+Ribeir%C3%A3o+Preto,+SP&entry=gmail&source=g


e-Book Launch – SBFTE Education Initiatives

Satellite Meeting



mailto:[email protected]


Keynote Speaker: Opening Lecture

Dr. Michael Spedding is General Secretary of IUPHAR since 2014. He has been Secretary (10 years) and President (15 years) of the IUPHAR Nomenclature Committee (IUPHAR/BPS Guide for PHARMACOLOGY). He obtained his BSc and PhD, and was a lecturer at Sutherland Polytechnic. He spent eight years as a researcher at Merrell Dow in Strasbourg before becoming Director of Pharmacology at Syntex, Edinburg. He has developed a very successful scientific career, with publications of more than 200 papers that have reached more than 7000 citations. His main research interests are in the area of drug discovery and

development, brain circuits in cognition, stress, and psychiatry, and how evolution, trophic factors, inflammation interact in disease. He has 35 years of experience in top level Research Review Committees of three pharmaceutical industries (Merrell Dow, Syntex, Servier). At Servier, he was responsible for IMI grant in Psychiatry and head of the EGIS neuroscience research center (120 employees, 1995-2011) and 70 doctoral/post-docs funded in Universities by Servier (2005-2010). He is responsible for more than 30 patents, 40 compounds into formal preclinical research for multiple indications, 11 compounds into clinical development, among other achievements. Currently, he is the President of Spedding Research Solutions, an independent research company, allowing consultancy and research (via coordination of multiple teams) to yield genuinely original solutions to crucial research or societal questions.

Keynote Speaker: Sergio Ferreira Memorial Lecture/Closing Lecture

Dr. Regina P. Markus obtained her bachelor degree in Biomedical Sciences and her PhD at EPM/Unifesp. She is Professor at Department of Physiology, Institute of Biosciences at University of São Paulo (USP), and representative member at the Board of the Deliberative Council/CNPq. She is a member of the Brazilian Academy of Science (ABC) and São Paulo State Academy of Science (ACIESP). Dr. Markus is a one of the greatest specialists in pineal gland and melatonin research worldwide. Her scientific work established the molecular and cellular basis for a cross talk between the circadian

system and innate immune response. This research has also been directed to the organismic level leading to the theory of the immune-pineal axis. Dr. Markus presents an outstanding contribution to the pharmacology research field in Brazil, including a very active involvement in our Scientific Society and Brazilian Society for Advancement of Science (SBPC). As President of SBFTE from 2006 to 2008, she contributed to key aspects of pharmacology research in Brazil, including the approval of ethics legislation for the experimental use of animals. She has also actively contributed to the discussion of the Brazilian Legislation on the access to biodiversity and natural genetic resources that has been discussed in Brazil since that time. She has served on different positions on SBFTE board, always enthusiastically participating and contributing to the development of SBFTE. Her contribution is extended to the International Union of Pharmacology (IUPHAR), where she is the chair of IUPHAR Membership Committee (2014-2018).

Keynote Speaker: Congress’ Theme Lecture

Dr. Amim Rostami-Hochaghan received his PharmD from Tabriz Medical Sciences University and his PhD from the University of Sheffield where he became Professor in 2008. Since 2009 he is the Chair of Systems Pharmacology at the Centre for Applied Pharmacokinetic Research (CAPKR), Pharmacy School, University of Manchester. He has an active program of training PhD students involving proteomics, physiologically-based pharmacokinetics and pharmacodynamics and precision dosing within CAPKR and numerous graduates from his team are currently active in pharmaceutical industry or

academic research. Dr. Rostami has authored/coauthored over 200 peer-reviewed full articles and serves on the Editorial Boards of several journals. He has been an invited speaker at over 170 conferences and has led a number of hands on workshops in the area of in vitro–in vivo extrapolation as applied to ADME in Drug Development. Dr. Rostami is also the Senior Vice President of Research & Development and Chief Scientific Officer at Certara, a company with a scientific team which includes PhDs and MDs. His mission is to ensure that the latest science is incorporated into all of the company’s products and activities across Certara’s Business Units.





José Ribeiro do Valle Award – First Place Winner History

1998 – Maria Martha Campos (UFSC; Adviser: João Batista Calixto) 1999 – José Eduardo da Silva Santos (UFSC; Adviser: Jamil Assreuy) 2000 – Ana Paula V. Dantas (ICB-USP; Adviser: Maria Helena Catelli de Carvalho) 2001 – Liliam Fernandes (ICB-USP; Adviser: Maria Helena Catelli de Carvalho) 2002 – Isaias Gleizer (ICB-USP; Adviser: Cristoforo Scavone) 2003 – Juliano Ferreira (UFSC; Adviser: João Batista Calixto) 2004 – João Alfredo de Moraes (UERJ; Adviser: Thereza Christina Barja-Fidalgo) 2005 – Tiago Chiavegatti (Unifesp-EPM; Adviser: Rosely O. Godinho) 2006 – Ana Letícia G. Cabral Maragno (FMRP-USP; Adviser: Marcelo Damário Gomes) 2007 – Maria Fernanda de Paula Werner (UFSC; Adviser: Giles A. Rae) 2008 – Ana Luiza Andrade de Paula Lopes (Unifesp-EPM; Adviser: Rosely O. Godinho) 2009 – Silvio Manfredo Vieira (FMRP-USP; Adviser: Fernando de Q. Cunha) 2010 – Vanessa Olzon Zambelli (Instituto Butantan; Adviser: Yara Cury) 2011 – Tatiana Paula Teixeira Ferreira (Fiocruz; Adviser: Patrícia Machado Rodrigues e Silva) 2012 – Maíra Assunção Bicca (UFSC; Adviser: João Batista Calixto) 2013 – Jaqueline Raymondi Silva (FMRP-USP; Adviser: Fernando de Q. Cunha) 2014 – Jhimmy Talbot (FMRP-USP; Adviser: Fernando de Q. Cunha) 2015 – Daniele Maria Ferreira (UFPR; Adviser: Maria Fernanda de Paula Werner) 2016 – Gabriela S Kinker (USP, Adviser: Pedro Augusto Carlos Magno Fernandes)

José Ribeiro do Valle Award – 2017 Finalists

na Elisa on alves BA Pharmacy – Univali (2009-2014) MSc Pharmaceutical Sciences (Univali) (2015-2017) Doctoral student Pharmaceutical Sciences (Univali) Adviser: Márcia Maria de Souza (Univali)

Bruno Marcel Silva de Melo BA Pharmacy– UFPA (2010-2015) MSc Basic and Applied Immunology (FMRP-USP) (2015-2017) Doctoral Student, Basic and Applied Immunology (FMRP-USP) Adviser: José Carlos Farias Alves Filho (FMRP-USP)

Bryelle Eccard de Oliveira Alves BA Pharmacy – Faculdade Pitagoras (Uniminas) (2005-2010) MSc, Medicine and Biomedical Sciences (IEP Santa Casa BH) (2013) Doctoral Student Medicine (Cardiology) (UFRJ) Adviser: Gisele Zapata-Sudo (UFRJ)

Fernando Olinto Carreño Farmácia – UEM (2008-2012) MSc degree Pharmaceutical Sciences (UFRGS) (2013-2015) Doctoral student Pharmaceutical Sciences (UFRGS) Advisor: Teresa Dalla Costa (UFRGS)

Lucas Antonio Duarte Nicolau Biomedicina – UFPI (2008-2012) MSc degree Pharmacology (UFPI) (2012-2014) Doctoral student Pharmacology (UFC) Adviser: Marcellus Henrique Loiola Ponte de Souza (UFC)


Inaugural Senior Pharmacologist Award

2017: Inaugural Senior Pharmacologist Award. The rules can be found at: http://www.sbfte.org.br/edital-para-o-premio-farmacologista-senior-uma-realizacao-sbfte-e-laboratorio-ache/

2017 – SBFTE/Ache Senior Pharmacologist Award Section – Oct 17, 2017, 18:30-19h45

Prize Awards – First Senior Pharmacologist Award Recipient

Dr. João Batista Calixto graduated in Biology at Universidade de Brasilia (1973), obtained his MSc in Pharmacology at Escola Paulista de Medicina/Universidade Federal de São Paulo (1976) and his PhD in Pharmacology at Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto (1984). In 1976, he moved to the Department of Pharmacology at Universidade Federal de Santa Catarina (UFSC) where, in 1991, he established and was the first Coordinator of UFSC’s raduate Program in Pharmacology. In 2013, he retired from the Department of Pharmacology/UFSC as a Full Professor. At present, he is CNPq Research

Fellow/1A and the Director from CIENP (Centro de Inovação e Ensaios Pré-clínicos; Centre for Innovation and Preclinical Assays). He was President of the Brazilian Society of Pharmacology and Experimental Therapeutics (SBFTE) for two terms. He has received the following prizes and distinctions: National Order of Scientific Merit (2002), UFSC University Merit (2002), FINEP Innovation Prie (2006), SCOPUS/CAPES Prize (2007), Innovation Campus Prize Natura (2008), Caspar Stemmer Innovation Prize (2010), Distinguished Investigator Prize UFSC 50 years, João David Ferreira Lima Medal/Florianopolis Mayorship (2014), Industrial Pharmaceutical Merit “Cândido Fontoura”/Sindusfarma (2015), Frey-Wherle Foundation Silver Medal ( ermany) (2015), “Kurt Politzer” Technology Prize/ABIQUIM (2015), among several others. He has published more than 400 papers that have reached more than 14,000 citations (h index 49). He has supervised dozens of MSc dissertations, PhD thesis and Postdoctoral training, as well as more than a hundred undergraduate students under scientific training. He has served the Editorial Board of several international journals and has been Editor of three international periodicals. His main expertise is in general pharmacology, pain, inflammation and biologically active compounds from plants. He has partnerships with several top pharmaceutical industries national and international, 24 patents in Brazil and abroad and has participated of the development of three products that are in the market in Brazil. He was the Coordinator of the “Biological Sciences rea II” from C PES and the national Coordinator of Science Teaching Network form CAPES. From 2015 onwards he was nominated as the Vice-President (South) of the Brazilian Academy of Sciences and in 2016 he was nominated as Member of the National Council of Science and Technology. He is an advocator of pharmacology in Brazil and abroad; he is a very active SBFTE member.


About SBFTE Jovem

SBFTE “Jovem” (SBFTE Young) founded on 2013, is a Committee of the Brazilian Society of Pharmacology and Experimental Therapeutics (SBFTE). Our Committee is composed by young Pharmacologists members of SBFTE, working in association with SBFTE Board of Directors. Our mission is to create a permanent political-scientific discussion forum dedicated to undergraduate, graduate students, post-docs, as well as young investigators and junior faculty members of SBFTE to discuss scientific topics related to Pharmacology, which will help them developing their careers, stimulating their participation, insertion and collaboration into the

activities of our society.

This year we will promote two activities that will be held during the 49th Brazilian Congress of Pharmacology and Experimental Therapeutics. One of them is entitled “Meet the Pharmacologist”. The section is scheduled for October 19th, 2017 from 12h10 pm to 01h20 pm. This session provides trainees and young scientists the opportunity to engage in an active discussion with senior leader scientists in an informal environment about any topic of interest related to building a strong career in Science and Pharmacology, such as challenges in getting funding, establishing a research group, choosing and being a good mentor, as well as topics of your area of expertise. Especially this year, the opening of this session will be provided by a short-talk by Prof. Michael Spedding entitled “Managing you and others creativity, and avoiding mistakes”.

Another activity is a roundtable about Doutores na Indústria (Doctors in Industry). The section is scheduled for October 18th, 2017 from 1:30pm to 3:30pm. In this activity, the aim is to open a discussion about opportunities to Brazilian scientists to turn their ideas into innovation products or engage in industry carriers,, as well as to pinpoint the private and public financing role as encouraging sources to this initiative. In summary with this activity, we intend to approach the current reality of pharmaceutical innovation technology in Brazil, its challenges and perspectives.

We would like to invite all the attendee students and young professionals to participate and support SBFTE Jovem activities in the SBFTE Congress at Ribeirão Preto.

SBFTE Young Committee Sanseray da Silveira Cruz Machado (Coordinator, USP) Ana Maria Orellana (USP) Enio Setsuo Arakaki Pacini (Unifesp-EPM) Fabio Cardoso Cruz (Unifesp-EPM) Juliano Quintella Dantas Rodrigues (Unifesp-EPM)




Program at a Glance

17/10/2017 (Tuesday)

08h00-15h00 SBFTE e Divulgação de Farmacologia na Escola Pública (Promoting Pharmacology in Primary Public Schools in Ribeirão Preto)

Room Turquesa

9h00-10h00 Meeting of the Board of SBFTE Directors and Deliberative Council (Council and Directory Board Members only)

Room Turquesa

10h00-12h00 Meeting SBFTE Board of Directors and Deliberative Council IUPHAR, Representative Members

12h00-13h00 Lunch

Room Ágata

13h00-15h00

SBFTE Permanent Forum of Graduate Programs in Pharmacology Coordinators and Representative Members from Graduate Programs in Pharmacology Representative Members from Graduate Programs that have Pharmacology in their Curriculum Other Representative Members

14h00 Venue Secretariat and SBFTE Secretariat Opening

Room Ágata

15h00–16h30 SBFTE-IUPHAR building bridges for Cooperative Partnership (Education Initiatives)

Room Rubi

18h30-19h45 Opening Ceremony Special Tributes SBFTE/Ache Senior Pharmacologist Award Section

19h45-20h45 Keynote Speaker: Opening Lecture


18/10/2017 (Wednesday)

Courses

08h00-08h50 Room Topázio Room Safira Room Ágata Room Rubi

Farmacogenômica (Pharmacogenomics)

Modelos Animais em Farmacologia Translacional (Animal Models in Translational Pharmacology)

Farmacometria e Farmacologia dos Sistemas (Pharmacometrics and System Pharmacology)

Descoberta e Desenvolvimento Pré-Clínico de Fármacos: Abordagem Crítica e Quantitativa das Estratégias e Ensaios (Drug Discovery and Preclinical Development: Critical and Quantitative overview of Strategies and assays)

Lectures

09h00-09h50 Room Topázio Room Rubi

Glowing pharmacology: Imaging the life and times of G protein coupled receptors

Epithelial proteases and inhibitors: major actors of epithelial homeostasis

09h50-10h10 Coffee-break

Symposia/Oral Communication

10h10-12h10 Room Topázio Room Safira Room Rubi

Vascular and endothelial changes associated with pregnancy

New vistas on cardiotonic steroids and Na/K-ATPase

Neuroinflammation as a target for the treatment of CNS diseases

Room Rubi

12h10-13h20 SBFTE Assembly with Lunch Box

Symposia/Oral Communication

13h30-15h30 Room Topázio Room Safira Room Rubi

Inflammation: New Therapeutic Frontiers

Natural Products Doutores na Indústria


Lectures


Consensomes: Leveraging publically archived “omics” datasets to illuminate the biology of nuclear receptor signaling pathways

The rational development of novel alosteric modulators of CXCR2 receptors for inflammatory diseases

Symposia / Roundtable


Purines and inflammation

Nitros(yl)ation as a Mechanism involved in Disease and Drug Response,

microRNA based therapy

BD - Flow Cytometry: Cell signaling, death and everything between

18h50-20h20 Poster Session 1


19/10/2017 (Thursday)

Courses



Modelos animais em Farmacologia translacional (Animal models in translational pharmacology)

Farmacometria e Farmacologia dos Sistemas (Pharmacometrics and System Pharmacology) Coordinator: Bibiana Verlindo de Araujo (UFRGS)

Descoberta & desenvolvimento pré-clínico de fármacos: Abordagem crítica e quantitativa das estratégias e ensaios (Drug Discovery and Preclinical Development: Critical and Quantitative overview of Strategies and assays)

Lecture

09h00-09h50 Room Rubi

What is Systems Pharmacology? For sure no longer Pie in the Sky!


Symposia/Oral communication

10h10-12h10 Room Topázio Room Ágata Room Rubi

From big data to system biology Oxidative stress, inflammation and increased protease activity in cardiovascular diseases

Alternative tests to the use of animals in pre-clinical studies


Meet the Professor with Lunch Box

Symposia/Oral communication

13h30-15h30 Room Topázio Room Rubi Room Agata

José Ribeiro do Valle Award Session

Cannabis-based drugs Design, discovery and development of multitarget drug candidates


Roundtable


IUPHAR, How to address modern molecular pharmacology via international collaboration: impact on drug discovery and development, and on natural products

Lectures


Targeting the oncogenic TBX3 and its co-factor, nucleolin, in anti-cancer drug development

Mechanisms of pain and neuro-immune communication in bacterial host defense

19h30 Open party Cervejaria Invicta


20/10/2017 (Friday)

Course



Modelos animais em Farmacologia translacional/ (Animal models in translational pharmacology)

Farmacometria e Farmacologia dos Sistemas (Pharmacometrics and System Pharmacology)

Descoberta & desenvolvimento pré-clínico de fármacos: Abordagem crítica e quantitativa das estratégias e ensaios (Drug Discovery and Preclinical Development: Critical and Quantitative overview of Strategies and assays)

Lectures


Neuroplasticity in stress-related neuropsychiatric disorders: New paths for drug discovery

Adipokines, endothelial dysfunction and vascular damage: A role for interleukin-1beta

10h00-11h30 Poster Session 2 with Coffee break

Room Topázio

11h30-12h40 Sergio Ferreira Lecture

12h40-13h50 Awards and Prize Announcements Closing Ceremony


Scientific program

17/10/2017 (Tuesday)

8:00h-15h00

SBFTE e Divulgação de Farmacologia na Escola Pública (Promoting Pharmacology in Primary Public Schools in Ribeirão Preto) Coordinators: Maria Christina W. Avellar (Unifesp-EPM) and Francois G. Noel (UFRJ) Collaborators: SBFTE Jovem and Local Organizing Committee Escola Neuza Michelutti Marzola. 4 turmas (oitavo ano: 4 Turmas)

9h00-10h00 Room Turquesa

Meeting of the Board of SBFTE Directors and Deliberative Council (Council and Directory Board Members only)

10h00-12h00 Room Turquesa

Meeting of the SBFTE Board of Directors, Deliberative Council and Representative Members with IUPHAR (Secretary General)

12h00-13h00 Lunch

13h00-15h00 Room Ágata

Meeting of the SBFTE Permanent Forum of Graduate Programs in Pharmacology Coordinators and Representative Members from Graduate Programs in Pharmacology Representative Members from Graduate Programs that have Pharmacology in their Curriculum

14h00 Venue Secretariat and SBFTE Secretariat Opening

15h00–16:30 Room Ágata

SBFTE-IUPHAR: building bridges for Cooperative Partnership (Education Initiatives)

Open Remarks Maria Christina W. Avellar (SBFTE President) SBFTE perspective: Pharmacology in Brazil, Education Initiatives

IUPHAR Perspective Michael Spedding (IUPHAR)

Open discussion, final remarks and conclusions


Opening Ceremony

Special Remarks and Tributes

SBFTE/Aché Inaugural Senior Pharmacologist Award Award Recipient: João Batista Calixto (CiENP, UFSC)

Opening Lecture: How metabolism and recent human evolution (to run!) opens up new therapeutic opportunities in neurodegeneration and ALS Michael Spedding (IUPHAR) Introduced by: Maria Christina W. Avellar (Unifesp-EPM)


18/10/2017 (Wednesday)

8h00-08h50 Courses

Room Topázio

Farmacogenômica (Pharmacogenomics) Coordinator: Guilherme Suarez Kurtz (INCa) • Class 1: Farmacogênomica: Introdução (Pharmacogenomics: Introduction)

Guilherme Suarez Kurtz (INCa)

Room Safira

Modelos Animais em Farmacologia Translacional (Animal Models in Translational Pharmacology) Coordinator: Iraci L. S. Torres (UFRGS) • Class 1: Modelos animais em farmacologia experimental: Validação e previsão (Animal

models in experimental pharmacology: Validation and prediction) Rosane Gomez (UFRGS)

Room Ágata

Farmacometria e Farmacologia dos Sistemas (Pharmacometrics and System Pharmacology) Coordinator: Bibiana Verlindo de Araujo (UFRGS) • Class 1: Antimicrobianos e antifúngicos (Antimicrobials and Antifungals)

Francine Johansson Azeredo (UFBA)

Room Rubi

Descoberta e Desenvolvimento Pré-Clínico de Fármacos: Abordagem Crítica e Quantitativa das Estratégias e Ensaios (Drug Discovery and Preclinical Development: Critical and Quantitative overview of Strategies and assays) Coordinator: François G. Noël (UFRJ) • Class 1: Desafios e estratégias (Challenges and strategies)

François G. Noël (UFRJ)

09h00-09h50 Lectures

Room Topázio Glowing pharmacology: Imaging the life and times of G protein coupled receptors Nicholas Holliday (University of Nottingham, UK) Introduced by: Rafael Roesler (UFRGS)

Room Rubi Epithelial proteases and inhibitors: major actors of epithelial homeostasis Nathalie Vergnolle (INSERM, France) Introduced by: Soraia Katia Pereira Costa (USP)


10h10-12h10 Symposia/Oral Communication

Room Topázio

Vascular and endothelial changes associated with pregnancy Chairs: Rita Tostes Passaglia (USP)/Cristina Antoniali Silva (Unesp) Innate immune mechanisms and maternal vascular dysfunction in preeclampsia

Styliani (Stella) Goulopoulou (University of North Texas, USA) Vascular endothelial cell dysfunction in pregnancy complications

Sandra T. Davidge (University of Alberta, Canada) Alterations in post-translational regulation of eNOS increase NO bioavailability in blood

vessels of late pregnant spontaneously hypertensive rats (SHR) Cristina Antoniali Silva (Unesp)

CO: 06.007 Hydrogen Sulfide (H2S) attenuates hypertension in pregnancy and blunts fetal growth restriction through an increase in placental efficiency in hypertensive pregnant rats. Possomato-Vieira JS, Chimini JS, Santos-Silva ML, Gonçalves-Rizzi VH, Dias-Junior CA IBB-Unesp – Farmacologia

CO: 01.004 Putative alpha1d / alpha1a-Adrenoceptors heterodimerization in the abdominal aorta from preeclamptic rats Silva KP1, Kiguti LRA1, Lim L2, Kocan M2, Summers RJ2, Caldeira-Dias M1, Sandrim V1, Pupo AS1 1IBB-Unesp – Farmacologia, 2Monash University – Drug Discovery Biology


Room Safira

New vistas on cardiotonic steroids and Na/K-ATPase Chair: Luís Eduardo M. Quintas (UFRJ) Hypothermia-induced dystonia and abnormal cerebellar activity in a mouse model with a

single disease-mutation in the sodium-potassium pump Karin Lykke-Hartmann (Aarhus University, Denmark)

The new facet of ouabain in the Central Nervous System (CNS) Cristoforo Scavone (USP)

Effect of Iron Overload on Na/K-ATPase Leandro Augusto de Oliveira Barbosa (UFSJ)

New insights into cardiotonic steroids-Na/K-ATPase interaction Luís Eduardo M. Quintas (UFRJ)

Room Rubi

Neuroinflammation as a target for the treatment of CNS diseases Chair: Thiago Mattar Cunha (USP) Antibiotics and neurodegenerative disease: new role for old drugs

Elaine Del Bel (USP)

Cytokines and Alzheimer's disease Foo Y. Liew (University of Glasgow, UK)

TRP channels play a neuroinflammatory role in Alzheimer’s disease Maíra Assunção Bicca (Northwestern University)

CO: 05.001 Related mechanisms of C5a/C5aR during neuropathic pain. Quadros AU1, Fonseca MMD2, Ferreira MD3, Sagar DR4, Cunha FQ2, Chapman V4, Cunha TM2 1FM-USP – Farmacologia, 2FMRP-USP – Farmacologia, 3FMRP-USP – Bioquímica e Imunologia, 4University of Nottingham – School of Life Sciences

CO: 02.005 Activity-dependent neuronal klotho production induces astrocytic lactate release through FGFR1 activation and ERK phosphorylation. Mazucanti CH1, Kawamoto EM1, Mattson MP2, Camandola S2, Scavone C1 1ICB-USP – Farmacologia, 2NIH-NIA


SBFTE Assembly with Lunch Box

13h30-15h30 Symposia/Oral Communication

Room Topázio

Inflammation: New Therapeutic Frontiers Chairs: John L. Wallace (University of Calgary, Canada)/Marcelo Muscará (USP) Efferocytosis of apoptotic cells is impaired in elderly humans due to reduced

macrophage TIM-4 expression Derek Gilroy (University College London, UK)

Inflammation and epigenetic mechanisms are involved on soluble guanylate cyclase (sGC) transcriptional regulation Fabiola Taufic Monica Iglesias (Unicamp)

Promoting resolution of inflammation: A 3 billion year old solution John L. Wallace (University of Calgary, Canada)

CO: 01.002 H2S is a key antisecretory molecule against cholera toxin-induced diarrhoea in mice: evidence for non-involvement of the AC/CAMP/PKA pathway and AMPK.

Sousa FBM1, Souza LKM1, Araújo TSL1, Sousa NA1, Araújo S2, Silva RO3, Nicolau LAD3, Souza FM1, Silva IS4, Souza MHLP3, Medeiros JVR2 1Renorbio – Farmacologia, 2UFPI – Farmacologia, 3UFC – Farmacologia e Fisiologia, 4UFMG – Farmacologia e Fisiologia

CO: 04.008 Resolvin E1 reduces rat paw edema and nociception locally through leukotriene B4 receptor type one.

Fonseca FCS, Turchetti-Maia RMM, Francischi JN UFMG


Room Safira

Natural Products Chair: Fernanda Regina de Castro Almeida (UFPI) Pharmacological potential of the natural nitro compound, 1-nitro-2-phenylethane and its

synthetic derivatives as vasorelaxant agents Mohammed Saad Lahlou (UFC) Monoterpenes as promising substances for the treatment of painful neuropathies: Role

of biotechnology Fernanda Regina de Castro Almeida (UFPI) CO: 09.017 Zingiber zerumbet promotes arterial vasodilation by blockade of calcium

influx. Graça ACS1, Batista NY1, Pessoa EV1, Pinheiro CCS2, Correa JWN3 1UFAM, 2Inpa, 3UFAM

CO: 05.013 Further investigation of antinociceptive and pronociceptive mechanisms of Acmella oleracea in mice.

Dallazen JL1,2, Maria-Ferreira D1, Luz BB1, Nascimento AM1, Cirpriani TR1, Souza LM3, Werner MF1 1UFPR, 2Farmacologia, 3Instituto de Pesquisa Pelé Pequeno Príncipe

CO: 08.007 Esophageal mucosal barrier in different phenotypes of gastroesophageal reflux disease (GERD) patients: Diferential effect of topical protection with sulfated polysaccharide obtained for Gracilaria caudata (GC).

Sales TMAL1, Silva RO2, Nicolau LAD2, Moreira RLR3, Bingana RD3, Alencar POC3, Pereira IS3, Santos AA2,1, Souza MAN1, Barros FCN3, Freitas ALP3, Sifrim D4, Souza MHLP2,1 1UFC – Ciências Médicas, 2UFC – Fisiologia e Farmacologia, 3UFC

CO: 04.032 Dilodendron bipinnatum extract ameliorates TNBS-induced colitis in rats by inhibiting TNF-α, supporting mucus production and promoting antioxidant effect.

Oliveira RG2,1, Ferreira LA2, Miyajima F3, Pavan E1, Damazo AS1, Martins DTO1 1UFMT – Basic Sciences in Health, Faculty of Medicine, 2UNIC – Pharmacy, 3UFC – Neuropharmacology, Drug Research and Development

Room Rubi

Doutores na Indústria (Doctors in Industry) Chairs: Sanseray da Silveira Cruz-Machado / Juliano Quintella Dantas Rodrigues (SBFTE Jovem)

Doutorado Acadêmico-Industrial – DAI Erik Gustavo Del Conte (UFABC) Supporting research for technological innovation in the State of São Paulo Sergio Robles Reis de Queiróz (Fapesp) Cellco Biotec: O destaque está na diferença! Maria Amélia Vilela Oliva Dotta (Cellco Biotec)



Room Topázio

Consensomes: Leveraging publically archived “omics” datasets to illuminate the biology of nuclear receptor signaling pathways Neil J. McKenna (Baylor College of Medicine, USA) Introduced by: Maria Christina W. Avellar (Unifesp-EPM)

Room Rubi

The rational development of novel alosteric modulators of CXCR2 receptors for inflammatory diseases Marcello Allegretti (Dompé, Italy) Introduced by: Emiliano Barreto (UFAL)


16h50-18h50 Symposia / Roundtable

Room Topázio

Purines and inflammation Chair: Patricia Machado Rodrigues e Silva Martins (Fiocruz) Purinergic signalling in inflammatory bowel diseases

Robson Coutinho Silva (UFRJ) Low expression of CD39 (ectonucleotidases involved in adenosine synthesis) on

regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis Fernando de Queiroz Cunha (USP)

Role of adenosine in lung fibrosis caused by silica particles in mice Patricia Machado Rodrigues e Silva Martins (Fiocruz)

CO: 08.003 “Extracellular cAMP-adenosine pathway” modulates airway smooth muscle contraction via A1 receptor activation Pacini ES, Silveira SS, Godinho RO Unifesp-EPM – Farmacologia

CO: 07.006 The role of adenosine receptor A2A on the hyperactivity of hypothalamus-pituitary-adrenal axis observed in diabetic animals. Buriche ALR, Magalhães NS, Silva PMR, Martins MA, Carvalho VF Fiocruz

Room Safira

Nitros(yl)ation as a Mechanism involved in Disease and Drug Response Chair: Jose Eduardo Tanus dos Santos (USP)

An overview of critical mechanisms regulating nitrosation José Carlos Toledo Júnior (USP)

Nitros(yl)ation and the antihypertensive responses to oral nitrite Lucas C. Pinheiro (USP)

The expression of human inducible nitric oxide synthase (NOS-2) and its splice variants S2 and S3 is associated with the development of colon and breast human tumors Hugo P. Monteiro (Unifesp)

Nitros(yl)ation in sepsis Jamil Assreuy (UFSC)

Room Ágata

microRNA based therapy Chair: Alice Cristina Rodrigues (USP) Circulating miRNAs as biomarkers of cardiotoxicity and therapeutic potential in breast

cancer Edilamar Menezes de Oliveira (USP)

microRNA based therapy - microRNAs in cancer cachexia Robson Francisco Carvalho (Unesp-Botucatu)

miRNAs from 14q32 region in thyroid cancer: biological role and clinical implication Murilo Vieira Geraldo (Unicamp)

Roles of non-coding RNAs (microRNAs and lncRNAs) in cardiovascular development, function and disease Da-Zhi Wang (Harvard Medical School, USA)

Room Rubi BD - Flow Cytometry: Cell signaling, death and everything between Renan Antonialli (BD Biosciences) Chair: André Cardoso (BD Biosciences)


18h50-20h20 Poster Session 1

01. Cellular and Molecular Pharmacology (01.001-01.023) 02. Neuropharmacology 02.001-02.022) 03. Psychopharmacology 03.001-03.016 04. Inflammation and Immunopharmacology (04.001-04.036) 05 Pain and Nociception Pharmacology (05.001-05.016) 06. Cardiovascular and Renal Pharmacology (06.001-06.043) 07. Endocrine, Reproductive and Urinary Pharmacology (07.001-07.012) 08 – Respiratory and Gastrointestinal Pharmacology (08.001-08.009) 09. Natural Products and Toxinology (09.001- 09.033) 10. Cancer Pharmacology (10.001-10.015) 11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Toxicology

(11.001-11.018) 12. Drug Discovery and Development (12.001-12.008) 13. Systems Pharmacology (13.001-13.002) 14. Pharmacology Education and Technology (14.001) 15. Pharmacology: Other (15.001-15.013)

20h30-23h00 Dinner at Restaurante Epicurista (purchase ticket at the Congresss Secretariat)


19/10/2017 (Thursday)

08h00-08h50 Courses

Room Topázio

Farmacogenômica (Pharmacogenomics) Coordinator: Guilherme Suarez Kurtz (INCa) • Class 2: Pharmacogenomics: Current status (Farmacogenômica: Estado Atual)

Guilherme Suarez Kurtz (INCa)

Room Safira

Modelos animais em Farmacologia translacional (Animal models in translational pharmacology) Coordinator: Iraci L. S. Torres (UFRGS) • Class 2: Modelos animais para estratégias terapêuticas (Animal models for

therapeutic strategies) Iraci L. S. Torres (UFRGS)

Room Ágata

Farmacometria e Farmacologia dos Sistemas (Pharmacometrics and System Pharmacology) Coordinator: Bibiana Verlindo de Araujo (UFRGS) • Class 2: Modelagem PK/PD no Desenvolvimento de Fármacos na Oncologia (PK/PD

Modeling in Oncology Drug Development) Maiara Cassia Pigatto (Instituto Vita Nova)

Room Rubi

Descoberta & desenvolvimento pré-clínico de fármacos: Abordagem crítica e quantitativa das estratégias e ensaios (Drug Discovery and Preclinical Development: Critical and Quantitative overview of Strategies and assays) Coordinator: François G. Noël (UFRJ) • Class 2: Tipos de ensaios farmacodinâmicos (Types of pharmacodynamics assays)

François G. Noël (UFRJ)

09h00-09h50 Keynote Lecture

Room Rubi What is Systems Pharmacology? For sure no longer Pie in the Sky! Amin Rostami-Hochaghan (University of Manchester, UK) Introduced by: Teresa Dalla Costa (UFGRS)


10h10-12h10 Symposia/Oral communication

Room Topázio

From big data to system biology Chair: Pedro Augusto Carlos Magno Fernandes (USP) Post-transcriptional control involving miRNA-mRNA interactions in the immune

tolerance Geraldo Aleixo da Silva Passos Junior (USP)

Big Data: linking arrows to targets Pedro Augusto Carlos Magno Fernandes (USP)

CO: 13.001 Is body weight gain under regulation of circadian melatonin? Cruz-Machado SS1, Pereira EP1, Oliveira AP2, Silva-Souza E1, Markus RP1 1IB-USP – Departamento de Fisiologia, 2UFPI – Biologia e Fisiologia

CO: 13.002 Early-life stress promotes alterations in intestinal permeability and hippocampal 5-HT 1A mRNA expression in juvenile rats. Bravo JA1, Astudillo-Guerrero C1, Rossi-Vargas G1, Escobar-Luna J1, Barrera-Bugueño C1, Gotteland M2, Julio-Pieper M1 1Pontificia Universidad Católica De Valparaíso – NeuroGastroBioquímica, 2Universidad de Chile – Nutrición


Room Ágata

Oxidative stress, inflammation and increased protease activity in cardiovascular diseases Chairs: Michele Mazzaron de Castro (USP) / Lusiane Maria Bendhack (USP) Cytokines, Toll-like receptors and heart failure

Pawan K. Singal (University of Manitoba, Canada)

The crosstalk between aldosterone and inflammation in the cardiovascular system Rita de Cassia Aleixo Tostes Passaglia (USP)

Redox regulation of hepatic lipid metabolism and its effects on the cardiovascular system Markus Michael Bachschmid (Boston University, EUA)

Matrix metaloproteinases and oxidative stress in the vascular remodeling of hypertension Michele Mazzaron de Castro (USP)

Room Rubi

Alternative tests to the use of animals in pre-clinical studies Chair: João B. Calixto (CIEnP) Reconstructed Human Epidermis for safety assessment and early drug development

Rodrigo De Vecchi (Episkin Academy) Interlaboratorial comparison applied to non-animal alternative methods

Áurea Valadares Folgueras-Flatschart (Inmetro) Standardization of cutaneous permeation tests and in vitro release by using vertical

diffusion system (Franz cell) João B. Calixto (CIEnP)

Room Rubi

12h10-13h20 Meet the Professor with Lunch Box (pre-registered participants only) Chair: SBFTE Jovem Committee

Openning Managing your and others creativity, and avoiding mistakes Michael Spedding (IUPHAR) Amin Rostami-Hochaghan University of Manchester, UK) Concepción Peiró Vallejo (Universidad Autónoma de Madrid, Spain) Derek Gilroy (University College London, UK) Emiliano de Oliveira Barreto (UFAL) Foo Y. Liew (University of Glasgow, UK) Maria Laura Bolognesi (Universty of Bologna, Italy)

Michael Spedding (IUPHAR) Neil J. McKenna (Baylor College of Medicine, USA) Nicholas Holliday (University of Nottingham, UK) Rafael Roesler (Universidade Federal do Rio Grande do Sul (UFRGS) Sandra Davidge (University of Alberta, Canada) Sharon Prince (University of Cape Town, South Africa)


13h30-15h30 Symposia/Oral communication

Room Topázio

José Ribeiro do Valle Award Chair: Maria Christina W. Avellar (Unifesp-EPM) JRV Evaluation Committee:

Edson Antunes (Session Coordinator, Unicamp) Concepción Peiró Vallejo (Universidad Autónoma de Madrid, Spain) Sharon Prince (University of Cape Town, South Africa)

inalist Ana lisa on al es

02.010 Evaluation of anti-Alzheimer effects of tacrine dimers in animals with peptide Aβ -42-induced Alzheimer. Gonçalves AE1, Mariano LNB1, Silva LM1, Aquino RAN, Fatima A2, Andrade SF1, Souza MM1 1Univali – Ciências Farmacêuticas, 2UFMG – Química

Finalist 2: Bruno Marcel Silva de Melo 04.026 The alarmin S100A9: A key target for treatment of psoriasis. Melo B1, Protasio F1,

Prado D1, Costa L2, Souza C2, Lima D3, Nakaya H3, Cunha T1, Cunha F1, Alves-Filho JC1 1FMRP-USP – Farmacologia, 2FMRP-USP, 3FCF-USP – Análises Clínicas e Toxicológicas

Finalist 3: Bryelle Eccard de Oliveira Alves 06.008 Novel DPP4 inhibitor reduces cardiac and vascular dysfunction induced by

diabetes Type 2 in rats. Eccard B1, Reina E1, Araújo JSC1, Barreiro EJ1, Lima LM1, Trachez MM2, Sudo RT1, Zapata-Sudo G1 1UFRJ, 2UFF

Finalist 4: Fernando Olinto Carreño 11.001 Lipid core nanocapsules modulate quetiapine hippocampal exposure in a

neurodevelopmental model of schizophrenia. Carreño F1, Helfer VE1, Staudt KJ1, Paese K1, Meyer FS1, Silva CM1, Herrmann AP2, Rates SMK1, Guterres SS1, Dalla Costa T1 1UFRGS, 2UFFS

Finalist 5: Lucas Antonio Duarte Nicolau 08.002 Promissingtherapeutic approach in GERD: Topical protection to oesophageal

mucosa and anti-inflammatory outcome of a biopolymer in mice and human biopsies. Nicolau LAD1,2, Batista-Lima FJ1, Santana AP1, Sales TM3, Oliveira TM4, Medeiros JVR4, Silva DA4, Vale ML1, Nobre-e-Souza MA3, Santos AA1, Sifrim D2, Souza MHP1 1UFC – Fisiologia e Farmacologia, 2Queen Mary University of London – Neurogastroenterology, 3UFC – Ciências Médicas, 4UFPI – Biotecnologia

Room Rubi

Cannabis-based drugs Chair: Alline Cristina Campos (USP)

THC, GPR119 and the metabolic syndrome Kenneth Paul Mackie (Indiana University, USA)

(−)-β-Caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor paralysis and neuroinflammation in a murine model of multiple sclerosis Rafael Cypriano Dutra (UFSC)

Cannabinoids, neuroplasticity and Antidepressant Drugs: Is there a Link? Alline Cristina Campos (USP)

CO: 02.007 The BNST endocannabinoid system modulates learned, but not innate fear in rats. Borges-Assis AB, Uliana DLM, Resstel LBM FMRP-USP – Farmacologia

CO: 03.011 Cocaine oral self- administration by ADHD male and female rats with neonatal injury with 6-OHDA. Fernandes PR, Umpierrez LS, Barros HMT UFCSPA


Room Ágata

Design, discovery and development of multitarget drug candidates Chair: Carlos Alberto Manssour Fraga (UFRJ) Polypharmacology in a single drug: multitarget drugs against complex diseases

Maria Laura Bolognese (University of Bologna, Italy)

Searching new multi-target directed drug candidate prototypes for Alzheimer’s disease: a case of novel feruloyl-donepezil hybrids Claudio Viegas Júnior (Unifal)

Discovery of multitarget prototypes for treatment of multifactorial diseases: N-acylhydrazone framework as privileged structure Carlos Alberto Manssour Fraga (UFRJ)

CO: 06.066 Effect of PDE9 Inhibitor (BAY 73-6691) on the contractile response of cavernous smooth muscle of heart failure rats submitted to treatment with tadalafil. Janussi SC, Tartarotti SP, Mora AG, Andrade DR, Barbosa JWP, Priviero F, Claudino MA USF – Multidisciplinary Research

CO: 04.004 Quercetin suppression of pulmonary fibrosis triggered by silica particles in Swiss-Webster mice. Guimarães FV, Ferreira TPT, Arantes ACS, Alexandre TL, Martins MA, Silva PMR Fiocruz – Inflamação


15h50-17h20 Roundtable

Room Rubi

Brazilian Pharmacology and IUPHAR: Building bridges for collaborative partnership Chair: Maria Christina W. Avellar (Unifesp-EPM)

IUPHAR, How to address modern molecular pharmacology via international collaboration: impact on drug discovery and development, and on natural products

Michael Spedding (IUPHAR)

SBFTE’s Remarks

Open discussion, Conclusions


Room Topázio Targeting the oncogenic TBX3 and its co-factor, nucleolin, in anti-cancer drug development Sharon Prince (University of Cape Town, South Africa) Introduced by: Leticia V. Costa Lotufo (USP)

Room Rubi Mechanisms of pain and neuro-immune communication in bacterial host defense Isaac M. Chiu (Harvard Medical School, USA) Introduced by: Waldiceu Aparecido Verri Junior (UEL)

19h30 23h00 Social Event: Dinner/dance party (to all attendees) Cervejaria Invicta


20/10/2017 (Friday)

08h00-08h50 Course

Room Topázio

Farmacogenômica / (Pharmacogenomics) Coordinator: Guilherme Suarez Kurtz (INCa) • Class 3: Farmacogenômica: Implementações Clínicas (Pharmacogenomics: Clinical

implementation) Guilherme Suarez Kurtz (INCa)

Room Safira

Modelos animais em Farmacologia translacional/(Animal models in translational pharmacology) Coordinator: Iraci L. S. Torres (UFRGS) • Class 3: Drosophila como modelo para prospecção de fármacos (Drosophila as a

suitable model for drug screening) Régis Adriel Zanette (UFRGS)

Room Ágata

Farmacometria e Farmacologia dos Sistemas (Pharmacometrics and System Pharmacology) Coordinator: Bibiana Verlindo de Araujo (UFRGS) • Class 3: Modelagem PK/PD de fármacos anti-diabéticos (PK-PD modeling of anti-

diabetics drugs) Bibiana Verlindo de Araújo (UFRGS)

Room Rubi

Descoberta & desenvolvimento pré-clínico de fármacos: Abordagem crítica e quantitativa das estratégias e ensaios (Drug Discovery and Preclinical Development: Critical and Quantitative overview of Strategies and assays) Coordinator: François G. Noël (UFRJ) • Class 3: Fluxograma de ensaios: In vitro, in vivo e clínico (Assays flow chart: in vitro, in

vivo and clinical) François G. Noël (UFRJ)


Room Topázio Neuroplasticity in stress-related neuropsychiatric disorders: new paths for drug discovery Maurizio Popoli (University of Milan, Italy) Introduced by: Francisco S. Guimarães (USP)

Room Rubi Adipokines, endothelial dysfunction and vascular damage: A role for interleukin-1beta Concepción Peiró Vallejo (Universidad Autónoma de Madrid, Spain) Introduced by: Andre S. Pupo (Unesp)

10h00-11h30 Poster Session 2 with Coffee break

11h30-12h40 Keynote Speaker: Sergio Ferreira Memorial Lecture

Room Topázio

Melatonin – the ubiquitous indolamine – multiple sources, multiple targets – New pharmacological chapter? Regina P. Markus (USP) Chair: Maria Christina W. Avellar (Unifesp-EPM) Introduced by Leticia Lotufo (USP)

12h40-13h50 Closing Session

Room Topázio Awards and Prize Announcements Closing Ceremony




Lecture abstracts

Courses

Farmacogenômica (Pharmacogenomics). Guilherme Suarez-Kurtz (INCa) Introduction to pharmacogenetics/genomics. Historical landmarks in the development of pharmacogenetics. The genetic component of interindividual variation in drug response. Pharmacogenetic polymorphisms in drug metabolic pathways, transporters and receptors, and their impact of pharmacokinetics and pharmacodynamics. Population pharmacogenomics: Brazil as a model case. Examplos of pharmacogenetic trials: gene-candidate and genome-wide association studies. Adoption of pharmacogenetics-informed prescription in clinical practice: challenges, current status and perspectives. Modelos Animais em Farmacologia Translacional (Animal Models in Translational Pharmacology). Iraci L.S. Torres, Rosane Gomez, Regis A Zanette. Programa de Pós-graduação em Ciências Biológicas: Farmacologia e Terapêutica (PPGFT). Departamento de Farmacologia. Instituto de Ciências Básicas da Saúde (ICBS). Universidade Federal do Rio Grande do Sul (UFRGS). Porto Alegre/RS The use of animal models in developing novel therapeutic strategies for human diseases overlaps with basic research that uses animal models to understand physiological and disease pathways. Beyond research centers and universities, pharmaceutical/biotechnology industries have also employed animal models, mainly mammalian species such as mice, rats, dogs, cats, pigs, and primates. The selection of a validated and predictive animal model is essential, since a proper design, execution and reporting of results help to make preclinical data more reproducible and translatable to the clinic. However, ethical and logistical constraints associated with the use of mammalian models slow the evolution of our understanding in the field of pharmacology, which must progress more rapidly if we wish to hinder, for example, the ever-growing resistance of pathogens to antimicrobial compounds. This emerging need for an easier and faster method of in vivo experiments on fungal pathogenesis can be addressed by using invertebrate model hosts, such as the fruit fly Drosophila melanogaster. Moreover, integration of knowledge in animal disease models is important in the drug development process. Indeed, preclinical studies using specific animal models contribute to a better understanding of the disease and of the drug-action mechanisms, besides drug safety and efficacy evaluations. The hypotheses generated in this phase can be further proved in clinical trials. Therefore, this course aims to promote to undergraduate and graduate students a better understand on animal models and their use in pharmacology, contributing positively to their academic formation. Antimicrobial and antifungal. PK/PD Modeling. Francine Johansson Azeredo. – Drug Department of Faculty of Pharmacy at Federal University of Bahia Over the past decades, data from infected animal models, in vitro pharmacokinetics (PK) and pharmacodynamics (PD) studies, volunteer studies, and clinical trials have enabled clinicians to establish the best mode of drug administration and posology in order to maximize the killing of microorganisms and to minimize the patient toxicity, the emergence of bacterial resistance, and costs. Systems pharmacology represents a hybrid, multi-scale modeling approach that seeks to combine systems or network-based structures with basic principles of PK and PD. The increasing knowledge base about molecular mechanisms of interactions between antibiotics and antibiotic targets, coupled with advanced experimental techniques and computational capability, makes the development of mechanism-based PK/PD models incorporating receptor binding and bacterial physiology possible. This new generation of mechanism-based PK/PD models will enable the exploration and increased understanding of the underlying complex mechanisms of the infectious process. The transition toward systems-based approaches requires the ability to integrate diverse data types and experimental platforms. Most approaches for translating preclinical antimicrobial research focus only on antibiotic activity and interactions between the drug and bacteria. Mathematical modeling can assist in this process by integrating the behavior of multiple components into a comprehensive network-based model, and by addressing questions that are not yet accessible to experimental analysis. Modelagem PK/PD de fármacos anti-diabéticos (PK-PD modeling of anti-diabetics drugs) Bibiana Verlindo de Araújo (UFRGS) Diabetes mellitus is a metabolic disorder which affects millions of people around the world characterized by reduced insulin sensitivity and loss of beta-cell mass, resulting in hyperglycemia. The disease provokes several changes in the tissue physiology that can affect the distribution of anti-diabetics drugs in the biophase. In this context, the investigation of free levels reached by anti-diabetics drugs in the target tissues by microdialysis is a valuable approach to gain insight into disease and drug effect. In this presentation data from the tissue distribution of three anti-diabetics (metformin, glimepiride and vildagliptin) on the liver were investigated by microdialysis in diabetic and healthy Wistar male rats to evaluate the impact of disease on the drug’s distribution. By physiologically based pharmacokinetic modeling (PBPK) the levels expected in the human’s tissues were predicted and the effect of free interstitial levels of


drugs were evaluated by PKPD modeling incorporating glucose tolerance test data from the pre-clinical and clinical studies. Modelagem PK/PD no Desenvolvimento de Fármacos na Oncologia (PK/PD Modeling in Oncology Drug Development). Maiara Cassia Pigatto (Instituto Vita Nova) Computational systems biology has accelerated the progress and increased the success rates of anticancer drug development programs and it has gained increasing recognition by the regulatory agencies such as FDA. Mechanism-based computational models, which integrate molecular cell biology and drug pharmacology may provide robust support in critical drug development decisions when implemented in early stage of the development program during the preclinical research, and throughout all clinical phases. In oncology, modeling and simulation can be extremely useful guiding the selection of adequate doses that improve treatment efficacy and reduce toxicity, since the anticancer agents often have a narrow therapeutic index. This course will discuss three examples of population PK/PD models that demonstrate the importance of this approach in anticancer drug development and that are widely applied: (1) the tumor growth inhibition (TGI) model for tumor response, (2) the indirect response (IDR) model for biomarker response and (3) the myelosuppression model for leukocyte and neutrophil responses. Moreover, we will discuss how the monitoring of free tumor concentrations can be crucial to elucidate the relationship between antitumoral drug levels and response to anticancer agents in the TGI models. Descoberta e Desenvolvimento Pré-Clínico de Fármacos: Abordagem Crítica e Quantitativa das Estratégias e Ensaios (Drug Discovery and Preclinical Development: Critical and Quantitative overview of Strategies and assays). François G. Noël (UFRJ). ICB-Universidade Federal do Rio de Janeiro Neste curso iremos apresentar uma visão geral, atual e crítica do processo de descoberta de novos fármacos, com ênfase nas etapas de descoberto e desenvolvimento pré-clínico de novos fármacos, nós limitando aos fármacos tradicionais (pequenas entidades químicas, e não biofármacos). Assim sendo, iremos abordar os critérios para escolha de produto a ser desenvolvido (nichos/oportunidades), estratégias de planejamento e tipo de ensaios farmacológicos a serem usados (desenho racional, alvo-dirigido, ou avalia ão “cega” de compostos em ensaios fenotípicos). Iremos discutir os tipos de ensaios a serem realizados (in silico, in vitro e in vivo) na etapa pré-clínica, dando exemplos de modelos/ensaios atualmente preconizados para cada etapa, à luz da regulamentação internacional em vigor. Iremos também dar uma abordagem quantitativa com discussão sobre os resultados a serem considerados como desejados ou limitantes. Iremos apresentar uma possível sequência de testes a serem realizados através de fluxograma com indica ão dos momentos críticos de decisões (“go / no-go”).


Lectures

How metabolism and recent human evolution (to run!) opens up new therapeutic opportunities in neurodegeneration and ALS Michael Spedding, Secretary General, IUPHAR ; 2Spedding Research Solutions Drug discovery for neurodegenerative disease has not taken into account recent human evolution to run, and increase metabolic efficiency. Humans evolved to run between 2-4 million years ago, which involved major changes in brain, skeleton, skeletal muscle perhaps using the same molecular levers (Noakes & Spedding, 2012). This evolution has led to human’s interest in sports performance. However, performance and mitochondrial function decline with ageing according to Moore’s law, (Marck et al, 2017) and are very susceptible to inflammation. Metabolic impairment is a major factor in Amyotrophic Lateral Sclerosis (ALS) patients and in presymptomatic (SOD1) G86R mice (Henriques et al., 2015) with changes in the ceramide/glucosylceramide ratio - inhibiting glucosylceramide synthase is deleterious to neuromuscular junctions, with associated effects on lipid metabolism. In contrast, inhibiting glucosylceramidase may be beneficial. We used transcriptomic analysis of spinal cord and muscle and metabolomic analysis (3000 lipids) to define the lesions in ALS and compare with other neurodegenerative diseases. SOD1 Mice have metabolic impairment with triglycerides being almost fully depleted in plasma, muscle soleus and spinal cord at end-stage. At early symptomatic disease stage, spinal cord showed immune system changes, but soleus muscle showed links to neurodegenerative disease due to downregulation of mitochondrial/Krebs cycle genes (below) opening new therapeutic directions which we shall describe. Financial support from Les Laboratoires Servier, Spedding Research Solutions. Henriques et al 2015, Hum Mol Genet, 24, 7390-7405 ; Noakes & Spedding, 2012, Nature, 487, 295-296. Marck et al, 2017, J Ger A Biol Sci Med Sci, 72, 455-463.

Pathway/disease similarity to soleus changes - SOD1

Gene Set Size Gene Candidates p-value q-value

Parkinson’s disease 143 45 (31.5%) 5.01e-18 1.13e-15

Oxidative Phosphorylation 133 42 (31.6%) 5.72e-17 6.43e-15

lzheimer’s disease 168 44 (26.2%) 2.19e-14 1.65e-12

Huntington’s disease 193 45 (23.3%) 1.01e-12 5.66e-11

Glowing pharmacology: imaging the life and times of G protein coupled receptors Nick Holliday1, Rachel Richardson1, Laura Humphrys1, Liciane Medeiros1,2, Marco Filho1,2, Dani Olguins1,2, Rafael Roesler2 1School of Life Sciences, University of Nottingham, QMC, Nottingham NG72UH UK. 2Institute for Basic Health Sciences, Federal University of Rio Grande do Sul, 90050-170 Porto Alegre RS Brazil. The G protein coupled receptor (GPCR) family is highly tractable for drug discovery, but many of its members have yet to be targeted successfully by therapeutics. New opportunities for drug development have arisen through recent advances in our understanding of GPCR pharmacology, including biased ligands directing signalling to particular downstream pathways; tailoring the spatiotemporal organisation of receptor responses; and selectively manipulating particular GPCR dimers. Our group focuses on understanding these mechanisms for peptide, nutrient and dopamine receptors involved in appetite, reward, and gastrointestinal pathways, using fluorescence imaging techniques. For example, our development of fluorescent ligands for the gastrin releasing peptide (GRP) and Neuropeptide Y receptor families enables quantitative assessment of ligand binding and kinetics using high content imaging approaches. Protein-protein interaction assays using fluorescence and luminescence complementation allow analysis of the pharmacology of particular GPCR signalling complexes involving specific effectors or receptor dimer combinations. Finally we will describe how optogenetic techniques can explore the role of receptor regulation in the control of spatiotemporal GPCR signalling. Supported by the CAPES Drug Discovery Programme, the British Pharmacological Society and the Nottingham-Monash PhD program. Sykes DA et al (2017) Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nature Comm (accepted) Stott LA et al (2016) Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: a practical guide to assessing functional data. Biochem Pharmacol 101:1 Kilpatrick LE et al (2015) A G protein-coupled receptor dimer imaging assay reveals selectively modified pharmacology of neuropeptide Y Y1/Y5 receptor heterodimers. Mol Pharmacol 87:718 Website: http://www.nottingham.ac.uk/life-sciences/people/nicholas.holliday Consensomes: Leveraging publically archived “omics” datasets to illuminate the biology of nuclear receptor signaling pathways. Neil J. McKenna (Baylor College of Medicine, USA) Current knowledge of cellular signaling pathways is based largely upon observations in the published research literature. lthough publically archived discovery scale (‘omics) datasets have the potential to fill gaps in pathways, deficits in their management have prevented such re-use. Using transcriptomic and cistromic datasets in the field of nuclear receptor signaling as a proof of principle, we introduce here the concept of consensomic analysis. We ranked genes based on the discovery rate of their significant differential expression across more than 2500 publically archived transcriptomic and cistromic experiments that mapped to a given nuclear receptor and biosample category. These


consensus lists, or consensomes, are validated by comparison with existing literature knowledge, gene-level integration of transcriptomic and cistromic datasets, and in a series of experimental bench use cases. In addition, integration with the Ominer search engine provides detailed knowledge on the receptor-ligand pharmacology underlying each consensome. Consensomes represent a practical and enduring solution to making full use of ‘omics datasets in the field of cellular signaling and pharmacology, and are abstractable to resolving biological patterns and trends across any cellular signaling pathway. What is Systems Pharmacology? For sure no longer Pie in the Sky! Amin Rostami, Professor of System Pharmacology, Centre for Applied Pharmacokinetics Research (CAPKR), University of Manchester, UK & Chief Scientific Officer, Certara, Princeton, USA Broader use of drug-independent ‘system’ information is a concept that distinguishes quantitative systems pharmacology (QSP) from classical descriptive models of observed data using purely statistical/mathematical models. Building QSP models requires a series of drug-dependent parameters measured in vitro or in species other than human. Translation of these values within QSP models is associated with uncertainties related to not only the gaps in system parameters, but also the accuracy and translatability (scaling) of the drug parameters. Significant events have taken place shaping the recent industrialization of QSP family of models, particularly those related to physiologically-based pharmacokinetics (PBPK) where in vitro in vivo extrapolation (VIVE) is incorporated. One of the factors influencing the wider use of the models has been the regulatory acceptance under judicious assessment of models as crystalized recently by the regulatory guidance notes issued by FDA and EMA on the use of PBPK models. However, in the absence of wide experience in forward translational through IVIVE approaches, qualification of the model can be obtained by reverse translation via fitting the models to observed data and optimising the drug or system parameters for which prior confidence is not high. This concept, when initiated after clinical observations, can be viewed as “reverse translation” since it refers back to available systems information pre-clinical data before trying to describe the observations. This presentation demonstrates the advantages of such strategies in filling knowledge gaps and discusses the perceived hurdles in widening applications. It is paramount that no clinical data are assessed on their own but in conjunction with other studies for that drug in different populations, and/or other similar drugs in the same population. Targeting the oncogenic TBX3 and its co-factor, nucleolin, in anti-cancer drug development. Tarryn Willmer1, Shannon Smyly1, Danica Smuts1, Dhiren Govender2, Jonathan Blackburn3 and Sharon Prince1 1Division of Cell Biology, Department of Human Biology, 2Department of Pathology, 3Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Observatory, 7925, Cape Town, South Africa. Sarcomas are heterogeneous neoplasms of mesenchymal origin whose clinical management is compromised due to inadequate diagnostic markers and limited therapeutic options. The transcription factor TBX3 is overexpressed in a diverse range of sarcoma subtypes where it plays a direct oncogenic role and it may thus represent a novel target for their treatments. Direct targeting of transcription factors for therapies is however challenging. We thus performed affinity purifications coupled with mass spectrometry to identify TBX3 protein co-factors that regulate its oncogenic activity in sarcomas because they may be more amenable as anti-cancer drug targets. Here we describe the identification and validation of the multifunctional phosphoprotein nucleolin as a TBX3 co-factor. We show that the overexpression of TBX3 and nucleolin are common in a number of sarcoma subtypes and we provide compelling evidence that nucleolin interacts with and co-operates with TBX3 to promote proliferation and migration of chondrosarcoma, liposarcoma and rhabdomyosarcoma cells. Finally, the effect of the nucleolin targeting aptamer, AS1411, on the cell viability of a range of sarcoma subtypes was tested. We show that AS1411 exhibits potent anti-cancer activity in these sarcomas whilst it has no effect on normal cells. In conclusion, we propose that TBX3 and nucleolin can be used in combination as biomarkers for the diagnosis and targeted therapy of a diverse range of sarcomas which are highly aggressive and treatment resistant cancers. Financial support: SA Medical Research Council, SA National Research Foundation, Cancer Association of South Africa and the University of Cape Town. Mechanisms of pain and neuro-immune communication in bacterial host defense. Isaac M. Chiu Harvard Medical School, Department of Microbiology and Immunobiology, Division of Immunology, Boston, MA, USA. It is increasingly clear that the nervous system actively communicates with microbes and the immune system during host-pathogen interactions. Pain often accompanies infection, but the underlying mechanisms of pain are not well understood. Here we investigate the mechanisms of pain and neuro-immune communication that occurs during gram-positive bacterial infections. Pain is mediated by nociceptor neurons, which detect noxious stimuli including heat, cold, mechanical injury. We find that nociceptors directly sense bacterial pathogens and their secreted toxins, leading to neuronal depolarization and pain. We target nociceptor neurons, finding a significant role for these neurons in regulating immune cell function and bacterial clearance. Therefore, the sensory nervous system plays an active role in detecting bacterial pathogens and modulating immunity during bacterial infection. Targeting neurons during infection


may lead to better treatments for pain and infectious diseases. Financial Support: National Institutes of Health (NIH/NCCIH and NIH/NIAID) Neuroplasticity in stress-related neuropsychiatric disorders: New paths for drug discovery. Maurizio Popoli Laboratory of Neuropsychopharmacology and Functional Neurogenomics - Department of Pharmacological and Biomolecular Sciences, University of Milano Stressful events represent a major risk factor for neuropsychiatric disorders. Whereas the effects of chronic stress have been investigated in animal models, the long-term consequences of acute stressors have been seldom investigated, although it is known that even a single trauma may trigger a pathology in humans (e.g., PTSD). Recently, we have dissected the destabilizing effects of acute stress in the rat excitatory glutamate (Glu) system. Acute inescapable stress rapidly enhanced depolarization-evoked Glu release/transmission in the prefrontal cortex (PFC), via a corticosterone-mediated rapid (non-genomic) enhancement of trafficking of Glu synaptic vesicles for release, sustained for 24 h. Acute stress also dramatically increased the total number of excitatory synapses in PFC. Unexpectedly, significant atrophy of apical dendrites was observed at 24 h, sustained for at least 14 days. Prior chronic treatment with traditional antidepressants (2 weeks) and single administration of ketamine (KET; 10 mg/kg) 24 h before stress blocked the enhancement of Glu release. We used the Chronic Mild Stress (CMS) protocol to look at the effects of chronic stress and to the antidepressant mechanism of KET. Rats were subjected to CMS for 5 weeks. Sucrose Preference Test (SPT) was used to distinguish stress-resilient (CMS-R) from vulnerable (CMS-V) rats. KET (10 mg/kg) was acutely administered to CMS-V 24 hours before sacrifice. A decrease in basal and depolarization-evoked Glu release was measured in hippocampus from CMS-V. In situ hybridization showed reduced dendritic trafficking of total-BDNF and BDNF-6 splice variant mRNAs in CA1 and CA3 of CMS-V. Morphological analysis of CA3 pyramidal neurons showed a reduction in total length and branching of apical dendrites. KET reversed most of these CMS-induced changes in CMS-V. Overall, our results suggest that KET may be used both as rapid-acting antidepressant to restore many maladaptive changes induced by chronic stress, and for prophylactic treatment to reduce the prevalence of PTSD after traumatic events. Financial support: MIUR, Cariplo Foundation, Brain & Behavior Research Foundation. Melatonin – the ubiquitous indolamine – multiple sources, multiple targets – New pharmacological chapter? Regina P. Markus, Pedro A Fernandes, Zulma F Silva - DDark LAB, Department of Physiologym Institute of Bioscience, University of São Paulo. Melatonin, the pineal gland hormone, is an indolamine derived from sequential N-acetylation and methylation of serotonin. In the pineal gland, the enzyme that catalyzes the first step is regulated by environmental light, through a multisynaptic pathway that links the retina to the pineal gland through the central clock located in the hypothalamus. Darkness promotes the activation of the enzyme and the synthesis of N-acetylserotonin (NAS). Seasonal photoperiodical changes regulate the conversion of NAS to melatonin. Daily changes in melatonin orchestrate diurnal and nocturnal functions at the molecular level. Nocturnal melatonin peak imposes a daily rhythm of leukocytes rolling, adhesion and transmigration, as it reduces the expression of adhesion molecules. It also induces the retention of myeloid and lymphoid progenitor cells in the bone marrow. Melatonin synthesized by extra-pineal sources play important role in mediating acute inflammatory responses and modulating the grade of neuroinflammatory diseases and cancer. Understanding the coordination of extra-pineal and pineal melatonin synthesis in order to balance circadian and defense responses was our initial goal in the field. We evaluated the involvement of membrane receptors, translation pathways, transcription factors, and gene/ protein expression in the switching melatonin sources, and the functional context that favors organismic timing regulation or defense responses. Interestingly, this coordination relies on the specificity of each dimer of the transcription factor nuclear factor kappa B (NFkB) in regulating the transcription of aral-alkyl-N-acetyltransferase (Aa-nat). In sequence, we disclosed how the loop is closed, by the restoration of pineal melatonin synthesis, and the mechanisms that impair this recovery. It is noteworthy that lzheimer’s patients did not produce nocturnal melatonin since the early phases of the disease. Finally, the relevance of extra-pineal synthesis of melatonin in controlling cell proliferation in several types of cancers was evaluated “in vitro” and “in silica”. The coordination of melatonin produced by different sources discloses the relevance of target-directed effects of melatonin and the impairment of the interaction between the organism and the external world in order to provide the best conditions for reacting to injuries. Financial Support: FAPESP 2013/13.691-1 (RPM); 2015/50.166/8; 2015/23348-8 (PAF); CNPq; CAPES.


Symposia and Roundtables

Innate immune mechanisms and maternal vascular dysfunction in preeclampsia. Stella Goulopoulou, PhD – University of North Texas Health Science Center Preeclampsia is a pregnancy-specific syndrome of unknown etiology that affects both placental and maternal vascular physiology. Maternal vascular dysfunction is an underlying mechanism of maternal hypertension and altered hemodynamics in preeclampsia. There is consensus that in preeclampsia, an underperfused placenta releases factors that act on the systemic maternal vasculature, promoting vascular dysfunction. However, the molecular pathways linking placenta-derived factors and maternal vascular dysfunction are not known. In addition, the mechanisms determining the release of placenta-derived factors in the maternal circulation are not understood. The objectives of this presentation are: 1) To familiarize the audience with the normal maternal vascular adaptations to pregnancy, 2) To address critical gaps in our knowledge of the interactions between placental physiology and maternal cardiovascular and immune system functions in pregnancies with preeclampsia, 3) To introduce the concept that circulating nucleic acids may act as molecular signaling molecules to induce maternal vascular dysfunction and preeclampsia.

Vascular endothelial cell dysfunction in pregnancy complications. Sandra T. Davidge Departments of Obstetrics/Gynecology & Physiology, Women and Children’s Health Research Institute, University of Alberta, Edmonton, Alberta, Canada, T6G 2S2 Pregnancy is a fascinating physiological state whereby essential vascular adaptations are necessary for healthy outcomes. Vascular bed adaptations include the uterine arterial bed to maintain blood supply to the fetal-placental unit. In complicated pregnancies, such as in preeclampsia, vascular dysfunction occurs that includes insufficient remodeling, increased vasoconstriction, endothelial dysfunction, and oxidative stress. Ultimately, uterine artery dysfunction results in increased vascular resistance impeding blood flow to the fetal-placental unit that can limit fetal growth and development. Understanding and improving pregnancy outcomes is vital to the population as a whole as the quality of the fetal environment during early development impacts later-life health and disease of the offspring. Preeclampsia, defined as new-onset hypertension with proteinuria after 20 weeks of gestation, remains a leading cause of maternal and perinatal morbidity and mortality with the only known ‘cure’ being the delivery of the placenta. Our studies focus on understanding how factors in the circulation alter maternal vascular function leading to reduced blood flow to the placenta. We show that circulating factors, including placental extracellular vesicles (STBEVs) acting via the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), contribute to endothelial dysfunction observed in preeclampsia. In addition, women of advanced maternal age have an increased risk for preeclampsia. We show that delaying pregnancy in a rat model alters maternal vascular function (e.g. increases myogenic tone and reduces nitric oxide modulation), increases maternal systolic blood pressure and causes poor fetal outcomes. Our studies are also showing that there is an effect on later-life cardiovascular health in the offspring of these pregnancies as well as having an impact on the postpartum cardiovascular health of the dams. Understanding the pathophysiological mechanisms will lead to novel therapeutic strategies to improve pregnancy outcomes and minimize the impact of pregnancy complications on both maternal health and later-life health of affected offspring. Financial Support: Canadian Institute of Health Research, Women and Children’s Health Research Institute Hypothermia-induced dystonia and abnormal cerebellar activity in a mouse model with a single disease-mutation in the sodium-potassium pump. Isaksen, Kros, Vedovato, Holm, Vitenzon, Gadsby, Khodakhah and Lykke-Hartmann, Karin The neurological spectrum associated with mutations in the TP1 3 gene, encoding the α3 isoform of the Na+/K+-ATPase, is complex and still poorly understood. To elucidate the disease-specific pathophysiology, we examined a mouse model harboring the mutation D801Y, which was originally found in a patient with Rapid onset Dystonia Parkinsonism, but recently, also in a patient with Alternating Hemiplegia of Childhood. We found that this model exhibited motor deficits and developed dystonia when exposed to a drop in body temperature. Cerebellar in vivo recordings in awake mice revealed irregular firing of Purkinje cells and their synaptic targets, the deep cerebellar nuclei neurons, which was further exacerbated and evolved into abnormal high-frequency burst firing during dystonia. The development of specific neurological features within the ATP1A3 mutation spectrum, such as dystonia, are thought to reflect the functional consequences of each mutation, thus to investigate the consequence of the D801Y mutations we characterized mutated D-to-Y Na+/K+-ATPases expressed in Xenopus oocytes. These in vitro studies showed that the D-to-Y mutation abolishes pump-mediated Na+/K+ exchange, but still allows the pumps to bind Na+ and become phosphorylated, trapping them in conformations that instead support proton influx. Financial support PUMPkin (DNRF85 (Danish National Research Foundation, http://dg.dk/en/), Graduate School of Health, Aarhus University, The Lundbeck Foundation (J. Nr. 234/06234/06), Th. Maigaards Eft. Fru Lily Benthine Lunds Fond, Fonden til Lægevidenskabens Fremme and NIH grant HL36783. The new facet of ouabain in the Central Nervous System (CNS). Elisa Mitiko Kawamoto Department of Pharmacology - Institute of Biomedical Sciences - University of São Paulo

http://dg.dk/en/)


Endogenous cardiotonic steroids have been shown to play important roles in the modulation of different body functions in the periphery and in central nervous system (CNS) such as renal sodium transport, blood pressure, glucose metabolism, cell growth and differentiation. Na,K- TPase (NK ) is constituted of 3 subunits: α, β and γ, and each subunit presents more than one isoform providing multiple functions in different cell types. Cardiotonic steroids (CTS) are specific ligands of α subunit which plays an important role in the modulation of learning and memory. Recent studies have now focusing on the function of CTS as hormones, which modulate signaling pathways through NKA. Ouabain (OUA), an endogenous CTS is produced in the adrenal cortex and hypothalamus. Studies have shown that OUA can induce calcium oscillation and Src-Ras-mitogen activated protein kinase (MAPK) pathways, which indicates a novel and key role for the OUA/NAK complex as a regulator of TNF- -binding activity and BDNF levels. In addition, OUA pretreatment presents anti-inflammatory and anti-apoptotic effects in the hippocampus against LPS-induced inflammation. This effect seems to be mediated by NF-can activate WNT/β-Catenin signaling pathway as well as CREB/BDNF and AKT pathways leading to important changes in cellular microenvironment that results in increased dendritic branching in CA1 and dentate gyrus, with spatial reference memory improvement. Altogether, these data suggest OUA as an important signaling pathway modulator in the brain. All procedures were approved by the Biomedical College of Animal Experimentation and the Ethical Committee for Animal Research ICB/USP. Financial Support: FAPESP and CNPq. Effect of Iron Overload on Na/K-ATPase. Tamara GF Costa, Leilismara S Nogueira, Vanessa F Cortes, Herica L Santos, Leandro A Barbosa1. Laboratório de Bioquímica Celular, Universidade Federal de São João del Rei, Campus Centro-Oeste Dona Lindul Introduction: Iron is an essential chemical element for human life. However, iron overload induces the production of reactive oxygen species that may lead to lipid peroxidation and a change in the plasma-membrane lipid profile. Objective: In this study, the effects of iron overload on the Na,K-ATPase activity of erythrocytes were investigated. Material and Methods: For this, we treated erythrocytes from healthy subjects with 0.8 mM H2O2 and 1 μM FeCl3 for 24 hours. After the treatment, the erythrocyte lipid composition, lipid peroxidation and Na,K-ATPase activity were evaluated in the presence and absence of plasma proteins. The activity of Na,K-ATPase was also measured against different concentrations of Na+, K+ and Mg+2 ions, in order to understand the interaction mechanisms of this metal with the enzyme and the conformation involved in its modulation. Results: The results showed that Fe+3 promoted a reduction in lipid content by about 50% in erythrocytes submitted to treatment, but the levels of lipid peroxidation did not change. An increase in Na,K-ATPase activity was observed around 130%. In the absence of plasma proteins, the activity profile of the enzyme was maintained, with an increase of around 100%. In contrast, erythrocytes treated with 0.8 mM H2O2 for 24 hours showed no significant change in any of the above-mentioned parameters. The pre-incubation with different concentrations of Na+ and K+ it is observed that iron appears to alter the affinity of the enzyme for sodium, one time that we only observed activation of the Na,K-ATPase in conditions that are involved with the E1 conformation of the enzyme. Moreover, magnesium appears to be important to the modulation of iron to the Na,K-ATPase, since the previously incubation with magnesium prevented the activation of the enzyme by 1 μM FeCl3. Taken together, the results indicate that treatment with 1 μM FeCl3 alters the lipid content of erythrocytes and at the same time increases Na,K-ATPase activity. The observed effects are modulated by the increased iron content and do not require the presence of plasma proteins and seems not to be related to lipid peroxidation. The presence of iron alters the affinity of the enzyme by sodium and the modulation of the Na,K-ATPase seems to be dependent on the E1 conformation. Acknowledgment: CAPES, FAPEMIG, CNPq New insights into cardiotonic steroids-Na/K-ATPase interaction. Luis Eduardo M. Quintas. Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil. Cardiotonic steroids (CTS) are a class of natural compounds better known as selective ligands of Na+/K+-ATPase (NKA), an integral plasma membrane and active pumping protein that plays an essential role in cell homeostasis. Structurally, CTS are composed by a steroidal nucleus in cis-trans-cis configuration (“U shape”), different from all-trans, planar, classical cholesterol-derived steroids, and this may contain one to four sugar moieties in C-3 position. CTS are divided into two major families: cardenolides and bufadienolides, depending if there is a 5- or 6-membered lactone in the C-17 position, respectively. Originally found in plants and amphibians, several CTS have been discovered in mammals and are now considered steroidal hormones. Recently, we have postulated that diverse endogenous CTS may evoke unique cellular effects. Indeed, in LLC-PK1 renal proximal tubule cells, the structurally similar endogenous bufadienolides marinobufagin (MBG) and telocinobufagin (TCB) triggered opposite effects. While MBG (and ouabain) induced proliferation, TCB (and bufalin) had an antiproliferative effect. Both TCB and MBG stimulated ERK1/2, but only MBG effect was blocked by ERK1/2 inhibition. Bcl-2/Bax ratio was decreased with TCB, as well as the S phase cell fraction with a decrease in the G2/M phase, indicating apoptosis. Inhibition of other kinase pathways (p38, JNK or PI3K) did not prevent cell death, but treatment with the caveolar disruptor cyclodextrin was partially effective. Interestingly, TCB

inhibited Wnt pathway activation, and the constitutively active -catenin S33A or the Wnt-dependent transcription factor TCF4 impaired TCB effect. In order to look more closely at how CTS interact with NKA, we evaluated thirteen


cardenolides and bufadienolides and found, for instance, that, in contrast to cardenolides, bufadienolides are poorly sensitive to K+, i.e., lose less potency as K+ concentration rises; the amount of hydroxyl groups present in the steroidal nucleus is inversely (genins) or directly (with sugar) proportional to NKA inhibitory potency; cyclization at C-14 position affects potency. Experiments are in course to evaluate other pharmacological parameters such as residence time and to determine structure-activity relationships. Financial support: FAPERJ, CNPq, CAPES. Antibiotics and neurodegenerative disease: New role for old drugs Elaine DelBel University of São Paulo School of Odontology of Ribeirão Preto, Department of Morphology, Physiology and Basic Pathology, Ribeirão Preto, SP, Brazil; Parkinson disease (PD) is a neurodegenerative disorder characterized by dopaminergic neurons affected by inflammatory processes. Current medications only provide symptomatic relief but fail to halt the dopaminergic neuronal death. Studies from experimental animal models have provided crucial insights into the molecular mechanisms in disease pathogenesis and recognized possible targets for therapeutic interventions. Post-mortem analyses of brain and cerebrospinal fluid from PD patients show the accumulation of proinflammatory cytokines, confirming an ongoing neuroinflammation in the affected brain regions. The tetracycline-derivative doxycycline (α-6 deoxy-5-hydroxytetracycline) has been shown to be neuroprotective in in vitro and in vivo models of neurodegenerative diseases. The proven reliability and safety of the medication suggests its potential as an effective and inexpensive treatment to protect or at least mitigate the central nervous system from neurodegenerative diseases such as PD. It has been suggested that the modulation of astrocyte and microglial activation could prevent neuronal demise and thus the progression of neurodegeneration. We hypothesize that doxycline could exert a neuroprotective effect by suppressing astrocyte and microglial activation induced by the neurotoxin 6-hydroxydopamine (6-OHDA), a preparation with similarities to PD. We investigated in striatal 6-OHDA lesioned mice the effects of a doxycycline given chronically either orally or subcutaneously at sub-antibiotic concentrations. To assess the protective mechanism conveyed by doxycycline we quantified using immunoreactive labeling tyrosine hydroxylase (neurons), glial fibrillary acid protein for astrocytes and cell surface marker macrophage antigen complex-1 for microglial cells. Brain regions containing cell bodies and fibers of dopamine in the nigrostriatal pathway were evaluated. Neuroinflammation indicators were sampled by Western blot analysis of metalloproteinase-3, cycloxygenase-2 and caspase-3 from the striatum. Chronic treatment with doxycycline, either administered orally or injected subcutaneously at sub-antibiotic concentrations, mitigates the loss of dopaminergic neurons in the substantia nigra compacta and nerve terminals in the striatum. This protective effect was associated with a decrease in the astrocyte and microglia response to the neurotoxin 6-OHDA in the globus pallidus and substantia nigra compacta, and a decrease of the astrocyte reaction in the striatum. No change in the expression of MMP-3, Caspase-3 and COX-2 was observed. Our results suggest that doxycycline blocks 6-OHDA neurotoxicity in vivo by inhibiting microglial and astrocyte expression. This action of doxycycline in nigrostriatal dopaminergic neuron protection is consistent with a role of glial cells in PD neurodegeneration. Cytokines and lzheimer’s disease. Eddy F Y Liew FRS. University of Glasgow, UK Cytokines are hormones of the immune system. Cytokine-targeting represents a major triumph in immunology scientifically, clinically and commercially. There is therefore considerable interest in discovering novel cytokines. I will illustrate the pleiotropic role of cytokines by focusing on interleukin (IL)-33. IL-33 is a member of the IL-1 family. It is the ligand of ST2, which is expressed mainly on Th2 cells, epithelial cells, neuronal cells and mast cells. IL-33 can skew a predominantly Th1 cell population to Th2 cells phenotype in vivo. Furthermore IL-33 potently induces Type 2 innate lymphocyte (ILC2) and alternatively activated macrophages (M2), leading to the differentiation of regulatory T cells (Tregs). This pleiotropic nature is demonstrated in the role of IL-33 in tissue and metabolic homeostasis, infection, inflammation, cancer and diseases of the central nervous system. lzheimer’s disease is characterized by an

accumulation of -amyloid in the brain that triggers chronic neuro-inflammation and leads to microglia activation, and synaptic and neuronal dysfunction. Systemic injection of IL-33 reversed synaptic plasticity impairment and cognitive

deficits in PP/PS1 mice (a model of lzheimer’s disease) and reduced soluble -amyloid levels and amyloid plaque

deposition by promoting the recruitment and uptake of -amyloid by microglia. In addition, intra-peritoneal injection of IL-33 modulates the innate immune response by polarizing microglia towards an anti-inflammatory phenotype and reducing the expression of pro-inflammatory genes, such as NLRP3, IL-1β and IL-6 in the cortices of APP/PS1 mice. In humans, IL-33 expression was decreased in the brain of patients with lzheimer’s disease, and levels of serum sST2 are elevated in patients with mild cognitive impairment. Furthermore, genetic studies have linked IL33 and ST2 single nucleotide polymorphism to lzheimer’s disease. Therefore, mobilization of innate immunity by IL-33 to prevent and clear established β-amyloid accumulation represents a new treatment paradigm for lzheimer’s disease. TRP channels play a neuroinflammatory role in lzheimer’s Disease. Maíra Assunção Bicca1,2, Evelyn C. Silva Santos1, Kirsten L. Viola2, Gecioni Loch-Neckel1, Matthew Marunde2, Haoming Jiang2, Kyle C. Wilcox2, Pauline T. Velasco2, William L. Klein2 and João B. Calixto1 1Department of Pharmacology, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil 2Department of Neurobiology, Northwestern University, Evanston, IL, United States of America


Different Transient Receptor Potential (TRP) channels that have been recently described to be involved with lzheimer’s disease (AD) pathogenesis. Among the very few described, the Transient Receptor Potential Ankyrin 1 (TRPA1) channel. TRPA1 is a member of the transient receptor potential (TRP) superfamily well known to be expressed in the spinal horn and other tissues, and recognized to mediate a diversity of pain and inflammatory states. lzheimer’s disease ( D) is a neurodegenerative disease characterized by accumulation of both tau and β peptides, and for having the disease course affected by progressive oxidative stress and brain inflammation. Molecules produced and activated during the inflammatory process, notably reactive oxygen species (ROS), phospholipase C (PLC) and calcium (Ca2+) are augmented during AD initiation and progression. Intriguingly, these are also TRPA1 intracellular endogenous activators. Recently, we have originally shown the role of TRPA1 in AD pathogenesis (Bicca et al., 2017; under revision). We reported TRPA1 is largely expressed in neurons and microglia in the brain. TRP 1 selective antagonist treatment reduced β burden in plaques and oligomers with consequent improvement on βOs-induced synaptic loss. Also, TRPA1 augmented expression in the microglia following βOs accumulation in different in vivo and in vitro models, and its possible role in the neuroinflammatory process. n important question remained to be clarified: Is βOs-induced M1 phenotype in microglial cells driven by TRPA1 activation? Ongoing research has been showing promise results. Financial support: Conselho Nacional de Desenvolvimento Científico e Tecnol gico (CNPq), Coordena ão de perfei oamento de Pessoal de Nível Superior (C PES) and Funda ão de poio Pesquisa Científica Tecnol gica do Estado de Santa Catarina (FAPESC). Inflammation and epigenetic mechanisms are involved on soluble guanylate cyclase expression.. Fabiola Zakia Mónica 1,2, Ka Bian2 and Ferid Murad2 1 Department of Pharmacology, University of Campinas, Campinas, Sao Paulo 2 Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC, USA Soluble guanylate cyclase (s C) is the intracellular receptor for nitric oxide (NO) and a heterodimer composed α and β subunits. In several vascular and non-vascular diseases the expression sGC subunits is downregulated. For instance, in breast cancer tissues the higher levels of s Cβ1 was correlated with greater survival probability than tissues with lower s Cβ1. Other studies have been shown that pro-inflammatory substances reduce the transcriptional activity of sGC subunits in aorta smooth muscle cells and in visceral white adipose tissue from mice thus leading to lower levels of cyclic guanosine monophosphate (cGMP). To date, there is no information on whether epigenetic mechanisms can regulate sGC expression. Breast cancer cell lines, MDA-MB-231 or MDA-MB-468 were used to evaluate the role of histone deacetylase (HDAC) inhibitors, as previous studies showed that the sGC-cGMP levels is reduced, thus favoring cell proliferation. (HDAC) inhibitors were added in vitro in MDA-MB-231 or MDA-MB-468 cell lines and the gene and protein expression of s C subunits evaluated. The class I HD C inhibitors increased the expression of s Cβ1 more than s Cα1. Transient overexpression of HD C3 significantly reduced s Cβ1 mRN . Chip assay confirmed an enhanced binding of HDAC3 to the s Cβ1 proximal promoter, which could be reversed by the HD C inhibitor, LBH-589. Mutations at the CCAAT-binding sequence, a sequence that regulate s Cβ1 expression, markedly reduced the efficacy of LBH-589 in augmenting s Cβ1 promoter activity. In conclusion, HD C3 is an endogenous antagonist of s Cβ1 expression in breats cancer cells and its inhibition could benefit treatment of the diseases associated with s Cβ1 downregulation and/or deficiency such as cancer and several vascular-related diseases. Financial Support: FAPESP and CAPES Promoting Resolution of Inflammation: A Three Billion Year-Old Solution. John L. Wallace, Department of Physiology & Pharmacology, University of Calgary, Calgary, Alberta, Canada. Resolution of inflammation is not just a consequence of the disappearance of pro-inflammatory signals. Rather, there is a wide range of endogenous substances that play important roles in driving the resolution process, in concert with factors that promote healing. Failure of these resolution processes can result in chronic inflammation, tissue dysfunction and scarring. Considerable progress has been made on defining lipid mediators that drive resolution of injury and inflammation. Gaseous mediators also play important roles in dampening inflammatory responses and promoting homeostasis. In particular, hydrogen sulfide (H2S) has been shown to drive a number of processes that contribute to resolution and repair. H2S was a ‘fuel’ for cellular energy generation for ~2 billion years before there was significant oxygen in the atmosphere. Mitochondria of eukaryotic cells retain the capacity for generating ATP through the process of oxidizing H2S, and H2S administration has been shown to rescue mitochondria in circumstances of anoxia/hypoxia. In animal models, H2S has been shown to promote healing through stimulation of angiogenesis. In the GI tract, inflammation and injury (such as in colitis) results in marked up-regulation of H2S synthesis at sites of ulceration. Inhibition of this H2S synthesis results in exacerbation of tissue injury, while supplementation of H2S accelerates healing. Damage induced in the GI tract by nonsteroidal anti-inflammatory drugs (NSAIDs) can be prevented by administration of H2S donors. Recently, a novel H2S-releasing derivative of naproxen (ATB-346) was shown to be much more potent than naproxen and well tolerated when taken by patients with osteoarthritis. A clinical trial to examine the GI safety of this drug is currently underway. Animals studies demonstrated negligible GI toxicity of ATB-346. Supported by a research grant from the Canadian Institutes of Health Research and a Visiting Professor award from Fundação de Amparo à Pesquisa do Estado de São Paulo.


Monoterpenes as promising substances for the treatment of painful neuropathies: Role of biotechnology. Fernanda Regina de Castro Almeida. Laboratory of Pain Pharmacology, Research Center on Medicinal Plants, Health Sciences Center, Federal University of Piauí, Teresina, Brazil. Neuropathic pain originates from an injury in the somatosensory system responsible for the perception of pain, characterized by the appearance of hyperalgesia, spontaneous pain, paresthesia and mechanical and thermal allodynia. This picture is present in numerous autoimmune diseases, metabolic, infectious, vascular, trauma and cancer. Currently, there are several substances used to treat painful neuropathy, such as anti-inflammatories, antidepressants, anticonvulsants, among others, but its chronic use is limited because of the numerous side effects. Several compounds of natural origin have been studied, and the monoterpenes from the essential oils have a high potential for this treatment, such as 2-phenylethanol (2-PHE). 2-PHE, an aromatic alcohol with rose-like odor, can be found in the essential oil of many plants, such as Rosa galica L. and Citrus aurantium var. sinensis, it has shown antibacterial activity and the similarity of its chemical structure to other compounds found in essential oils with antinociceptive activity suggested another potential effect for this substance. However, monoterpenes in general present instability in the preparation and storage process due to their low solubility in water, so complexation with β-cyclodextrin appears as a solution to reverse this problem. So, we have complexed 2-PHE with β-cyclodextrin (2-PHECD) and evaluated in the same tests. 2-PHECD by oral route increased the paw mechanical threshold measured by von Frey filaments and reduced acetone-induced cold allodynia in a sciatic ligature-induced neuropathy model (p <0.05). This effect was more effective and potent than that observed with 2-PHE. Furthermore, 2-PHE (50, 100 and 200 mg/kg, p.o.) was effective in reducing the levels of reactive species to thiobarbituric acid and increased GSH and SOD levels. Taken together, our findings suggest that 2-PHE has potential antinociceptive effect and 2-PHECD is a promising compound for the treatment of chronic pain.Financial support: UFPI/FAPEPI-CAPES Pharmacological potential of the natural nitro compound, 1-nitro-2-phenylethane and its synthetic derivatives as vasorelaxant agents. Mohammed Saad Lahlou. Laboratory of Cardiovascular Pharmacology, Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza, Brazil. Hypertension is a common, progressive disorder that constitutes a major risk for diabetes, stroke, cardiovascular, and renal diseases. A great number of studies have focused on bioactive compounds from natural sources as potential remedies for treatment of hypertension. Our group has sought for a number of years to identify novel antihypertensive compounds with vasodilator activity, especially those derived from essential oils of aromatic plants from northeastern Brazil. Nitroderivatives found in higher plants are rare. 1-Nitro-2-phenylethane was the first nitro compound isolated from a plant, and is responsible for the plant's cinnamon scent. 1-Nitro-2-phenylethane relaxes isolated rat aorta by stimulating the soluble guanylate cyclase (sGC)-cGMP pathway, through a endothelial nitric oxide (NO)-dependent mechanism. Its structural analog, 1-nitro-2-phenylethene (trans-β-nitrostyrene) formed by substitution of the alkane for the alkene moiety, was nearly 3.5 times more potent as a relaxing agent than NPa. We hypothesized that an electron donor substitution in the para-position of the aromatic ring would stabilize NPe, further increasing its interaction with sGC and/or its vasorelaxant potency. Using NPe as a lead compound for electronic structural modifications, several new nitroderivatives have been synthesized by our research group. Among them, trans-4-methoxy-β-nitrostyrene shows interesting vasodilatory effects that will be discussed in this presentation. These effects were studied in conductance or resistance vascular arteries, as well as in pulmonary arteries. New NO-independent sGC stimulators, NFa and trans-4-methoxy-β-nitrostyrene, are promising candidates not only as antihypertensive drugs, but also for treatment of pulmonary arterial hypertension, heart failure, thrombosis, and erectile dysfunction among other diseases. Supported by: CNPq, FAPESPA. Doutorado Acadêmico Industrial – DAI (Academic Industrial PhD – DAI). Erik Gustavo Del Conte (UFABC) O Doutorado Acadêmico Industrial (DAI) integra universidade e empresa promovendo a formação de doutores (as) com visão empreendedora e voltados para a inovação tecnológica. Os indicadores de produção científica nacionais apresentam evolução importante, principalmente na quantidade de artigos publicados em periódicos internacionais nas diversas áreas do conhecimento. Já a transformação do conhecimento em produtos e serviços com inovação tecnológica não apresenta desenvolvimento satisfatório, e mostra a necessidade de criação de um ecossistema que proporcione o desenvolvimento de teses de doutorado com retroalimentação para inovação tecnológica. Para criar o ecossistema acadêmico industrial o DAI contempla duas fases, a primeira que dura de 2 a 6 meses é a fase de pré-doutorado, onde o candidato (a) faz a busca do projeto de pesquisa no ambiente empresarial, e tem como proposta o desenvolvimento de produtos, processos ou serviços inovadores de interesse comum da empresa e da universidade. A segunda fase é caracterizada pelo ingresso num dos cursos de doutorado acadêmico da UFABC. A fase de pré-doutorado é um dos pontos principais. Para realizar esta fase o candidato precisa de um orientador acadêmico e de um supervisor industrial, tornando necessário o credenciamento no DAI de uma empresa que desenvolva atividades de pesquisa, desenvolvimento ou inovação. Essa última atividade é realizada com o apoio do setor de convênios da UFABC, que edita os termos de colaboração técnicos científicos e com apoio da Agência de Inovação que realiza a análise sobre propriedade intelectual dos termos. Atualmente o DAI conta com 20 estudantes que realizam o doutorado com bolsa


do CNPq e 5 estudantes que realizam sem bolsa, o que totaliza 25 projetos DAI. Os professores credenciados são 77 vinculados aos cursos de doutorado da UFABC e um total de 29 empresas estão credenciadas. No ano de 2017 foi realizada a primeira defesa de doutorado no âmbito do DAI. A possibilidade para credenciamento de empresas inovadoras com o corpo docente interdisciplinar da UFABC e o apoio do CNPq tornam a proposta do DAI um ecossistema propício para realizar a retroalimentação da inovação tecnológica no ambiente acadêmico industrial. O DAI conta com o apoio do Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) na concessão das bolsas. Maiores informações estão disponíveis no site do DAI http://dai.ufabc.edu.br. Apoio financeiro: O DAI conta com o apoio do Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) na concessão das bolsas.


Cellco Biotec: o destaque está na diferença! Fernando Vasconcelos Maluf (Cellco Biotec)[ A biotecnologia tem inundado nosso dia a dia com seus avanços, seja pela introdução de espécies geneticamente modificadas em nossa agricultura (e.g., algodão, milho, cana-de-açúcar), pela possibilidade de re-introdução de alimentos (e.g., leite livre de lactose), produção de combustíveis alternativos (e.g., etanol de segunda geração), e sem deixar de mencionar as diversas ferramentas diagnósticas e fármacos oriundos do domínio desta tecnologia. Mesmo considerando este enorme potencial, o setor ainda sofre pela ausência de empresas nacionais que promovam e forneçam as ferramentas (i.e. reagentes/insumos básicos) para um desenvolvimento acelerado e competitivo com o resto do mundo, sendo altamente dependente da obtenção de reagentes biotecnológicos provenientes do exterior. Aproveitando esta oportunidade de mercado, a empresa Cellco Biotec nasceu em 2013 após a materialização do desejo de 3 jovens doutores, apoiados pela sólida e experiente empresa alemã Jena Bioscience, que decidiram empreender e promover a diferença. O sonho ganhou forma e a empresa atualmente oferece série de produtos biotecnológicos com produção totalmente nacional, servindo ao mercado brasileiro e internacional. Seu portfólio cresce aceleradamente em virtude de esforços em seu setor de pesquisa, que conta hoje com mais de 20 projetos de desenvolvimento, sendo 3 deles apoiados com recursos PIPE-FAPESP. Há ainda, grande envolvimento através de parcerias com o setor público (e.g. Universidade de São Paulo, Hospital de Câncer de Barretos) e privado (e.g. Centro de Tecnologia Canavieira) buscando catalisar os desenvolvimentos de tecnologia com nossas ferramentas. Ao longo dessa jornada os desafios foram diversos e a burocracia de nosso sistema com certeza pode ser considerada o principal deles, no entanto, podemos afirmar que a combinação de persistência, preparo, planejamento e positividade podem assegurar o sucesso. Nitros(yl)ation and the antihypertensive responses to oral nitrite. Lucas Cezar Pinheiro, Pos-doc Fellow Department of Pharmacology, Faculty of Medicine of Ribeirao/ Preto, University of Sao Paulo Several studies show antihypertensive effects of nitrate and nitrite, which persist for more than 24 hours after a single dose. The current hypothesis is that nitrite generates nitric oxide does not fully support this long duration effect, as the increases in plasma nitrite concentrations do not correlate with the antihypertensive effects at all times. Results from Tanus-Santos´ laboratory support the notion that oral nitrite treatment promotes S-nitrosothiols formation and vascular S-nitrosylation. This could be the main mechanism for the antihypertensive effects of both oral nitrite and nitrate. Chemical reactions involving nitrite in the acid conditions of the stomach result in several nitrosylation agents, which generate nitrosothiols and nitrosamines. The S-nitrosothiols could deliver of nitric oxide or transnitrosylate proteins in the organism. Further evidence emerged in recent years that S-nitrosothiols could change protein function, particularly inhibiting or increasing activity. It is not yet understood the physiological function of S-nitrosothiols and their formation in vivo. Adding complexity to this problem, there is clear modulation of these chemical reactions by the redox state of cell. In this lecture, we will discuss the gastric formation of S-nitrosothiols from nitrite, which could result of pharmacological interventions or physiological mechanisms. Further, we will discuss alterations in cardiovascular system promoted by S-nitrosylation, with special attention to changes in hypertension and interactions among S-nitrosothiols and renin angiotensin system. Financial support: FAPESP, CAPES e CNPQ. The expression of human inducible nitric oxide synthase (NOS-2) and its splice variants S2 and S3 is associated with the development of colon and breast human tumors. Eloisa D. Castro1, Wagner L. Batista2, Antonio Hugo J.F.M. Campos3, Arnold Stern

4 & Hugo P. Monteiro

1 1Department of Biochemistry, Center for Cellular and Molecular Therapy-CTCMol,

Escola Paulista de Medicina/Universidade Federal de São Paulo, SP, Brazil. 2Department of Pharmaceutical Sciences, Universidade Federal de São Paulo/Campus Diadema, SP, Brazil. 3Department of Anatomic Pathology, A C Camargo Cancer Center, São Paulo, Brazil. 4New York University School of Medicine, New York, NY, USA. Nitric oxide (NO) produced in high and sustained amounts by the inducible isoform of NO synthase (NOS-2) stimulated by inflammatory cytokines in macrophages result in cytostatic and/or cytotoxic effects on tumor cells. However, during the past decade numerous clinical trials showed the presence of NOS-2 in a large number of cancers. Low and sustained concentrations of NO generated by constitutively expressed NOS-2 in cancer cells may represent an important factor for their development. Alternative splicing of NOS-2 may function down-regulating the intracellular NO concentrations. Two splice variants, variant S2 which lacks exons 8 and 9 and variant S3 which lacks exons 9, 10, and 11 were suggested to play this role. To investigate this regulation in colon and breast cancer we used two different approaches: 1) We used a couple of isogenic human colon cancer cell lines derived either from the primary tumor (SW480) or from a lymph node metastasis (SW620). We found that SW480 cells expressed higher levels of variant S3, as compared to SW620 cells. Using SW480 cells knocked down for the expression of NOS-2 variant S3 we strongly implied that S3 plays an important role regulating intracellular NO production in these cells. Higher intracellular levels of NO were determined in SW480 knocked down for NOS-2 variant S3 (S3C9 cells), as compared to the levels determined for wild type SW480 cells. Higher NO levels result in loss of viability of S3C9 cells. Loss of cell viability correlated positively with autophagy. Autophagy may operate as a cytotoxic response to nitrosative stress. 2) Two breast cancer cell lines were used: MCF7 Estrogen Receptor positive (ER+) and MDA-MB-231 Estrogen Receptor negative (ER-). In addition, we used cells obtained from clinical samples of ER+ and ER- patients. Endogenous NO levels


were higher in MDA-MB-231 cells and epithelial cells, and fibroblasts from tumor cells obtained from ER-patients if compared with MCF-7 cells and epithelial cells, and fibroblasts from tumor cells obtained from ER+ patients. Southern blotting analysis of variants S2 and S3 showed a correlation between the expression of both variants and the stage of tumor development independent of its subtype. Financial Support: FAPESP: Proc. 2012/10470-1 and CNPq: Proc. 481154/2013-2 Nitros(yl)ation in sepsis. Jamil Assreuy – Dept Pharmacology/CCB – UFSC Florianópolis – SC Cardiovascular dysfunction, mainly characterized by hypotension and hyporesponsiveness to vasoconstrictors and the ensuing organ damage are hallmarks of sepsis and septic shock. Nitric oxide (NO) has been implicated as one of the main effector of this dysfunction. Besides it actions on soluble guanylate cyclase and potassium channels, it is widely known that NO avidly reacts with sulphydryls (thiol) present in proteins or in low molecular weight compounds yielding S-nitrosothiols. Nitrosothiols can operate like sink or reservoirs of NO. In any event, protein S-nitrosylation by NO has been described as an important modifier of protein function. We have studied the impact of protein S-nitrosylation/denitrosylation in the cardiovascular dysfunction of sepsis, using NO donor infusions in healthy animals, injection of live bacteria and cecal ligation and puncture (CLP) as cardiovascular dysfunction and sepsis experimental models, respectively. Infusion of NO donor into the whole animal (rat) or incubation of NO donors with aorta rings induced a substantial loss in the ability to respond to vasoconstrictors. In rats bearing CLP-induced sepsis or injected with live E. coli, there was a reduction in the basal arterial pressure and a substantial loss in the vasoconstrictive response to phenylephrine. In addition, CLP increased plasma levels of NOx (nitrite + nitrate), organ damage markers, induced a mortality of 60% and substantially increased S-nitrosylation of aorta proteins. Previous oxidation of sulphydryls with DTNB [5,5'-dithio-bis-(2-nitrobenzoic acid); a cell-impermeant thiol oxidant] blocked the effect of NO infusion and of the incubation of aorta rings with NO donors. More important however was the finding that if given to rats 12 hours after CLP sepsis onset, DTNB reversed the reduced response of aorta rings and blood pressure to vasoconstrictors, reduced organ damage and protein nitrosylation and increased survival to 80%. These results taken collectively indicate that: 1) the presence of reduced sulphydryls seems to be essential for NO cardiovascular effects; 2) loading sulphydryls with exogenous or endogenous NO induced a profound reduction in the ability of isolated vessels or of whole animals to respond adequately to vasoconstrictors; iii) oxidation of sulphydryls with DTNB prevented or reversed the vascular effects caused by NO; iv) DTNB reduced the levels of S-nitrosylated proteins in a relevant sepsis model along to an overall improvement in the animals condition and substantially reduced mortality. Therefore, it is conceivable that protein S-nitrosylation is an important target in sepsis and thus protein denitrosylation may be a suitable avenue of research for sepsis treatment. Financial support: CNPq; CAPES; FAPESC; FINEP. microRNA based therapy - microRNAs in cancer cachexia. Sarah Santiloni Cury, Geysson Javier Fernandez Garcia, Paula Paccielli Freire, Grasieli de Oliveira, Patricia Pintor dos Reis, Maeli Dal Pai-Silva, Robson Francisco Carvalho. Institute of Bioscience of Botucatu, Sao Paulo State University (UNESP) Cancer cachexia is defined as a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Cachexia has commonly been considered a paraneoplastic syndrome in which tumor-derived factors induce widespread alterations in gene expression or metabolic flux that may function to release intermediate metabolites, which can then be used by the tumor for growth and expansion. For the past several decades, investigators have searched for the elusive mediators of cancer cachexia in hope of developing novel therapeutics to protect against tumor-induced skeletal muscle loss. In general, these mediators, including some recently discovered microRNAs (miRNAs), are thought to derive from immune or tumor cells, or the skeletal muscle undergoing wasting. Moreover, the role of miRNAs in the regulation of different cellular processes points to their clinical utility as revolutionary tissue-based biomarkers and future therapeutic targets. Therefore, we performed a tumor miRNA and gene expression analysis of 195 patients with non-small cell lung cancer (NSCLC), defined as cachectic or non-cachectic by a clinically applicable muscular index determined by computed tomography (CT) analysis, to identify potential biomarkers of cancer cachexia. The expression and clinical profiles were obtained from The Cancer Genome Atlas (TCGA; https://tcga-data.nci.nih.gov/tcga/), Gene Expression Omnibus NSCLC Radiomics-Genomics (https://www.ncbi.nlm.nih.gov/geo/; series GSE58661), and The Cancer Imaging Archive (TCIA; http://www.cancerimagingarchive.net/) public data portals. We also modelled cancer cachexia in mice bearing Lewis lung carcinoma and performed an integrative analysis of miRNA and mRNA expression profiles in the tibialis anterior skeletal muscle. We have discovered deregulated miRNAs and their target mRNAs in cancer cachexia that modulate important biological processes such as cytokine-mediated signaling pathways and ECM organization, in the both tumor and skeletal muscle. In addition, our data showed upregulated miRNAs (miR-10a-5p, miR-10b-5p, miR-29b-3p, miR-146a-5p, miR-146b-5p, miR-223-3p, miR-338-5p, and miR-350-3p) and transcripts encoding predicted secreted proteins (APOD, IL6, IL1R2, and COL6A6). Herein, our integrative miRNA and mRNA analysis unravel new regulatory networks and molecular pathways involved in muscle wasting and highlight potential biomarkers and therapeutic targets of cancer cachexia. Financial support: FAPESP and CNPq.


miRNAs from 14q32 region in thyroid cancer: biological role and clinical implication. Murilo V Geraldo. Department of Structural and Functional Biology, Institute of Biology, State University of Campinas Papillary thyroid carcinoma (PTC) is the most prevalent histological subtype of thyroid cancer with increasing incidence worldwide. Although the abnormal expression of microRNAs (miRNA) has been explored as promising diagnostic and prognostic tools for PTC, the role of miRNAs in thyroid cancer progression, as well as its therapeutic potential remains unclear. Our previous results show the downregulation of several miRNAs from DLK1-DIO3 genomic region using an in vivo model of thyroid cancer progression and in human PTC samples. This genomic region, mapped at 14q32, harbors several coding and non-coding genes, including more than 50 miRNA genes, which have been implicated as tumor suppressors in a variety of tumor types. Due to the large number of miRNAs present in the 14q32 region that are concomitantly deregulated, the characterization of their biological role and clinical implications in PTC may be a complex and time-consuming. Thus, we combine computational prediction of targets, online-available gene expression datasets and gene set enrichment analysis, in order to construct the post transcriptional network potentially modulated by these miRNAs, unmasking key signaling pathways and biological processes for tumorigenesis and progression of PTC, as well as to identify potential tumor suppressors. Our results show that the predicted targets for these miRNAs participate on cancer-related biological processes, such as cell adhesion, proliferation, angiogenesis and Extra-cellular matrix remodeling. In vitro functional analyses confirm the tumor suppressive role for selected candidate miRNAs. In conclusion, by aligning in silico and in vitro approaches, we hope to shed light on the role of the miRNAs from DLK1-DIO3 in thyroid follicular cell biology and open up perspectives for the development of new adjuvant therapy for thyroid cancer. Funding: FAPESP/FAEPEX.

Roles of non-coding RNAs (microRNAs and lncRNAs) in cardiovascular development, function and disease. Da-Zhi Wang. Department of Cardiology Boston Children’s Hospital Harvard Medical School. It is now recognized that more than 98% of our genome is actively transcribed to produce thousands of non-coding transcripts in many cell types and tissues. However, the molecular nature and functional significance of noncoding transcripts remains largely unknown. The Wang lab is mostly interested in non-coding RNAs, including microRNAs and long non-coding RNAs (lncRNAs) and RNA binding proteins (RBPs) in cardiovascular development, function and disease. Though genome-wide transcriptome profiling in animal models for human cardiomyopathy, the lab identified candidate miRNAs and lncRNAs that are dysregulated in diseased hearts. Using combination of gain- and loss- of function approaches and molecular dissection, the Wang lab shows that loss-of-miRNAs in the cardiovascular system leads to severe cardiac defects and lethality in mice. The lab has generated and studied multiple lines of knockout and transgenic mice for miRNAs (miR-208a, miR-22, miR-17-92 and miR-155). These investigations demonstrate that miRNAs play a key role in controlling cardio homeostasis in response to pathological and mechanical stress. The lab is currently testing the therapeutic potential of miRNAs in protecting heart from myocardial infarction. The ultimate goal of the Wang lab is to delineate the molecular pathways for the development and function of cardiovascular system and to use this information to design pharmacologic and genetic therapies for human cardiovascular diseases, cardiac hypertrophy and heart failure. In his presentation, Dr. Wang will discuss one of their recent studies focusing on the Trbp-miR-208a-Sox6 pathway in cardiac function and cardiomyopathy. (Research in the Wang laboratory is supported by National Institutes of Health (NIH), American Heart Association (AHA) and Muscular Dystrophy Association (MDA)) Big Data: linking arrows to targets. Pedro ACM Fernandes, Gabriela S. Kinker, Luiza E. Ostrowski, Regina P. Markus. Department of Physiology, Bioscience Institute, University of São Paulo, SP/Brazil. The generation/analyzes of huge amount of biological data increased the detection of hidden patterns, correlations and the emerge of unexpected insights which resulted in new strategies to evaluate and understand healthy and pathological conditions. Efforts toward the integration of correlational and causal data adds speed and reliability to biomedical researches. In this sense, our group have been addressing the role of the melatonergic system on the development and therapeutics of several solid tumors. Based on the concept of the immune-pineal axis characterized in in the last 20 years, we hypothesized that the production of melatonin by tumor cells would affect cell fate and disease progression. Using public data sets, we designed a predictive model of melatonin content in tumor microenvironments, the ASMT:CYP1B1 index, combining the gene expression levels of melatonin synthesis and metabolism enzymes. In fact, this index was shown to be an independent prognostic factor for glioma, medulloblastoma, bladder urothelial carcinomas, cervical/endocervical cancers, colorectal adenocarcinomas, lung squamous cells carcinomas, pancreatic adenocarcinomas, paraganglioma/pheochromocytomas, stomach adenocarcinomas, and endometrial cancer. In this sense, patients with reduced predictive melatonin production presented lower survival. Accordingly, we confirmed that the synthesis of human glioma and medulloblastoma cell lines reduces cell proliferation on a melatonin receptor dependent manner. Using in vitro, in vivo and in silico strategies, we are addressing the specific roles of melatonergic receptors on the development of solid tumors. In the future, the combination of experimental background to big data analysis, focusing in the association of known oncostatic pathways to the melatonergic system could lead to multitarget strategies in the treatment of tumors. Financial support: FAPESP (2013/13691-1; 2015/23348-8).


Cytokines, Toll-like Receptors and Heart Failure. Pawan K. Singal, PhD, DSc Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada We and others have reported that heart failure subsequent to myocardial infarction is associated with an increase in

tumor necrosis factor- (TNF-) and a decrease in interleukin-10 (IL-10). In isolated cardiomyocytes, IL-10 has been

shown to antagonize the pro-apoptotic effect of TNF-. Although the anti-apoptotic action of IL-10 in cardiomyocytes is now generally accepted, its molecular basis is not yet well understood. We studied the differential role of Toll-like Receptors (TLR4 and TLR2) and its downstream signals in the survival of adult cardiomyocytes in the presence of IL-10, Il-10-/- and ischemia/reperfusion (I/R). In IL-10 stimulated cardiomyocytes, TLR4 expression followed the upregulation of myeloid differentiation primary gene 88 (MyD88). Its activation led to IRF3 dimerization and phosphorylation which

augmented IL-1 translational activity. Increase in TLR2 in IL-10-/- hearts indicated its negative regulation by IL-10.

Circulating and myocardial levels of TNF-α were higher in IL-10-/- hearts. The ex-vivo I/R of the hearts caused a marked upregulation of TLR2. However, 40min reperfusion with IL-10 triggered an increase in TLR4 expression. Increase in interleukin-1 receptor-associated kinase-M (IRAK-M) and IRAK-2 activity during I/R injury suggested their role in TLR2

signaling. Inhibition of MyD88 modulated IL-10 induced expression of TLR4, IRF3-dependent IL-1 production and NFB p65 phosphorylation and translocation. These data suggest that IL-10 through TLR4 activation, may be a key molecule in restoring heart health from I/R injury. (Supported by CIHR.) The crosstalk between aldosterone and inflammation in the cardiovascular system. Thiago Bruder-Nascimento; Nathanne S. Ferreira; Rita C. Tostes. Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP, Brazil. Inflammation is a key feature of aldosterone-induced vascular damage and dysfunction, but molecular mechanisms by which aldosterone triggers inflammation remain unclear. The NLRP3 inflammasome is a pivotal immune sensor that recognizes endogenous danger signals triggering sterile inflammation. After a brief overview of the effects of aldosterone in the innate and adaptive immune systems, we will discuss data showing that NLRP3 inflammasome plays a central role in aldosterone-induced vascular dysfunction, including that 1) chronic infusion of aldosterone in mice results in elevation of plasma interleukin-1β (IL-1β) levels as well as vascular abnormalities; 2) mice lacking the IL-1β receptor (IL-1R) or inflammasome components, NLRP3 and caspase-1, are protected from aldosterone-induced vascular damage; 3) aldosterone stimulates NLRP3-dependent IL-1β secretion by bone marrow-derived macrophages, by activating NF-kB signaling and reactive oxygen species generation; and 4) NLRP3 in immune cells mediates aldosterone-induced vascular damage. Data to be presented supports the idea that NLRP3 inflammasome, via activation of IL-1 receptor, is critically involved in the deleterious vascular effects of aldosterone. Financial Support: FAPESP-CRID, CNPq and CAPES. Redox regulation of hepatic lipid metabolism and its effects on the cardiovascular system. Markus Bachschmid, Shao Di, Jingyan Han, Maya Kim, Lija Swain Francesca Seta, Richard A. Cohen, Reiko Matsui (Boston University, EUA) Nonalcoholic fatty liver (NAFL) is a common liver disease associated with metabolic syndrome, obesity, and diabetes that is rising in prevalence worldwide. Various molecular perturbations of key regulators and enzymes in hepatic lipid metabolism cause NAFL. However, redox regulation through glutathione (GSH) adducts in NAFL remains largely elusive. Glutaredoxin-1 (Glrx) is a small thioltransferase that removes protein GSH adducts without having direct antioxidant properties. The liver contains abundant Glrx but its metabolic function is unknown. Here we report that normal diet-fed Glrx-deficient mice (Glrx-/-) spontaneously develop obesity, hyperlipidemia, and hepatic steatosis by 8 months of age. Adenoviral Glrx repletion in the liver of Glrx-/- mice corrected lipid metabolism. Glrx-/-mice exhibited decreased sirtuin-1 (SirT1) activity that leads to hyperacetylation and activation of SREBP-1 and upregulation of key hepatic enzymes involved in lipid synthesis. We found that GSH adducts inhibited SirT1 activity in Glrx-/- mice. Hepatic expression of nonoxidizable cysteine mutant SirT1 corrected hepatic lipids in Glrx-/- mice. Wild-type mice fed high-fat diet develop metabolic syndrome, diabetes, and NAFL within several months. Glrx deficiency accelerated high-fat-induced NAFL and progression to steatohepatitis, manifested by hepatic damage and inflammation. Furthermore, the perturbed lipid metabolism in Glrx-/- mice accelerated atherosclerosis in the carotid arteries and cardiac hypertrophy. We provide a novel redox-dependent mechanism for regulation of hepatic lipid metabolism, and propose that upregulation of hepatic Glrx may be a beneficial strategy for NAFL. Funding: This work was support by American Heart Association and National Institutes of Health grants 16GRNT27660006, 15POST21790006, 14SDG20140036, R01 DK103750, and RO1 HL133013. Matrix metaloproteinases and oxidative stress in the vascular remodeling of hypertension. Michele M. de Castro. Department of Pharmacology Ribeirao Preto Medical School University of Sao Paulo Hypertension is a chronic disease characterized by maladaptive vascular remodeling and excessive oxidative stress. Increased formation of peroxynitrite in the vasculature may contribute to extra- and intracellular proteolytic effects of matrix metalloproteinase (MMP)s, a group of zinc-dependent endopeptidases especially known to contribute to tissue


remodeling. In fact, increased levels of reactive oxygen and nitrogen species (RONS) activates important signaling pathways such as focal adhesion kinase and MAPK into the vascular smooth muscle cells that leads to increase expression of MMP-2 and cells migration and proliferation. It contributes to hypertension-induced hypertrophic vascular remodeling, which is associated with increased arterial cross sectional area and media per lumen ratio, and are predictors of many cardiovascular complications. The use of antioxidants generally contributes to decrease hypertrophic vascular remodeling during hypertension by decreasing oxidative stress and also the activity of MMP-2. On the other hand, peroxynitrite also directly activate MMP-2 by S-glutathiolation of its catalytic site, a mechanism in which peroxynitrite and intracellular glutathione react to the cysteine sequence in the catalytic domain of MMP-2, thus disrupting the binding between cysteine and Zn2+. This reaction exposes its catalytic domain without removing the pro-peptide, and may occur inside the cells in oxidative stress conditions. Increased MMP-2 activated by S-glutathiolation occurred in aortas of endotoxemic and hypertensive rats and then contributed to proteolyze calponin-1, an important intracellular protein and differentiation marker of vascular smooth muscle cells. During early hypertension, decreased levels of calponin-1 by MMP-2 contributed to stimulate vascular smooth muscle cells proliferation and medial hypertrophy, and treatment with an MMP inhibitor or antioxidant significantly restored these effects and decreased hypertension-induced hypertrophic remodeling. Financial support: FAPESP, CNPQ and FAEPA. Reconstructed Human Epidermis for safety assessment and early drug development. Rodrigo De Vecchi (Episkin Academy) Drug discovery process cost time and money, thus early prediction of human hazard avoid termination of promising candidates in latest development stages. Pharmaceutical and Dermocosmetic industries are increasingly using the Reconstructed Human Epidermis (RHE) model for tests like skin permeation, inflammatory response, UV-induced effects, hormone metabolism, anti-aging and pigmentary disorders. Continuous optimization of RHE model has increased its predictivity, as a valuable tool for research and development of new drugs and formulas. Moreover, the possibility of easily combining diverse cell types with epidermal keratinocytes allows disease modelling, such as melanoma and psoriasis. Differentiation markers expression, such as keratins, integrins, fibronectin, involucrin, filaggrin and transglutaminase, can also be measured in similar levels to the human epidermis. In 2003, the 7th Amendment to the Cosmetics Directive introduced in Europe the regulatory framework for the phasing out of animal testing for cosmetics purposes. Since 2013, this testing and marketing ban fully entered in force and is now part of the European Cosmetic Regulation. Following this European regulation, OECD countries show a strong trend for progressive shifting from animal to non-animal methods, especially for toxicological tests of ingredients and final products. Mechanistic approaches to replace the animal are based on in silico, in chemico and in vitro assays and can inform on one or more key events of Adverse Outcome Pathways (AOP). To be as predictive as possible of human being, such individual in vitro test systems rely more and more on cells of human origin with a 3D organization allowing a better mimic to the in vivo condition. To this point of view, Reconstructed Human Epidermis (RHE) presents several advantages that make it an alternative method of choice for evaluating some safety endpoints, including correlation level. To date, several alternative methods in toxicology have been developed based upon in vitro skin: Skin penetration, skin corrosion and irritation, phototoxicity and genotoxicity. However, an in vitro alternative method must be validated before being recognized by the concerned regulatory bodies. Today, two alternative methods based on in vitro skin models have been validated as full replacement methods to animal: the OECD-TG 431, for in vitro skin corrosion, and the OECD-TG 439 for in vitro skin irritation of new drugs and excipients. Moreover, two other methods based on human reconstructed epidermis and full thickness models have been submitted for validation, namely skin sensitization and genotoxicity. Financial support: L´Oréal Research & Innovation THC, GPR119 and the metabolic syndrome. Kenneth Paul Mackie (Indiana University, USA). THC, GPR119, and the metabolic syndrome. Mackie, K. (Bloomington, IN, USA)1, Dhopeshwarker, A. (Bloomington, IN, USA) Indiana University and the Gill Center, Bloomington, IN, USA Cannabis use is highly prevalent in many populations, and its use is likely to increase following ongoing legalization efforts around the world. While the cognitive and psychiatric consequences of chronic cannabis use have been much studied, fewer studies have investigated the metabolic effects of long-term cannabis use. n individual’s metabolic state is a likely target for cannabis as several of the compounds abundant in cannabis (e.g., delta-9-tetrahydrocannabinol, THC) directly affect feeding behaviors and/or metabolism. There is a well-defined role for the endocannabinoid system in promoting energy storage and cannabis use is popularly known to enhance consumption of calorically dense food ( K “the munchies”). These observations suggest that chronic cannabis users would be at risk for increased obesity, the metabolic syndrome, and type II diabetes. However, several studies have found the opposite. These studies find that chronic cannabis use is often associated with a decreased body mass index (BMI), a decreased incidence of the metabolic syndrome, and a decreased risk for developing type II diabetes. The mechanism for this is unclear—stimulation of CB1 cannabinoid receptors by THC would be expected to increase consumption of calorically rich foods and increase fat deposition. Thus, it is possible that THC is targeting other receptor(s) involved in metabolism whose engagement by THC leads to favorable metabolic consequences. We have found that THC activates GPR119 in a


biased fashion. GPR119 is G protein-coupled receptor activated by lipids such as oleoylethanolamine and 2-oleoyl glycerol. It is found in pancreatic islets and enteroendocrine cells in the gut. Activation of GPR119 increases insulin and incretin (e.g., GLP-1) secretion. Plasma and gut contents are unlikely to contain THC at concentrations sufficient to activate GPR119. However, we have found that certain THC metabolites, some of which are present at micromolar concentrations in bile, activate GPR119 to increase GLP-1 secretion from an enteroendocrine cell line. Finally, in diet-induced obese mice, low dose (3 or 10 mg/kg) THC for two weeks causes significant weight loss. (−)-β-Caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor paralysis and neuroinflammation in a murine model of multiple sclerosis. Rafael Cypriano Dutra Laboratory of Autoimmunity and Immunopharmacology (LAIF), Department of Health Sciences, Center Araranguá, Universidade Federal de Santa Catarina, Araranguá, SC, Brazil. Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating disease of the central nervous system (CNS), and is the most common cause of non-traumatic neurologic disability in young adults, affecting over two million people worldwide. The mean age of onset is approximately 30 years, and almost 70% of patients manifest symptoms between 20 and 40 years; which causes permanent disability and compromises quality of life. MS causes a multitude of symptoms, including motor, cognitive and sensorial deficits, besides emotional, visual and bladder disturbances. Currently, there is no cure for demyelinating diseases and their progression, and since symptoms tend to vary within the patients, seeking early treatment is essential. Β-caryophyllene (BCP), a cannabinoid receptor type 2 (CB2)-selective phytocannabinoid, has already been shown in precedent literature to exhibit both anti-inflammatory and analgesic effects in mouse models of inflammatory and neuropathic pain. In this project, we attempted to investigate the therapeutic potential of BCP on experimental autoimmune encephalomyelitis (EAE), a murine model of MS. Financial Support: CNPq; FAPESC; PGN/UFSC; Faculty of Pharmaceutical Sciences/UFPA.

Cannabinoids, neuroplasticity and antidepressant drugs: Is there a Link? Alline Cristina Campos (FMRP-USP) Although several studies and clinical reports have demonstrated the efficacy of antidepressants, such as escitalopram, their clinical application is often associated with delayed therapeutic response, important side effects and low rates of response due treatment-resistance. Similar to clinically used antidepressants, cannabinoids can also regulate anxiety and depressive symptoms. Although the mechanisms of these effects are not completely understood, recent evidence suggests that changes in endocannabinoid system could be involved in some actions of antidepressants. Chronic antidepressant treatment modifies the expression of CB1 receptors and endocannabinoid (EC) content in brain regions related to mood and anxiety control. Moreover, both antidepressant and cannabinoids activate mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase(PI3-K)/Akt or PKB signalling, intracellular pathways that regulate cell proliferation and neural cell survival. Facilitation of hippocampal neurogenesis is proposed as a common effect of chronic antidepressant treatment. Genetic or pharmacological manipulations of cannabinoid receptors (CB1 and CB2) or enzymes responsible for endocannabinoid-metabolism have also been shown to control proliferation and neurogenesis in the hippocampus. Preliminary results from our groups suggest that cannabinoids participate in the behavioral and neuroplastic events induced by chronic treatment with escitalopram. Moreover, the combination of sub-effective doses of antidepressant and cannabinoids reduces the latency for the behavioral effects produced by the former. We believe that considering the widespread brain distribution of the EC system, a better understanding of this possible interaction could contribute to the development of therapeutic alternatives to mood and anxiety disorders. Financial support: F PESP, L’oreal-UNESCO-ABC. Polypharmacology in a single drug: multitarget drugs against complex diseases. Maria Laura Bolognesi . Department of Pharmacy and Biotechnology, Alma Mater Studiorum- University of Bologna, Italy Extending opportunities beyond the "one drug, one target" philosophy, polypharmacology offers a concrete model to develop medicines most suited to treating currently incurable diseases, such as neurodegenerative and neglected infectious diseases. It is driven by a global demand for safer, more effective, and affordable therapies against these complex diseases, and by the frequent failures of current drug discovery to provide these. Indeed, multitarget drugs opens up new prospects to tackle both efficacy and safety issues, which are key reasons for attrition and drug failure in these therapeutic areas. Although relatively new, polypharmacology in these fields has grown enormously over the last ten years, and drugs have already been introduced into the market. The successful clinical use of safinamide has demonstrated that a drug with a rationally designed multitarget mechanism of action would not have intrinsically overwhelming toxicity, even for the diseased Parkinson brain. In the infectious diseases field, several clinical candidates have demonstrated positive effects, by overcoming resistance and increasing potency. However, such promising molecules can be remarkably complex to obtain in terms of both design and optimization, and pharmacological profiling. In particular, two major issues arise when dealing with multitarget compound discovery and development: i) design of compounds with balanced profile against two or more targets; ii) in vitro and in vivo pharmacodynamics evaluation to understand the role of each target modulation on the overall pharmacological profile. In this lecture, we will discuss how we have tried to overcome these difficulties and developed small molecules with a hopefully improved profile against the two


diseases. Acknowledgments: This work was supported by University of Bologna, MIUR, Rome (PRIN Funds 201274BNKN_003) and Cost Action CA15135. Searching New Multi-Target Directed Drug Candidate Prototypes for lzheimer’s Disease: a case of novel feruloyl-donepezil hybrids. Claudio Viegas Jr. PeQuiM – Laboratório de Pesquisa em Química Medicinal, Institute of Chemistry, Federal University of Alfenas – UNIFAL-MG The design of Multi-target directed ligands is the most current rational strategy to access new drug candidates for multifactorial diseases like cancer, diabetes and neurodegenerative disorders, among others. In this context, a novel series of feruloyl-donepezil hybrid compounds were designed, synthesized and evaluated as multitarget drug candidates for the treatment of Alzheimer's Disease (AD). In vitro results revealed potent acetylcholinesterase (AChE) inhibitory activity for some of these compounds and all of them showed moderate antioxidant properties. Compounds (E)-(1-benzylpiperidin-4-yl)methyl-3-(4-hydroxy-3-methoxyphenyl)acrylate (12a), (E)-(1-(4-nitrobenzyl)piperidin-4-yl)methyl-3-(4-hydroxy-3-methoxyphenyl)acrylate (12b) and (E)-(1-(4-bromobenzyl)piperidin-4-yl)methyl-3-(4-hydroxy-3-methoxyphenyl)acrylate (12c) were the most potent AChE inhibitors, highlighting 12a with IC50= 0.46mM. In addition, these three most promising compounds exhibited significant in vivo anti-inflammatory activity in the mice paw edema, pleurisy and formalin induced hyperalgesy models, in vitro metal chelator activity for Cu2+ and Fe2+, and neuroprotection of human neuronal cells against oxidative damage. Molecular docking studies corroborated the in vitro inhibitory mode of interaction of these active compounds on AChE. Based on these data, compound 12a was identified as a novel promising drug prototype candidate for the treatment of AD with innovative structural feature and multitarget effects. Keywords: Feruloyl-donepezil hybrids, Alzheimer's disease, Multitarget-directed ligands Acknowledgements: The authors are grateful to the Brazilian Agencies CAPES, FAPEMIG, CNPq, INCT-INOFAR and FINEP for financial support and fellowships.

Discovery of multitarget prototypes for treatment of multifactorial diseases: N-acylhydrazone framework as privileged structure. Carlos Alberto Manssour Fraga. Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil The growing impact of the network pharmacology in the discovery of new drugs useful for treatment of multifactorial diseases changed the classical idea originally supported by Ehrlich's philosophy of magic bullets, which states that an efficient biologically active compound should act selectively on some specific disease-related biomacromolecule. The combination of two or more clinically validated therapeutic targets with mutual participation in specific multifactorial diseases can represent an interesting strategy to increase the available pharmacological space for the discovery of new drug candidates.

1 Emerging from this new Medicinal Chemistry approach, the concept of multitarget drugs appears as

an interesting therapeutic innovation in the search for more efficient and safe drugs for treating chronic diseases, by combining in a single molecular architecture structural requirements able to assure it molecular recognition by two or more distinct biological targets, involved in the same disease. In our research group, i.e. LASSBio-UFRJ, we have successfully exploited the N-acylhydrazone (NAH) framework as a privileged structure2 to the identification of compounds able to be selectively recognized by different biotargets, such as adenosine A2A receptors, PDE-4 inhibitors3 and selective inhibitors of HDAC6 and HDAC8,4 among others. This peptidomimetic framework, which is resultant from the fusion between amide and imine subunits, is able to provide points of interaction with a wide range of amino acid residues, comprising both H-bond acceptor and donor sites.

5 So, this lecture describes the structural design of novel

NAH compounds and their ability to modulate multiple targets associated with the target chronic disease. Acknowledgements: Thanks are due to INCT-INOFAR (BR), CNPq (BR) and also to FAPERJ (BR) for the financial support and fellowships. References: 1 Barreiro, E.J. & Fraga, C. A. M. Curr. Drug Ther. 2008, 1; 2Duarte, C. D.; Barreiro, E. J.. & Fraga, C. A. M. Mini-Rev. Med. Chem. 2007, 1108; 3Kümmerle, A. E. et al. J. Med. Chem. 2012, 55, 7525; 4Rodrigues, D. A. et al. J. Med. Chem. 2016, 59, 655; 5Senger, M. R.; Fraga, C. A. M. & Silva-Jr, F. P. Drug Discov. Today 2016, 21, 868. IUPHAR, How to address modern molecular pharmacology via international collaboration: impact on drug discovery and development, and on natural products. Michael Spedding1,2, 1Secretary General, IUPHAR ; 2Spedding Research Solutions SAS,6 Rue Ampère, Le Vésinet 78110, France. [email protected] The world is awash with scientific data, but interpretation for therapeutic benefit lags far behind. This is particularly difficult for the pharmaceutical industry because, there are so many new concepts, drug discovery becomes even more challenging. IUPHAR provides a precompetitive level playing field for collaboration between pharmaceutical industry, biotechs, and academics. IUPHAR has structured modern pharmacology by its nomenclature committee (NC-IUPHAR) and created 90 subcommittees of expert pharmacologists (and published>100 articles, h-index 75), setting up a series of web sites for education and research described in the online webinar (https://www.icsu-wds.org/news/news-archive/webinar-11) including the pharmacology education project, the guidetopharmacology, and now the guidetoimmunopharmacology, thanks to major grants from the Wellcome Trust and British Pharmacological Society (BPS). IUPHAR is therefore prioritizing the new variables and translational pharmacology:


a. Alternative splicing of proteins: Bonner TI et al (2014) Br J Pharmacol: 171, 1231-40 b. Receptor polymorphisms. c. Epigenetic drug targets: Tough DF et al, Br J Pharmacol: 171, 4981-510, d. Allosteric modulation of these targets: Christopoulos A et al (2014) Pharm Rev: 66, 918-47, e. Immunological/inflammatory targets: Tiligada E et al (2015) Br J Pharmacol: 172, 4217-4227. We have started a major initiative on natural products, via the Pharmacology of Natural Products Section to define molecular sites of action, in particular the anti-inflammatory/immunological effects, collaborating with IUIS.




Poster Session 1 – Oct 18, 2017

01. Cellular and Molecular Pharmacology

01.001 Angiotensin II induces extracellular vesicle production in vascular smooth muscle cells. Frony AC1, Renovato-Martins M2, Moraes JA3, Barja-Fidalgo C1 1UERJ – Biologia Celular e Molecular, 2LADETEC-IQ UFRJ, 3ICB-UFRJ

01.002 H2S is a key antisecretory molecule against cholera toxin-induced diarrhoea in mice: evidence for non-involvement of the AC/CAMP/PKA pathway and AMPK. Sousa FBM1, Souza LKM1, Araújo TSL1, Sousa NA1, Araújo S2, Silva RO3, Nicolau LAD3, Souza FM1, Silva IS4, Souza MHLP3, Medeiros JVR2 1Renorbio – Farmacologia, 2UFPI – Farmacologia, 3UFC – Farmacologia e Fisiologia, 4UFMG – Farmacologia e Fisiologia

01.003 Antinociceptive effect of imidazole alkaloids in inflammatory nociception: Role of cyclooxygenase. Rocha TM1, Silva MGV1, Moreira R2, Guedes RC2, Sousa JAC1, Leite JRSA3, Lima DF4, Leal LKAM1 1UFC, 2Universidade de Lisboa, 3UnB, 4UNIVASF

01.004 Putative alpha1d / alpha1a-Adrenoceptors heterodimerization in the abdominal aorta from preeclamptic rats. Silva KP1, Kiguti LRA1, Lim L2, Kocan M2, Summers RJ2, Caldeira-Dias M1, Sandrim V1, Pupo AS1 1IBB-Unesp – Farmacologia, 2Monash University – Drug Discovery Biology

01.005 Melanoma-derived microvesicles switch neutrophils phenotype in vitro Guimarães-Bastos D, Frony AC, Saldanha-Gama R, Barja-Fidalgo C, Moraes JA UERJ

01.006 Zymosan promotes IL-1β processing through NLRP3/ SC/Capsase-1 inflammasome independently of phagocytosis. Silva RL, Lopes AHP, Fonseca MD, Colon D, Saraiva ALL, Zamboni SD, Cunha FQ, Cunha TM FMRP-USP

01.007 PPARg blockage do not restore insulin sensitivity in pioglitazone treated adiponectin knockout mice possibly by a miR-222 dependent mechanism. Mendonca M1, Paixão AO1, Sousa E1, Rodrigues AC1 1ICB-USP – Farmacologia

01.008 Fenofibrate prevents weight gain through hypothalamic leptin resistance improvement in DIO mice Rocha KC1,

Santos BAC1, Rodrigues AC1 1USP – Farmacologia

01.009 LPS-induced acute epididymitis changed the functional alpha-1 adrenoceptor subtype in the cauda epididymis smooth muscle Mueller AM1,2, Silva AAS1, Silva EJR1, Pupo AS1 1IBB-Unesp – Farmacologia, 2UFMT-Campus de Sinop – Farmácia

01.010 New insights on β-defensins: differential expression in the central nervous system. Freitas GA2,1, Scavone C1, Pinna G3, Avellar MCW2 1ICB-USP – Farmacologia, 2Unifesp-EPM – Farmacologia, 3University of Illinois

01.011 Uvaol stimulates endothelial cell migration and fibronectin production in vitro. Carmo JOS1, Ferro JNS1, Correia ACC2, Barreto E1 1ICBS-UFAL, 2UPE-Campus Garanhuns-PE

01.012 Inhibitory Apoptosis Proteins (IAPs) as targets for anticancer therapy: Heterologous expression of XIAP Silva CSMR1, Branco PC2, Barbosa GH3, Paula C Jimenez3, Costa-Lotufo LV2 1UFSCar, 2ICB-USP, 3Unifesp

01.013 Influence of antipsychotics on leukocyte telomere length. Polho GB1, Cardillo GM2, Kerr DS, Gattaz WF2, Forlenza OV2, Brentani H3, Paula VJR3 1FMUSP – Acadêmico, 2FMUSP – Neurociências, 3FMUSP – Psicobiologia

01.014 Increased ROS production and P2Y2 receptor-mediated leukocyte adhesion to mesenteric endothelial cells during schistosomiasis. Monteiro MML1, Pereira LM1, Lanzetti M1, Valença SS1, Silva CLM1 1UFRJ – Farmacologia e Inflamação

01.015 Desensitization of Alpha-1a Adrenoceptors by Dopamine Wandekin RR, Pupo AS IBB-Unesp – Farmacologia

01.016 Evaluation of Mitochondrial Metabolism in Different Pharmacological Models of Amyotrophic Lateral Sclerosis. Brito MD, Rosenstock TR FCMSCSP – Ciências Fisiológicas

01.017 Epinephrine enhances osteoblastic differentiation of mesenchymal stem cells from spontaneously hypertensive rats (SHR) Barreto AEA1,2, Brito VGB1,2, Beltran CT1, Queiroz DP1,2, Oliveira SHP1,2 1FOA-Unesp – Ciências Básicas, 2FOA/Unesp/SBFis

01.018 Disassemble caveolae structure does not change the proteoglycans syndecan-2 and glypican-1 present on the endothelial glycocalyx. Potje SR1, Grando MD1, Antoniali C2, Bendhack LM1 1FCFRP-USP – Física e Química , 2FOA-Unesp – Ciências Básicas

01.019 Modulation of oxidative stress in vascular muscle cells from renal hypertensive rats by co-culture with endothelial cells. Paulo M1,2, Grando MD2, Vercesi JA2, Minshall RD1, Bendhack LM2 1University of Illinois at Chicago, 2FCFRP-USP – Física e Química

01.020 Functional new world monkey oxytocin forms elicit an altered signaling profile and promote parental care in rats. Parreiras-e-Silva LT1, Vargas-Pinilla P2, Duarte DA1, Longo D2, Espinoza-Pardo GV2, Finkler AD2, Paixão-Côrtes VR3, Paré P2, Rovaris D2, Oliveira EB1, Caceres RA4, Gonçalves G2, Bouvier M5, Salzano FM2, Lucion AB2, Costa-Neto CM1, Bortolini MC2 1FMRP-USP – Biochemistry and Immunology, 2UFRGS, 3UFBA, 4UFCSPA, 5University of Montreal

01.021 Is there a differential expression pattern of the β-defensin SPAG11C in hippocampus and cortex during aging? Machado IN1, Arantes G1, Viel TA2, Buch HS3, Avellar MCW1 1Unifesp-EPM, 2EACH-USP, 3FCMSCSP


01.022 Microparticles derived from obese adipose tissue elicit a pro-inflammatory phenotype of CD16+, CCR5+ and TLR8+ monocytes. Renovato-Martins M1, Andrade IR2, Matheus E3, Moraes JA3, Silva SV2, Souza AAP4, Silva CC4, Bouskela E5, Barja-Fidalgo C2 1UFRJ – Química Biológica, 2UERJ – Biologia Celular e Molecular, 3UFRJ – Farmacologia, 4UFRJ – Cirurgia, 5UERJ – Ciências Fisiológicas

01.023 Role of the fructose 1,6-bisfosfato on osteoclastogenesis and bone resorption in vitro. Wilches-Buitrago L1, Fukada SY2 1USP – Farmacologia, 2USP – Física e Química

02. Neuropharmacology

02.001 Pharmacogenetic inactivation of neuronal ensembles of the pre-limbic cortex attenuated the context-induced reinstatement of alcohol seeking. Palombo P1, Zaniboni CR1, Moreira J1, Bianchi PC2, Leao RM3, Planets CS2, Santos PCJL1, Cruz FC1 1Unifesp – Farmacologia, 2FCFar-Unesp-Araraquara, 3UFBA

02.002 Cannabinoid type 1 receptors in the dorsal hippocampus modulate autonomic responses and late behavioral consequences induced by acute restraint stress in rats. Hartmann A1, Fassini A1, Scopinho A1, Correa FM1, Guimarães FS1, Lisboa SF1, Resstel LBM1 1FMRP-USP – Farmacologia

02.003 Nitric oxide modulates DNA methylation and DNMT3b expression in the hippocampus. Maciel IS1, Sales AJ1, Biojone C2, Casarotto PC2, Castrén E2, Joca SRL3 1FMRP-USP – Farmacologia, 2University of Helsinki – Neuroscience Center, 3FCFRP-USP – Física e Química

02.004 The endocannabinoid system as a target for novel antipsychotic drugs. Pedrazzi JFC1, Issy AC2, Guimarães FS3, Del Bel EA2 1FMRP-USP – Neurociências, 2FORP – Fisiologia, 3FMRP-USP – Farmacologia

02.005 Activity-dependent neuronal klotho production induces astrocytic lactate release through FGFR1 activation and ERK phosphorylation. Mazucanti CH1, Kawamoto EM1, Mattson MP2, Camandola S2, Scavone C1 1ICB-USP – Farmacologia,

2NIH-NIA

02.006 The Medial Prefrontal Cortex CRF1 but not CRF2 receptors modulate the tachycardic component of the baroreflex activity. Lagatta DC, Bruffato JPT, Uliana DLM, Borges-Assis AB, Resstel LBM FMRP-USP – Farmacologia

02.007 The BNST endocannabinoid system modulates learned, but not innate fear in rats. Borges-Assis AB, Uliana DLM, Resstel LBM FMRP-USP – Farmacologia

02.008 Extrapyramidal effects induce by metoclopramide in mice. Prieto SG1, Torres CV1, França KC2, Echeverry MB1 1UFABC – Neurociências e Cognição, 2Universidade Metodista de São Paulo –Ciências Médicas e da Saúde

02.009 P2X receptors modulate depressive-related behavior and antidepressant effect. Ribeiro DE2,1, Stanquini LA2, Roncalho AL2, Silva MAP3, Casarotto PC4, Biojone C4, Pereira VS1, Abildgaard A1, Müller HK1, Elfving B1, Wegener G1, Joca SRL3,1,2 1Aarhus University – TNU, 2FMRP-USP, 3FCRP-USP, 4University of Helsinki – Neuroscience Center

02.010 Evaluation of anti-Alzheimer effects of tacrine dimers in animals with peptide β1-42-induced Alzheimer. Gonçalves AE1, Mariano LNB1, Silva LM1, Aquino RAN, Fatima A2, Andrade SF1, Souza MM1 1Univali – Ciências Farmacêuticas, 2UFMG – Química

02.011 Long-term changes in schizophrenia symptoms-related behaviors induced by repeated exposure to a cannabinoid agonist during pre-puberty and puberty in mice. Gonçalves PFR1, Cardoso AR2, Castro NG1, Neves G1 1UFRJ – Farmacologia e Química Medicinal, 2UFRJ

02.012 Combined use of alcohol and cigarette smoke increases pro-inflammatory cytokines and decreases BDNF levels in the frontal cortex of rats. Paula LF1, Quinteros DA2, Bandiera S2, Hansen AW2, Pulcinelli RR2, Bobermin L3, Quincozes-Santos A3, Gomez R2 1UFRGS – Acadêmico, 2PPGFT-UFRGS – Farmacologia e Terapêutica, 3UFRGS – Ciência Biológicas: Bioquímica

02.013 Effect of the combined use of alcohol and cigarette smoke on oxidative stress parameters in different brain areas of rats. Nietiedt NA1, Quinteros DA2, Garofalo CB1, Paula LF1, Bandiera S2, Pulcinelli RR2, Hansen AW2, Bellaver B3, Quincozes-Santos A3, Gomez R2 1UFRGS – Acadêmico, 2PPGFT-UFRGS – Farmacologia e Terapêutica, 3UFRGS -: Bioquímica

02.014 Investigation of the effects of caffeine on the ansiogenic changes caused by ethanol intoxication in binge pattern in female rats from adolescence to the adulthood. Silva CCS1, Pinheiro BG2, Fernandes LMP2, Melo AS2, Luz DA2, Maia CDSF1 1UFPA – Farmácia, 2UFPA – Neurociências e Biologia Celular

02.015 Central administration of cyclic Glycine-Proline (cGP) induced antidepressant-like effect in the mouse forced swimming test. Cavalcante GTS, Souza FMA, Santos-Neto JG, Nicácio DCSP, Mendes RA, Dias-Batista JB, Maciel DM, Duzzioni M UFAL – Farmacologia

02.016 PTEN deletion effects on neuronal morphology. Mello NP, Cabral-Costa JV, Mazucanti C, Scavone C, Kawamoto E ICB-USP


02.017 (−)-β-caryophyllene suppresses motor paralysis and neuroinflammation in a murine model of multiple sclerosis through CB2 cannabinoid receptor Alberti TB1, Gonçalves ECD1, Barbosa WLR2, Vieira JLF3, Raposo NRB3, Dutra RC1 1UFSC – Ciências da Saúde, 2UFPA – Ciências Farmacêuticas, 3UFJF – Ciências da Saúde

02.018 Time-dependent dual effect of pilocarpine in non-convulsive mice in the forced swimming test. Souza FMA1, Santos-Neto JG1, Nicácio DCS1, Cavalcante GTS1, Mendes RA1, Dias-Batista JB1, Duarte FS2, Lima TCM3, Duzzioni M1 1UFAL – Farmacologia, 2UFPE – Farmacologia e Fisiologia, 3UFSC – Farmacologia

02.019 Effect of repeated taurine administration on voluntary alcohol consumption and on behaviors in rats. Pulcinelli RR1, Nietiedt NA2, Paula LF2, Garofalo CB2, Bandiera S1, Hansen AW1, Almeida RF3, Fontella FU3, Gomez R1 1UFRGS – Farmacologia e Terapêutica, 2UFRGS – Acadêmico, 3UFRGS – Bioquímica

02.020 A single systemic injection of pilocarpine induces short- and long-term anxiogenic-like effects in non-convulsive mice. Nicácio DCSP1, Souza FMA1, Santos-Neto JG1, Cavalcante GTS1, Mendes RA1, Dias-Batista JB1, Maciel DM1, Duarte FS2, Lima TCM3, Duzzioni M1 1UFAL – Farmacologia, 2UFPE – Farmacologia e Fisiologia, 3UFSC – Farmacologia

02.021 Intrahippocampal injection of OUA triggers dendritic branching in neurons and memory improvement in adult rats. Orellana AM1, Leite JA1, Kinoshita PF1, Andreotti DZ1, Sá LL1, Kawamoto EM1, Scavone C1 1ICB-USP – Farmacologia

02.022 Evaluation of pain sensitivity in mice submitted to sporadic lzheimer’s-like dementia. Souza MM1, D'Aquino MS2, Solanha RL2, Gonçalves AE2 1Univali – Bioquímica e Farmacologia, 2NIQFAR-Univali

03. Psychopharmacology

03.001 Tactile stimulation prevents cocaine-induced depressive behavior in rats. Roversi KR, Antoniazzi CTD, Burger ME UFSM – Fisiologia e Farmacologia

03.002 Cannabidiol treatment reverses behavioral changes in a model of schizophrenia based on antagonism of NMDA receptors: possible involvement of 5-HT1A, but not CB1 or CB2 receptors. Rodrigues NS1, Sonego AB1, Silva NR1, Gomes FV

2, Guimarães FS

1 1FMRP-USP – Farmacologia,

2University of Pittsburgh – Pharmacology

03.003 Anandamide signaling neuromodulation in the dorsomedial hypothalamus attenuates the defensive behaviour displayed by mice threatened by rainbow Boidae wild snakes. Anjos-Garcia T1, Falconi-Sobrinho LL1, Coimbra NC1 1FMRP-USP – Farmacologia

03.004 Cannabidiol prevents impaired processing of conditioned fear in a rat model of ptsd: involvement of nitrergic and serotonergic systems. Vila-Verde C1, Lisboa SF1, Uliana DLM1, Restel LBM1, Guimarães FS1 1FMRP-USP – Farmacologia

03.005 Effect of scopolamine on persistence of object location memory in rats. Rohde BZ, Souza LB, Ramos D, Porto GP Unifra

03.006 Investigation of the possible antipsychotic effect of HU-910, a selective Type-2 cannabinoid receptor (CB2) agonist. Cortez IL1, Rodrigues NS1, Silva NR1, Mechoulam R2, Guimarães FS1 1FMRP-USP, 2Hebrew University

03.007 The combination of sub-effective doses of escitalopram and cannabidiol accelerates the onset of antidepressant effects in chronically stressed mice. Scarante FF1, Fusse EJ1, Aguiar RP2, Duarte-Souza PC1, Detoni VL1, Scomparin DS1, Guimarães FS1, Campos AC1 1FMRP-USP – Farmacologia, 2UEM – Ciências Farmacêuticas

03.008 Effect of allopregnanolone on depressive-like behavior of selectively-bred rats with high and low immobility profiles. Almeida FB1, Fonseca AR1, Heidrich N1, Silva FFS1, Costa LB1, Fernandes PR1, Freese L1, Nin MS2,1, Barros HMT1 1UFCSPA – Farmacociências, 2Centro Universitário Metodista IPA – Farmácia

03.009 Antidepressant-like activity of Colletia paradoxa Sprengel mediated by monoamines and sodium channel, changes Na(+),K(+)-ATPase activity in cortex and hippocampus of mice. Stein DF1, Machado CP1, Holtermann AR2, Linares CEB2, Giacomelli SR2, Santos KF2, Carvalho F3, Gutierrez J3, Cenci L2, Driemeier D4, Stein AC2 1UFRGS – Ciências Farmacêuticas, 2URI – Ciências Farmacêuticas, 3UFSM – Bioquímica Toxicológica, 4UFRGS – Patologia

03.010 Purinergic receptors p2x7 are involved in extinction but not reconsolidation of contextual fear conditional responses in rodents. Domingos LB1, Hott SC2, Terzian ALB1, Resstel LBM1 1USP – Farmacologia, 2UFES – Ciências Farmacêuticas

03.011 Cocaine oral self- administration by ADHD male and female rats with neonatal injury with 6-OHDA. Fernandes PR, Umpierrez LS, Barros HMT UFCSPA – Farmacologia

03.012 Fluoxetine facilitates consolidation of fear memory extinction through BDNF/TrkB hippocampal. Diniz CRAFD, Antero LS, Resstel LBM, Joca SRL

03.013 Physical exercise alters saccharin and ethanol self-administration learning and reward. Engi SA1, Crestani CC2, Planeta CS2, Cruz FC1 1Unifesp-EPM – Farmacologia, 2FCFar-Unesp-Araraquara – Princípios Ativos Naturais e Toxicologia

03.014 Adolescent exposition to a synthetic cannabinoid WIN55,212-2 modulates the cocaine-reward in mice. Gobira PH1, Silote GP1, Joca SRL1 1FCFRP-USP – Farmacologia e Toxicologia de Produtos Naturais


03.015 Context-induced reinstatement of alcohol seeking is associated with unique molecular alterations in prelimbic cortex neuronal ensembles Cruz FC1, Palombo P1, Bianchi PC2, Engi SA1, Planeta CS2, Leão RM3 1Unifesp-EPM – Farmacologia, 2PANT-FCFar-Unesp-Araraquara, 3UFBA – Biorregulação

03.016 Vapor Inhalation of alcohol reduces the resilience of Wistar rats to context-induced the reinstatement of alcohol seeking. Leão RM1, Palombo P2, Bianchi PC3, Oliveira-Carneiro PE4, Planeta CS3, Cruz F2 1UFBA – Biorregulação, ICS, 2Unifesp-EPM – Farmacologia, 3PANT-FCFar-Unesp-Araraquara, 4UFSCar

04. Inflammation and Immunopharmacology

04.001 TRPV1 deletion protects against cerebral malaria in mice. Pereira DMS, Murillo O, Peixoto EPM, Teixeira SA, Araújo MC, Monteiro-Neto V, Cunha TM, Marinho CRF, Muscará MN, Fernandes ES ICB-USP

04.002 The inflammatory response is an important part of the myonecrosis induced by snake venoms: neutralization by wedelolactone and dexamethasone. Patrão-Neto FC1, Monteiro-Machado M1, Tomaz MA1, Oliveira FL2, Moraes JA3, Melo PA1 1UFRJ – Farmacologia e Química Medicinal, 2ICB-UFRJ – Proliferação e Diferenciação Celular, 3ICB-UFRJ – Biologia Redox

04.003 Effect of n-acetylcysteine in hepatic oxidative stress in mice with severe ulcerative colitis. Andrade KQ1, Araújo ORP2, Martins ASP3, Moura FA4, Azevedo MLSG5, Goulart MOF2 1IBCCF-UFRJ, 2IQB-UFAL, 3 ICBS-UFAL, 4FANUT-UFAL – Nutrição, 5UFAL – Química e Biotecnologia

04.004 Quercetin suppression of pulmonary fibrosis triggered by silica particles in Swiss-Webster mice. Guimarães FV, Ferreira TPT, Arantes ACS, Alexandre TL, Martins MA, Silva PMR Fiocruz – Inflamação

04.005 Proteinase-activated Receptor (PAR)-2 Blockade Impairs Ovalbumin-induced Airway Inflammation Matos NA1, Lima OCO1, Rocha LK1, Mattos MS1, Alvarez ARP2, Ferreira RG2, Silva JF1, Lemos VS1, Alves-Filho JC2, Russo RC1, Tavares JC

1, Klein A

1 1ICB-UFMG – Farmacologia e Fisiologia,

2FMRP-USP – Farmacologia

04.006 Immunometabolic reprograming play a critical role in the pathogenesis of psoriasis through a PKM2-dependent mechanism. Veras FP1, Melo B1, Prado D1, Norbiato TS1, Melo P1, Costa L2, Cecilio N1, Publio G1, Schüller R4, Nikolaev A3, Lima D4, Alves M5, Cunha TM1, Nakaya H1,4, Sales KU5, Souza C2, Cunha FQ1, Waisman A3, Alves-Filho JC1 1CRID-FMRP-USP – Pharmacology, 2FMRP-USP – Dermatology, 3University Medical Center of the Johannes Gutenberg – Molecular Medicine, 4FCF-USP – Clinical and Toxicological Analyses, 5FMRP-USP – Cell, Molecular Biology and Biopathogenic Agents

04.007 Loss of capacity to up-regulate MKP-1 and down-regulate PP38 and GATA-3 underline glucocorticoid insensitivity in allergic asthma changes in A/J mice. Cotias AC1, Pão CRR1, Daleprane JB2, Couto GC1, Anjos-Valotta EA1, Cordeiro RSB1, Silva PMR1, Serra MF1, Martins MA1 1Fiocruz – Fisiologia e Farmacodinâmica, 2UERJ – Nutrição Básica e Experimental

04.008 Resolvin E1 reduces rat paw edema and nociception locally through leukotriene B4 receptor type one. Fonseca FCS, Turchetti-Maia RMM, Francischi JN UFMG – Farmacologia

04.009 Analysis of regulatory role of 5- and 12-Lipoxygenase pathways in skeletal muscle regeneration events induced by a myotoxin. Damico MV1, Zuntini ACS1, Fortes-Dias CL2, Spadacci-Morena DD3, Moreira V1 1Unifesp – Farmacologia, 2Fundação Ezequiel Dias – Pesquisa e Desenvolvimento, 3IBu – Fisiopatologia

04.010 Anti-inflammatory effect of trans-resveratrol loaded lipid-core nanocapsules on acute lung injury induced by LPS in mice. Oliveira MTP

1, Souza ET, Coutinho DS

1, Guterres SS

2, Pohlmann AR

2, Silva Martins PMR

1, Martins MA

1, Bernardi A

1

1Fiocruz, 2UFRGS

04.011 Hydrogen Sulfide (H2S) cutaneous biosynthesis is impaired in psoriasis: Role of exogenous supply of H2S. Rodrigues L1, Schimidt T1, Cerqueira ARA1, Soares AG1, Whiteman M2, Teixeira SA1, Muscará MN1, Costa SK1 1ICB-USP – Farmacologia, 2University of Exeter – St. Luke's Campus

04.012 Fructose 1,6-bisphosphate, a glycolytic metabolite, tunes the metabolic reprogram of pro-inflammatory macrophages. Viacava PR1, Nascimento DRB, Luiz JPM, Veras FP, Ferreira RG, Vitorino CA, Peres RS, Cunha FQ, Cunha TM, Alves-Filho JCF FMRP-USP

04.013 Effects of Resolvin D1 treatment on eosinophilic inflammation in lean and obese mice. Tavares EBG, André DM, Calixto MC, Antunes E Unicamp – Farmacologia

04.014 ERK5 is a molecular switch that controls the fate between Th17 and Treg cell differentiation and development of experimental autoimmune encephalomyelitis. Prado DS1, Damasceno LEA1, Ferreira RG1, Cunha TM1, Cunha FQ1, Ryffel B2, Alves-Filho JC1 1FMRP-USP – Farmacologia, 2CNRS – Immunologie et Neurogénétique Expérimentales et Moléculaires

04.015 Involvement of vasoactive amines in the anti-inflammatory mechanisms of sulfated polysaccharides from the alga Gracilaria birdiae. Soares VVM

1, Frota AF

1, Castro LGZ

1, Souza RM

1, Coura CO, Benevides NMB

1

1UFC – Bioquímica e

Biologia Molecular


04.016 Signaling pathway involved in the inhibitory effect of tumor necrosis factor alpha on platelet aggregation of rats: Role of SRC, PKC, IKK and MAP Kinases. Bonfitto PHL, Naime ACA, Bueno PI, Antunes E, Marcondes S FCM-Unicamp – Farmacologia

04.017 Blends of chitosan/polivinilalchool/macauba pulp oil in the wound cicatrization. Duarte LC1, Silva GGO2, Albuquerque TB1, Moreno SE2, Domingues NLC3 1UFGD – Biotecnologia, 2UCDB – Biotecnologia, 3UFGD – Química Orgânica

04.018 Effect of acetylcholine on the contractility of the ileum of wild type and P2X7-/- mice. Coutinho-Silva R1, Andrade KQ1, Silva CLM2 1UFRJ – Biofísica, 2UFRJ – Ciências Biomédicas

04.019 Anti-inflammatory of the N-Methyl-Trans-4-Hydroxy-L-proline isolated from the leaves of Sideroxylon obtusifolium. Carvalho MAJ1, Aquino PEA1, Silveira ER2, Costa RO3, Souza AG1, Lima KA1, Cavalcante TMB4, Viana GSB1, Fonteles MMF1 1UFC – Farmacologia, 2UFC – Química, 3UFC – Ciências Morfológicas e Fisiológicas, 4UFC

04.020 Nebulized gold nanoparticles down-regulates inflammation and lung remodeling in a murine model of steroid-resistant asthma via AKT suppression and HDAC2 activation. Serra MF1, Pimentel A S1, Cotias AC1, Lanzetti M1, Hickmann J2, Arantes ACS1, Silva PMR1, Cordeiro RSB1, Barreto E2, Martins MA1 1Fiocruz – Fisiologia e Farmacodinâmica, 2UFAL

04.021 Refractoriness of macrophages from atypical chemokine receptor (ACKR)2 mice towards stimulation to LPS and silica particles in vitro. Correa AMC, Dias DF, Sá YAPJ, Ferreira TPT, Serra MF, Martins MA, Martins PMRS Fiocruz

04.022 Production and release of pro-inflammatory cytokines induced by agonists of different toll like receptors on glial satellite cells in vitro. Domingues LM, Lopes AH, Silva RL2, Cunha TM – FMRP-USP – Farmacologia

04.023 Mechanism of anti-inflammatory action of Croton campetris essential oil and β-caryophyllene constituent – MAACCEOBCC. Oliveira-Tintino CDM1, Pessoa RT2, Fernandes MNM2, Alcântara IS2, Silva BAF2, Oliveira MRC2, Martins AOBPB

3, Menezes IRA

2 1UFPE – Antibióticos,

2Urca – Química Biológica,

3UFPE – Fisiologia e Farmacologia

04.024 A late component of neurogenic inflammation in the long-lasting orofacial model of oedema in rats. Queiroz BFG1,

Almeida MP1, Francischi JN1 1UFMG – Farmacologia

04.025 Succinate receptor GPR91 is critical for development of experimental psoriasis. Norbiato TS, Veras FP, Melo B, Saraiva A, Ryffel B, Cunha TM, Cunha FQ, Alves-Filho JC FMRP-USP

04.026 The alarmin S100A9: A key target for treatment of psoriasis .Melo B1, Protasio F1, Prado D1, Costa L2, Souza C2, Lima D3, Nakaya H3, Cunha T1, Cunha F1, Alves-Filho JC1 1FMRP-USP – Farmacologia, 2FMRP-USP, 3FCF-USP – Análises Clínicas e Toxicológicas

04.027 Influence of cyclooxygenase-2-derived prostaglandins on skeletal muscle degeneration and regeneration events. Zuntini ACS1, Damico MV1, Fortes-Dias CL2, Spadacci-Morena DD3, Moreira V1 1Unifesp-EPM – Farmacologia e Inflamação, 2Fundação Ezequiel Dias, 3IBu – Fisiopatologia

04.028 Mast cells depletion improves bone markers expression on mandible of spontaneously hypertensive rats with periodontal disease. Brito VGB1,2, Barreto AEA1,2, Patrocinio MS1, Sousa MCL1, Beltran CT1, Queiroz DP1,2, Vieira LV1,2, Lara V3, Santos CF4, Oliveira SHP1,2 1FOA-Unesp – Ciências Básicas, 2FOA-Unesp-SBFis, 3FOB-USP – Ciências Biológicas, 4FOB-USP – Estomatologia

04.029 Dimethylfumarate: Comprising its harmful effects in topical application. Prudente AS, Lückemeyer DD, Ferreira AM, Macedo Juniro SJ, Ferreira J UFSC – Farmacologia

04.030 Modeling acute exacerbation of chronic obstructive pulmonary disease by combining cigarette smoke inhalation and H1N1 infection in mice. Ferrero MR1, Ferreira TPT1, Torres J1, Bento S1, Arantes AC1, Coutinho D1, Garcia CC2, Martins MA1 1Fiocruz – Farmacologia e Inflamação, 2Fiocruz – Respiratory Virus and Measles

04.031 Characterization of model equivalent to sunburn induced by Ultraviolet B radiation in skin of Hairless mice. Freitas KM1, Barcelos LS2, Caliari MV3, Lopes MTP4 1UFOP – PPGBIOTEC/NUPEB, 2ICB-UFMG – Biofísica e Fisiologia, 3ICB-UFMG – Patologia, 4ICB-UFMG – Biofísica e Farmacologia

04.032 Dilodendron bipinnatum extract ameliorates TNBS-induced colitis in rats by inhibiting TNF-α, supporting mucus production and promoting antioxidant effect. Oliveira RG2,1, Ferreira LA2, Miyajima F3, Pavan E1, Damazo AS1, Martins DTO1 1UFMT – Basic Sciences in Health, Faculty of Medicine, 2UNIC – Pharmacy, 3UFC – Neuropharmacology, Drug Research and Development

04.033 Corticosterone and melatonin crosstalk in controlling inflammatory processes in toads (Rhinella ictérica). Bastos PR1, Cruz-Machado SS1, Markus RP1, Gomes FR1, Ferreira ZS1 1IB-USP – Fisiologia

04.034 Melatonin (MEL) synthesis by pineal gland is regulated by fungi and bacterial infectionMelatonin (MEL) synthesis by pineal gland is regulated by fungi and bacterial infection. Silva-Souza E, Cruz-Machado SS, Markus RP IB-USP – Fisiologia


04.035 A novel monocyte subset contributes to clearance of damage tissue during sterile inflammation and bacterial infection in the liver. Dal-Secco D1, Jenne CN2, Kolaczkowska E2, Wong CHY2, Petri B2, Ransohoff RM3, Charo IF4, Kubes P2 1UFSC – Farmacologia, 2University of Calgary, 3Lerner Research Institute, 4University of California

04.036 Liposomes of phosphatidylserine inhibit the respiratory burst induced by LPS, Zymosan or PMA in murine macrophages. Charão CCT1, Assreuy J2 1UFSC – Ciências Fisiológicas, 2UFSC – Farmacologia

05. Pain and Nociception Pharmacology

05.001 Related mechanisms of C5a/C5aR during neuropathic pain. Quadros AU1, Fonseca MMD

2, Ferreira MD

3, Sagar

DR4, Cunha FQ2, Chapman V4, Cunha TM2 1FM-USP – Farmacologia, 2FMRP-USP – Farmacologia, 3FMRP-USP – Bioquímica e Imunologia, 4University of Nottingham – School of Life Sciences

05.002 Antinociceptive effect of aripiprazole by PI3K/AKT/NO/cGMP/KATP pathway activation. Ferreira RCM, Pelaez JMN, Capettini LSA, Duarte IDG, Aguiar DC, Moreira FA, Romero TRL ICB-UFMG - Farmacologia

05.003 Arthritis-induced hyperalgesia in the TMJ of rats activates microglial cells from the trigeminal subnucleus caudalis. Bonfante R1, Rocha-Neto LM1, Abdalla HB1, Macedo CG2, Napimoga HN2, Clemente-Napimoga JT2 1FOP-UNICAMP – Ciências Fisiológicas, 2São Leopoldo Mandic – Imunologia e Biologia Molecular

05.004 Diabetes inhibits Na+/K+/ATPase in the peripheral neurons of trigeminal system. Rocha-Neto LM1, Furtado FF1, Bonfante R1, Abdalla HB1, Macedo CG2, Clemente-Napimoga JT2,1 1Unicamp – Fisiologia, 2Faculdade São Leopoldo Mandic – Fisiologia

05.005 Role of TRPA1 receptor in the nociception induced by irritants compounds in mice. Oliveira JRJM1, Norões MM2, Gonçalves MC3, Ferreira J3, André E1 1UFPR – Farmacologia, 2UFRN – Biofísica e Farmacologia, 3UFSC – Farmacologia

05.006 Interaction between hydrogen sulfide (H2S) and the different redox species of nitric oxide (NO) – Effects on nociception and inflammation in the rat temporomandibular joint (TMJ). Oliveira MF, Sandy MV, Teixeira SA, Costa SKP, Muscará MN ICB-USP – Farmacologia

05.007 N-Acylhydrazone derivative (LASSBio-1027) ameliorates hypernociception in acute and chronic pain murine model. Rezende B1, Montes GC, Fraga CAM, Barreiro EJ, Zapata-Sudo G, Sudo RT ICB-UFRJ

05.008 Mechanisms involved in the antinociceptive and anti-inflammatory effects of [4”,5”] dihydro-obovatin on a pre-clinical model of temporomandibular joint pain. Gomes FIF1, Do Val DR2, Santos RS1, Arriaga AMC3, Bezerra MM1, Chaves HV1 1UFC – Farmacologia, 2UFPE – Biotecnologia, 3UFC – Química Orgânica

05.009 Beneficial effect of lodenafil and sildenafil in reducing neuropathic pain signs in rats submitted to spinal nerve ligation. Silva CFB, Montes GC, Zapata-Sudo G, Sudo RT ICB-UFRJ – Pesquisa em Desenvolvimento de Fármacos

05.010 Angiotensin II Type 2 receptor activation is involved in an acute gouty attack in rodents. Vieira TN1, Ferreira J2, Silva CR1 1UFU – Genética e Bioquímica, 2UFSC – Farmacologia

05.011 Structural analogue of eugenol exhibits antinociceptive activity in mice. Aragão Neto HC, Fonsêca DV, Braga RM, Almeida RN UFPB – Psicofarmacologia

05.012 Evaluation of the toxicological activity and anotinociceptive potential of rose oxide in rodents. Leite LCTF, Piauilino CA, Lopes EM, Lima MPD, Aguiar LCT, Sousa DP, Almeida FRC UFPI – Farmacologia

05.013 Further investigation of antinociceptive and pronociceptive mechanisms of Acmella oleracea in mice. Dallazen JL1,2, Maria-Ferreira D1, Luz BB1, Nascimento AM1, Cirpriani TR1, Souza LM3, Werner MF1 1UFPR, 2Farmacologia, 3Instituto de Pesquisa Pelé Pequeno Príncipe

05.014 CAV2.3 knockdown reduces the secondary hyperalgesia induced by capsaicin. Ferreira MA1, Lückemeyer DD1, Gonçalves MC2, Prudente AS1, Macedo Junior SJ1, Ferreira J1 1UFSC, 2UFPR

05.015 Antihyperalgesic and anti-inflammatory activity of the hexanic and hydroalcoholic fractions extracted from Piper glabratum in mice. Leitão MM1, Santos JA1, Mota J2, Kassuya CAL1 1UFGD – Ciências da Saúde, 2UEMS – Química

05.016 Antinociceptive activity of LQFM 096, a new triazolic derivative. Cardoso CS1, Silva DPB1, Silva DM1, Florentino IF1, Vasconcelos JP2, Leão LM3, Menegatti M2, Costa EA1 1UFG – Farmacologia, 2UFG – Farmácia, 3UFG – Química

06. Cardiovascular and Renal Pharmacology

06.001 Pharmacological evaluation of a novel sulfohylhydrazone derivative (LASSBIO-1772) for the treatment of Type 2 diabetes in rats. Araújo JSC, Eccard BOA, Ramires MS, Delgobbo MS, Silva TF, Trachez MM, Lima LM, Barreiro EJL, Sudo RT, Zapata-Sudo G 1UFRJ – Desenvolvimento de Fármacos

06.002 Maternal exposure to fluoxetine during gestation and lactation decreases aortic contraction in adult female offspring: role of neuronal nitric oxide synthase. Higashi CM1, Sartoretto SM2, Echem C2, Carvalho MHC2, Pelosi GG1, Pinge-Filho P

3, Gerardin DCC

1, Moreira EG

1, Akamine EH

2, Ceravolo GS

1

1UEL – Ciências Fisiológicas,

2ICB-USP,

3UEL –

Patologia

06.003 Increased kidney Alpha1 adrenergic receptor density during sepsis. Rosales TO, Assreuy J UFSC – Farmacologia


06.004 Human mesenchymal stem cell therapy reverses Sugen5416/hypoxia-induced pulmonary arterial hypertension in mice. Silva AMS1, Alencar AKN1, Montes GC1, Mendes LVP1, Montagnoli TL1, Toledo MF2, Cunha VMN1, Fraga AG1, Pimentel-Coelho PM2, Mendez-Otero R2, Sudo RT1, Zapata-Sudo G1 1UFRJ – Programa de Pesquisa em Desenvolvimento de Fármacos, 2IBCCF-UFRJ

06.005 Oxidative stress induced by NO sintase uncoupling is responsible for sodium nitrite vascular tolerance. Araújo NF1, Reis D1, Nóbrega N1, Simplicio JAP2, Tirapelli CR2, Bonaventura D1 1UFMG – Farmacologia, 2USP – Enfermagem Psiquiátrica e Ciências Humanas

06.006 Influence of perivascular adipose tissue in vascular dysfunction of sepsis. Barp CG, Benedet PO, Assreuy J UFSC – Farmacologia

06.007 Hydrogen Sulfide (H2S) attenuates hypertension in pregnancy and blunts fetal growth restriction through an increase in placental efficiency in hypertensive pregnant rats. Possomato-Vieira JS, Chimini JS, Santos-Silva ML, Gonçalves-Rizzi VH, Dias-Junior CA IBB-Unesp – Farmacologia

06.008 Novel DPP4 inhibitor reduces cardiac and vascular dysfunction induced by diabetes Type 2 in rats. Eccard B1, Reina E1, Araújo JSC1, Barreiro EJ1, Lima LM1, Trachez MM2, Sudo RT1, Zapata-Sudo G1 1UFRJ, 2UFF

06.009 Perivascular adipose tissue modulates vascular tone in mice via renin angiotensin system. Nóbrega N, Reis D, Facine LM, Araújo N, Miranda C, Mota G, Capettini L, Bonaventura D UFMG – Fisiologia e Farmacologia

06.010 High-carbohydrate diet-induced obesity enhanced the anticontractile effect of Perivascular Adipose Tissue (PVAT) through activation of renin-angiotensin system. Reis D1, Silveira ALM2, Campos-Mota GP1, Nóbrega N1, Araújo NF1, Capettini LSA1, Ferreira AVM2, Bonaventura D1 1UFMG – Farmacologia, 2UFMG – Bioquímica e Imunologia

06.011 ANG II effects on rat aorta taken from rats submitted to adjuvant induced arthritis. (AIA) Tozzato GPZ1, Chies AB2 1IBB-Unesp,

2FAMEMA

06.012 Activation of matrix metalloproteinase-2 by oxidative stress decreases Calponin-1 and contributes to vascular remodeling in hypertension. Parente JM1, Mello MMB1, Chan BY2, Schulz R2, Castro MM1 1FMRP-USP – Farmacologia, 2University of Alberta – Pediatrics & Pharmacology

06.013 NLRP3 inflamasome contributes to endothelial dysfunction in mesenteric resistance arteries from type 1 diabetic mice. Pereira C1, Ferreira NS2, Zanotto CZ1, Carlos D3, Passaglia RT2 1FMUSP – Farmacologia, 2FMRP-USP – Farmacologia, 3FMRP-USP – Bioquímica e Imunologia

06.014 Deletion of the α7 nicotinic acetylcholine receptor changes the vascular remodeling induced by transverse aortic constriction in mice. Alves LF, Neto FPS, Seemann H, Santuchi MC, Alcântara TC, Lemos VS, Guatimosin S, Fernandes R UFMG

06.015 Periodontitis affects soluble guanylate cyclase function and hydrogen sulfide production in the rat mesenteric artery. Jesus FN, Teixeira SA, Costa SKP, Muscará MN ICB-USP – Farmacologia

06.016 AT1 receptors activation increases the reactive oxygen species (ROS) in renal hypertensive rats. Fahning BM, Bendhack LM FCFRP-USP

06.017 Carvacrol reduced blood pressure and improved vasodilatation: Role of TRPV4 and oxidative stress. Dantas BPV, Lima FO, Castro MVEA, Almeida AJPO, Santos PF, Ribeiro TP, Medeiros IA UFPB – Ciências Farmacêuticas

06.018 Carvacrol increases calcium levels dependent on TRPV4 endothelial cells. Dantas BPV1, Castro MVEA1, Lima FO1, Almeida AJPO1, Santos PF, Ribeiro TP1, Medeiros IA1 1UFPB – Ciências Farmacêuticas

06.019 Pharmacological evaluation of new acylhydrazone derivates in platelet aggregation. Autran LJ, Lima GF, Motta NAV, Brito FCF UFF – Farmacologia e Fisiologia

06.020 Hydrogen Sulfide (H2S) donor presents antihypertensive and antioxidant effects and attenuates fetal growth restriction in hypertensive pregnant rats. Santos-Silva ML, Possomato-Vieira JS, Chimini JS, Dias-Junior CA IBB-Unesp – Farmacologia

06.021 The evolution of cardiac dysfunction programmed by hyperleptinemia neonatal with aging. Marques EB1, Souza

KP1, Macedo FS2, Rocha NN1, Fernandes-Santos C2, Scaramello CBV1 1UFF – Farmacologia e Fisiologia, 2UFF – Neurociências

06.022 Potential cardioprotective effect of spironolactone is related to the QT interval shortening and ventricular diastolic relaxation in isolated rat heart. Silva-Neto JA, Oliveira VR, Souza DS, Sousa AA, Silva GBA, Vasconcelos CML UFS – Fisiologia

06.023 Effects of a hyperlipidic diet based on egg yolk and butter on cardiovascular system: functional, biochemical and molecular aspects. Silva RM, Marques EB, Rocha NN, Scaramello CBV UFF

06.024 Can LASSBio788 or LASSBio1425 modulate Ca2+ homeostasis in rats fed with a hypercholesterolemic diet? Pedro S, Farias R, Araújo G, Marques E, Motta N, Kümmerle AE, Maia R, Mansour CA, Barreiro E, Brito F, Scaramello C UFF


06.025 Cardiac alterations observed in early weaned male rats are related to the modulation of autonomic response and to left ventricular hypertrophy Alvim-Silva T1, Barros RBM1, Oliveira DF2, Macedo FS3, Fernandes-Santos C3, Nascimento JHM2, Scaramello CBV1 1UFF – Farmacologia e Fisiologia, 2UFRJ – Biofísica, 3ISNF-UFF

06.026 Does perinatal undernutrition raise cardiovascular risk in pre-pubertal and pubertal male and female rats? Farias RS, Araújo GA, Marques EB, Scaramello CBV UFF – Fisiologia e Farmacologia

06.027 In blood vessels, APO effect is associated with its antioxidant activity and inhibition of NAD(P)H oxidase. Ferreira BHSH1, Graton ME2, Troiano JA2, Potje SR3, Ximenes VF4, Antoniali C2 1Centro Universitário Toledo – Unitoledo, 2FOA-Unesp – Ciências Básicas, 3FCFRP-USP – Física e Química , 4Faculdade de Ciências – Química

06.028 Effects of chronic asenapine treatment on blood pressure in rats Campos HA1, Campos HM1, Neri HFS1, Oliveira TS1, Brito RB1, Filgueira FP2, Ghedini PC1 1UFG – Farmacologia, 2UFG – Ciências da Saúde

06.029 Chronic administration of asenapine does not alter the vascular function of rat thoracic aorta Campos HM1, Campos HA1, Neri HFS1, Oliveira TS1, Brito RB1, Brito RB1, Filgueira FP2, Ghedini PC1 1UFG – Farmacologia, 2UFG – Ciências da Saúde

06.030 Effects of NALP3 inflamassome inhibition with glibenclamide on the cardiac hypertrophy induced by a refined carbohydrate enriched-diet. Castor RGM1, Lopes PD1, Bruno AS1, Almeida DL1, Ferreira AJ2, Romero MGMC1, Cau SBA1 1UFMG – Farmacologia e Fisiologia, 2UFMG – Biologia Celular e Molecular

06.031 Influence of physical exercise on SHR rats treated with losartan. Watai P1, Castro QJT1,2, Silva SSC1, Becker LK1,3, Nogueira HN1, Guimarães AG1,4 1UFOP – Acadêmico, 2UFMG, 3CEDUFOP, 4CIPharma

06.032 Intrauterine and lactation exposure to fluoxetine blunted in the offspring the aortic adaptive response induced by acute restraint stress. Moura FK1, Marques VDB1, Novi RBSD1, Zanluqui GN2, Picinin R1, Pinge FP2, Gerardin CCD1, Gomes GP

1, Moreira EM

1, Ceravolo GS

1 1UEL – Ciências Fisiológicas,

2UEL – Patologia

06.034 Evaluation of pharmacological effects of inosine on hypercolesterolemic rats. Lima GF, Motta NAV, Autran LJ, Brito FCF UFF – Farmacologia e Fisiologia

06.035 Prazosin recovers the reduced response to vasoconstrictors induced by sepsis. Grando J, Assreuy J UFSC – Farmacologia

06.036 Investigation of anti-inflammatory and antioxidant activities of cilostazol in hypercholesterolemic rats. Lopes RO1, Motta NAV1, Lima GF1, Brazão SC1, Brito FCF1 1UFF – Farmacologia e Fisiologia

06.037 Evaluation of cardiovascular risk in descendants of female rats submitted to energy restriction during lactation. Fernandes ILM, Marques EB, Scaramello CBV UFF – Farmacologia e Fisiologia

06.038 Endothelium-dependent vasodilator effect of extract and fractions of the leaves from Plinia cauliflora. Vasconcelos WP1, Paula PL2, Lemos VS3, Castilho RO2, Côrtes SF1 1ICB-UFMG – Farmacologia, 2UFMG – Farmácia -, 3ICB-UFMG – Fisiologia e Biofísica

06.039 Chitosan nanoparticle as a promising carrier of nitric oxide donors in the treatment of hypertension. Carvalho CC1, Pinheiro LC1, Oliveira-Paula GH1, Pelegrino MT2, Seabra AB2, Tanus-Santos JE1 1USP – Farmacologia, 2UFABC – Centro de Ciencias Naturais e Humanas

06.040 Pravastatin attenuates increased blood pressure and fetal growth restriction in hypertensive pregnant rats. Chimini JS, Possomato-Vieira JS, Santos-Silva ML, Dias-Junior CA IBB-Unesp – Farmacologia

06.041 Time course effects of Tempol on nitric oxide metabolites levels after sodium nitrite treatment Ferreira GC, Pinheiro LC, Damacena-Angelis C, Portella RL, Oliveira-Paula GH, Tanus-Santos JE

06.042 Increased gastric pH impairs the antihypertensive effects of oral nitrite by reducing gastric nitric oxide formation. Sanches-Lopes JM, Ferreira GC, Pinheiro LC, Tanus-Santos JE FMRP-USP – Farmacologia

06.043 Prostanoids influence angiotensin II responses in mesenteric veins of from 2-KIDNEY-1-CLIP hypertensive rats during acute exercise. Oliveira PB, Pita LM, Oliveira PR, Chies AB FAMEMA – Pharmacology

07. Endocrine, Reproductive and Urinary Pharmacology

07.001 Spirulina platensis supplementation improves rat erections in a model of erectile dysfunction induced by hypercaloric diet. Souza ILL, Barros BC, Ferreira ES, Carvalho MTL, Interaminense LFL, Cavalcante FA, Silva BA DCF-UFPB

07.002 Aldosterone-induced cavernosal tissue impaired function depends on the NLRP3 activation in hematopoietic cells. Fais RS, Nascimento TB, Ferreira NS, Mestriner F, Tostes RC, Carneiro FS FMRP-USP – Farmacologia

07.003 CL 316,243 Fails to improve insulin sensitivity in diet-induced obese male mice offspring. Sousa E, Rodrigues AC ICB-USP – Farmacologia

07.004 Protective effect of supraphysiological testosterone replacement in voiding dysfunction in ovariectomized rat is estrogen-independent. Bonilla-Becerra SM, Oliveria MG, Calmasini FB, Rojas-Moscoso JA, Tobar N, Antunes E Unicamp – Farmacologia


07.005 Identification of a potential therapeutic target for abnormally invasive placenta. Botelho RM1, Silva ALM1, Souza LPG1, Pires KSN1, Santos JC1, Gonçalves CM1, Silva EMP1, Oliveira HGS1, Carmo JOS1, Borbely KSC1, Silva SV2, Freitas VM2, Borbely AU1 1UFAL, 2USP

07.006 The role of adenosine receptor A2A on the hyperactivity of hypothalamus-pituitary-adrenal axis observed in diabetic animals. Buriche ALR, Magalhães NS, Silva PMR, Martins MA, Carvalho VF Fiocruz

07.007 Effects of bacterial endotoxins on sperm parameters in a rat model of epididymitis reveal potential pathogen-specific male fertility outcomes. Silva AAS1, Mueller A1, Kushima H1, Ribeiro CM2, Avellar MCW2, Silva EJR1 1Unesp-Botucatu – Farmacologia, 2Unifesp – Farmacologia

07.008 Tissue- and gender-specific expression profile of the male contraceptive target epididymal protease inhibitor (Eppin) in mice. Camara AC, Kushima H, Silva EJR IBB-Unesp – Farmacologia

07.009 The guanine-based purines produced relaxation in isolated corpus cavernosum from mice. Nicoletti AS, Antunes E, Mónica FZ FCM-Unicamp – Farmacologia

07.010 The androgen regulation on the confluence of innate immunity and epididymal morphogenesis Ferreira LGA1, Ribeiro CM1, Hinton BT2, Avellar MCW1 1Unifesp-EPM – Pharmacology, 2University of Virginia – Cell Biology

07.011 MK 571, a multi-drug resistance protein inhibitor potentiated the relaxing responses in bladder and prostate from mice Bertollotto G, Alexandre EC, Antunes E, Mónica F Z Unicamp – Bioquímica e Farmacologia

07.012 Protein disulfide isomerase: differential gene expression and androgen dependence in the rat epididymis. Fernandes SG1, Benham A2, Avellar MCW1 1Unifesp-EPM – Farmacologia, 2Durham University, UK – Department of Biosciences

07.016 Deciphering Client Binding to PDILT, a Protein Disulfide Isomerase Required For Male Fertility. Alexander M1, Benham A

1 -

1Department of Biosciences, Durham University, UK

08. Respiratory and Gastrointestinal Pharmacology

08.001 Virgin coconut oil supplementation improves airway hyperresponsiveness in guinea-pigs with allergic chronic asthma by rho kinase signaling attenuation. Vasconcelos LHC1, Pessoa LD2, Silva MCC1, Costa AC3, Oliveira GA2, Cavalcante FA4,1, Silva BA5,1 1UFPB – PPgPNSB/CCS, 2UFPB – PIVIC/CNPq, 3UFPB – PIBIC/CNPq, 4UFPB – DFP/CCS, 5UFPB – DCF/CCS

08.002 Promissingtherapeutic approach in GERD: Topical protection to oesophageal mucosa and anti-inflammatory outcome of a biopolymer in mice and human biopsies. Nicolau LAD1,2, Batista-Lima FJ1, Santana AP1, Sales TM3, Oliveira TM4, Medeiros JVR4, Silva DA4, Vale ML1, Nobre-e-Souza MA3, Santos AA1, Sifrim D2, Souza MHP1 1UFC – Fisiologia e Farmacologia, 2Queen Mary University of London – Neurogastroenterology, 3UFC – Ciências Médicas, 4UFPI – Biotecnologia

08.003 “Extracellular cAMP-adenosine pathway” modulates airway smooth muscle contraction via A1 receptor activation Pacini ES, Silveira SS, Godinho RO Unifesp-EPM – Farmacologia

08.004 Relaxant Activity of Two Synthetic Derivatives of the LASSBio-448, a Phosphodiesterase 4 Inhibitor, on Guinea Pig Trachea in a Model of Chronic Allergic Asthma Silva MCC1, Costa AC2, Ferreira SRD1, Nunes IKC2, Moreira LL2, Barreiro EJL2, Cavalcante FA1, Silva BA1 1DCF-DFB-UFPB, 2FQM-LASSBio-UFRJ

08.005 Anti-diarrhoeal therapeutic potential mediated by activation of the angiotensin-converting enzyme II/Ang- (1-7)/Mas receptor axis in mice. Souza LKM1,2, Araújo TSL1, Nogueira KM1, Sousa FBM1, Oliveira AP1, Araújo S1, Sousa NA1, Chaves LS1, Iles B1, Medeiros JVR1 1LAFIDG-UFPI, 2CoPPEx-IESVAP

08.006 Gastroprotective value of berries: Evidences from methanolic extracts of Morus nigra and Rubus niveus fruits. Nesello LAN, Beleza MLML, Mariot M, Mariano LNB, Souza P, Campos A, Cechinel-Filho V, Andrade SF, Silva LM Univali – Ciências Farmacêuticas

08.007 Esophageal mucosal barrier in different phenotypes of gastroesophageal reflux disease (GERD) patients: Diferential effect of topical protection with sulfated polysaccharide obtained for Gracilaria caudata (GC). Sales TMAL

1,

Silva RO2, Nicolau LAD2, Moreira RLR3, Bingana RD3, Alencar POC3, Pereira IS3, Santos AA2,1, Souza MAN1, Barros FCN3, Freitas ALP3, Sifrim D4, Souza MHLP2,1 1UFC – Ciências Médicas, 2UFC – Fisiologia e Farmacologia, 3UFC, 4Queen Mary University of London

08.008 Spasmolitical and antidiarreatic activities promoted by the hexanic extract of the seeds of Platonia insignis Mart. in rodents. Lima IBC1, Fonseca OC1, Negreiros PS1, Almendra RB1, Costa DS1, Araújo LEPF1, Santos TMA1, Citó AMGL2, Costa-Júnior JS3, Oliveira RCM1, Santos RF1 1NPPM-UFPI, 2UFPI – Química, 3IFPI – Química

08.009 Kaempferol and quercitrin: Two flavonoids with gastroprotective and gastric healing effects in rodents. Beber AP, Silva LM, Boeing T, Somensi LB, Mariano LNB, Souza P, Andrade SF Univali


09. Natural Products and Toxinology

09.001 Diuretic effect of Mimosa bimucronata (DC.) Kuntze leaves extracts and its main constituent methyl gallate in rats. Mariano LNB1, Schlickmann F, Boeing T, Silva LM, Steimbach VMB, Krueger CMA, Andrade SF, Cechinel-Filho V, Souza P Univali – Ciências Farmacêuticas

09.002 Chlorella improves health-related quality of life in impaired glucose tolerance and type-2 diabetic patients Martins F1, Castro TCL1, Torello CO1, Fernandes EC2, Toledo JH2, Queiroz MLS1 1FCM-Unicamp – Farmacologia, 2FCM-Unicamp – Ciências Farmacêuticas

09.003 Central antinociception induced by resveratrol is mediated by endogenous opioids, µ-and Δ-opioid receptors. Oliveira CC, Almeida AFS, Teixeira LRM, Noronha TM, Duarte IDG, Santos SHS, Romero TRL, Perez AC UFMG – Fisiologia e Farmacologia

09.004 Chromomycin A2 is a putative modulator of transcription factor TBX2. Sahm BDB, Jimenez PC, Kimani S, Bauermeister A, Lopes NP, Prince S, Costa-Lotufo LV ICB-USP

09.005 Anti-diarrheal therapeutic potential and safety assessment of sulphated polysaccharide from Gracilaria intermedia seaweed in mice. Sousa NA1, Leodido ACM1, Araújo TSL1, Souza LKM1, Sousa FBM1, Filho MDS1, Nogueira KM1, Freitas ALP2, Medeiros JVR1 1UFPI, 2UFC

09.006 Effects of Loxosceles intermedia venom in rats skin Teixeira RGS1, Ribeiro MF1, Garcia TA1, Gama LF1, Bravo TP1, Oliveira KC1, Abreu VS1, Souza CMV2, Calil-Elias S1 1UFF – Farmacologia, 2IVB – Artrópodes

09.007 Evaluation of the renal profile of rats submitted to the subchronic treatment with the essential oil of Zingiber zerumbet. Batista NY1, Graça ACS1, Candido K1, Pessoa EV1, Lima ES2, Correa JWN3 1UFAM, 2UFAM – Ciências Farmacêuticas, 3UFAM – Ciências Fisiológicas

09.008 Effects of copaiba oil in dermonecrosis induced by Loxosceles intermedia venom. Ribeiro MF1, Teixeira RGS1, Garcia TA

1, Oliveira FL

2, Souza AM

1, Machado TB

1, Cardoso PF

3, Júnior SNS

3, Sobrinho AP

3, Nascimento AS

1, Souza CMV

3,

Calil-Elias S1 1UFF, 2UFRJ, 3IVB

09.009 Evaluation of cardiorenal properties and acute toxicity of the Luehea divaricata an indigenous species from Brazilian pantanal. Tirloni CAS, Palozi RAC, Silva AO, Tomazetto TA, Schadler MI, Marques AAM, Gasparotto Junior A UFGD – Ciências da Saúde

09.010 Pharmacological characterization of adenosine action in neuromuscular preparations in vitro. Schezaro-Ramos R, Hyslop S FCM-Unicamp – Farmacologia

09.011 Evaluation of anti-inflammatory, antinociceptive, anxiolytic, antidepressant and anticonvulsant potential of hydroalcoholic extract of Piper aduncum L. (Piperaceae) in Swiss mice. Oliveira ACT1, Aguiar MFR1,2, Feitosa IB1,3, Neves AB1,2, Facundo AV2, Dias QM1,2 1Fiocruz-RO – Neuro e Imunofarmacologia, 2UNIR, 3IBCCF-UFRJ

09.012 Effects of bergenin tratament on the activation of inflammatory mediators on TNBS-induced acute colitis. Oliveira GAL1, Chaves LS2, Sousa FBM1, Pacheco G, Rosillo MAR3, Martinez MLC3, Hidalgo MS3, Villegas I3, Medeiros JVR2, Lastra CA3 1Renorbio, 2UFPI, 3University of Sevilla

09.013 Antinociceptive and anti-inflammatory evaluation of ethanolic crude extract of P1 (EEP1) in rodents Freitas BR1, Lopes KS1, Queiroz LY1, Souza PHFS1, Santos RR1, Oliveira JP2, Silva CYY2, Silva MN2, Fontes-Júnior EA1 1UFPA – Pharmaceutical Sciences,

2UFPA – Organic Chemistry

09.014 Dilodendron bipinnatum Radlk. extract inhibits TNF-α independently of IL-8 in LPS-activated Caco-2 cells. Ferreira LA1,2, Martins DTO3, Miyajima F4, Oliveira RG2,1 1UFMT – Basic Sciences in Health, 2UNIC – Pharmacy, 3UFMT – Basic Sciences in Health, Faculty of Medicine., 4UFC – Neuropharmacology, Drug Research and Development Center

09.015 Endothelium-independent vasorelaxant effect of MTHP is mediate by potassium channels opening in rat thoracic aorta. Oliveira S1, Souza Neta OAC1, Sarmento DV1, Rodrigues LC2, Braga VA2, Vasconcelos U2, Travassos RA3 1UFPB, 2UFPB – Biotecnologia, 3UFPB – Biologia Celular e Molecular

09.016 Cytotoxic Potential of Pradimicin T in Cancer Cells Almeida LC1, Bauermeister A

2, Santos EA

3, Moraes LAB

2, Costa-

Lotufo LV1 1ICB-USP – Farmacologia, 2FFCLRP-USP – Química, 3ICB-USP – Biologia Celular e Desenvolvimento

09.017 Zingiber zerumbet promotes arterial vasodilation by blockade of calcium influx. Graça ACS1, Batista NY1, Pessoa EV1, Pinheiro CCS2, Correa JWN3 1UFAM, 2Inpa, 3UFAM – Ciências Fisiológicas

09.018 Latex proteins from Plumeria pudica ameliorates acetic acid-induced ulcerative colitis. Oliveira NVM, Souza BS, Moita LA, Oliveira LES, Brito FC, Barbosa ALR, Magalhães DA, Batista JA, Sousa SG, Oliveira JS UFPI

09.019 Toxicological assessement of proteins of Plumeria pudica latex in mice. Souza BS, Oliveira NVM, Moita LA, Oliveira LES, Brito FC, Oliveira JS UFPI

09.020 Antioxidant activity and vascular relaxation of selected red grape juices produced in different Brazilian regions. Britto Junior J, Leite KCS, Gil ES, Rocha ML UFG – Ciências Farmacêuticas


09.021 Effects of the infusion of Terminalia catappa leaves on treatment of duodenal injury induced by ischemia-reperfusion in female rats. Ohara R, Périco LL, Rodrigues VP, Santos BB, Santos RC, Santos LC, Vilegas W, Rocha LRM, Hiruma-Lima CA Unesp-Botucatu

09.022 Anticancer potential of marine microorganisms from Baixada Santista. Rigato DB1, Chain BG1, Souza BV1, Domingos HV2, Costa-Lotufo LV3, Branco P2, Jimenez PC1 1Unifesp – Ciências do Mar, 2ICB-USP – Farmacologia, 3USP – Farmacologia

09.023 Biotechnological potential of actinomicetes associated to ascidians and sediments collected at Brazilian oceanic islands. Velasco-Alzate K1, Silva J1, Del Bianco B1, Ferreira MP2, Maldonado GP3, Costa-Lotufo LV1 1ICB-USP – Farmacologia, 2USP, 3ICB-USP – Microbiologia

09.024 Cytotoxic Compounds from Streptromyces sp. Recovered from the ascidian Euherdmania sp. Furtado LC1, Pinto FCL2, Ferreira MJP3, Pessoa ODL2, Wilke DV4, Costa-Lotufo LV1 1ICB-USP – Farmacologia, 2UFC – Química Orgânica, 3USP, 4UFC – Farmacologia e Fisiologia

09.025 Aedes aegypti salivary gland extract inhibits pruriceptive responses via histaminergic and non histaminergic pathways. Cerqueira ARA1, Rodrigues L1, Teixeira SA1, Taniguchi ÉY, Muscará MN1, Cassola AC2, Sá-Nunes A3, Costa SKP1 1ICB-USP – Farmacologia,

2ICB-USP – Fisiologia e Biofísica,

3ICB-USP – Imunologia

09.026 The p-coumaric acid derivatives cinnamic acid and methyl cinnamate modulate migration and laminin synthesis in fibroblasts in vitro. Aquino FLT1, Ferro JNS1, Conserva LM2, Barreto E1 1ICBS-UFAL, 2IQB-UFAL – Química e Biotecnologia

09.027 Antinociceptive and anti-inflammatory effects in rodents of lyophilized aqueous extract of P1 (LAEP1). Lopes KS1, Pinheiro BG1, Barros MA1, Souza-Junior FJC1, Andrade DM1, Oliveira JP2, Silva CYY2, Silva MN2, Fontes-Júnior EA1 1UFPA – Pharmaceutical Sciences, 2UFPA – Organic Chemistry

09.028 Antiofidic activity of Sphagneticola trilobata extract. Santana PHDS1, Cons BL

1, Patrão-Neto FC

1, Monteiro-

Machado M1, Strauch MA1, Melo PA1 1UFRJ – Farmacologia e Química Medicinal

09.029 Pharmacological Potential of the 4’-O-Methylepigallocatechin, a flavonoid, for the treatment of Alzheimer's Disease. Veloso CC1, Matos NA2, Netto GPL3, Rodrigues VG4, Duarte LP4, Takahashi JA4, Matildes BLG4, Klein A2, Giusti-Paiva A5, Souza GG3 1UFAM – Ciências Farmacêuticas, 2UFMG – Farmacologia, 3Unifal – Fisioterapia, 4UFMG – Química, 5Unifal – Fisiologia

09.030 Effect of heparin on acute cutaneous lesions induced by Bothrops jararacussu venom in mice. Borges PA1, Strauch MA2,1, Patrão-Neto FC1, Nogueira TA3, Oliveira FL5, Melo PA1, Calil-Elias S5 1ICB-UFRJ – Farmacologia e Química Medicinal, 2IVB, 3UFF – Ciências Aplicadas a produtos para Saúde, 5ICB-UFRJ – Prolіfera ão e Dіferencіa ão Celular

09.031 Acute oral toxicity of Minthostachys mollis (Benth.) Griseb and antispasmodic activity in rat ileum. Rojas J1, Arroyo J1, Ortiz J2, Palomino M3, Paredes A4 1Universidad Nacional Mayor de San Marcos – Farmacologia, 2Universidad Nacional mayor de San Marcos – Fisiologia, 3Universidad Nacional Mayor de San Marcos – Química, 4Universidad Nacional Mayor de San Marcos – Medicina

09.032 Vaginal cream containing curcumin as a promising antifungal for the treatment of vulvovaginal candidiasis. Santos AJA1, Silva EL1, Peixoto FN1, Pires LMN1, Sakamoto RY1, Silva SC1, Amorim YM1, Pinto FCH2, Araujo MGF1 1UFSJ-Centro Oeste, 2UFSJ-Dom Bosco

09.033 MTHP-induced endothelium-independent vasodilatation in thoracic aorta rat: Role of calcium channels. Souza Neta OAC1, Dourado TMH1, Sarmento DM1, Albuquerque JSS1, Travassos RA2 1UFPB, 2UFPB – Biologia Celular e Molecular

10. Cancer Pharmacology

10.001 Paclitaxel reeducates tumor-associated M2-like Macrophages to M1 phenotype in a TLR-4/NF-kB dependent-manner and reduces tumor growth. Wanderley CWS1, Colón DF2, Luiz JPM2, Oliveira FFB1, Viacava PR2, Leite CAVG2, Pereira JA2, Silva CMS1, Silva CR2, Silva RL2, Mota JMSC2, Alvez-Filho J2, Cunha TM2, Cunha FQ2, Lima-Junior RCP1 1UFC – Fisiologia e Farmacologia, 2FMRP-USP

10.002 Identification of circulating microRNA signature as a potential non-invasive biomarker for prediction of colorectal cancer. Silva CMS1, Nobre LMS1, Lucetti LT1, Mello JBH2, Kuasne H2, Barros-Filho MC2, Muniz HA1, Falcão AL1, Fernandes C1, Aguiar MG1, Ferreira DPPF3, Cunha MPSS4, Santana RO4, Souza MHLP1, Quetz JS4, Wong DVT1, Rogatto SR2, Ribeiro RA1, Lima-Junior RCP1 1UFC, 2AC Camargo Cancer Center, 3Cesar Cals Hospital, 4Haroldo Juaçaba Hospital – Cancer Institute of Ceará

10.003 Abatacept, a CTLA4-Ig complex which inhibits T-cell activation, enhances irinotecan-induced intestinal mucositis. Nobre LMS1, Silva CMS1, Silva FWL1, Silva RL1, Pereira VBM1, Paiva IKD1, Fernandes C1, Alves APNN2, Lima-Júnior RCP1 1UFC – Fisiologia e Farmacologia, 2UFC – Farmácia, Odontologia e Enfermagem

10.004 Autophagy promotes cell survival in Temozolomide/SAHA treated glioma cells. Gonçalves RM, Zanotto-Filho A UFSC – Farmacologia


10.005 Bioguided fractionation of acetone extract from Annona muricata L. seeds for prospecting of molecules with cytotoxic potential in vitro. Rocha GGG1, Santos RS1, Silva MFS2, Moura AF1, Brito LM1, Santos CC3, Pessoa OC4, Moraes OM1 1UFC – Fisiologia e Farmacologia, 2UFC – Biotecnologia, 3UFERSA, 4Fiocruz

10.006 Probiotics prevents irinotecan-induced experimental steatohepatitis. Melo AT1, Aragão KS1, Wong DVT1, Fernandes C1, Freitas JA1, Gurgel DC1, Pereira MA2, Almeida PRC3, Lima-Júnior RCP1 1UFC – Farmacologia e Fisiologia, 2VP, 3UFC – Patologia e Medicina Legal

10.007 Melatonergic system enzymes ASMT and CYP1B1 as biomarkers and pharmacological targets for solid tumors Kinker GS1, Ostrowski LH1, Muxel SM1, Oba-Shinjo SM2, Marie SKN2, Markus RP1, Fernandes PA1 1IB-USP – Physiology, 2FM-USP – Neurology

10.008 Cytotoxic effect of telocinobufagin on human colorectal ileocecal adenocarcinoma cells. Godoy TM, Castelo-Branco MTL, Quintas LEM UFRJ – Ciências Biomédicas

10.009 Cytotoxic and genotoxic effects of a Stevia urticifolia extract on animal and plant cells. Sousa IJO1, Ferreira JRO2, Silva JN2, Machado KN3, Nascimento AM3, Costa MP1,2, Cavalcante AACM4, Ferreira PMP5,2 1UFPI – Farmácia, 2UFPI – Cancerologia Experimental, 3UFOP – Química, 4UFPI – Genética Toxicológica, 5UFPI – Departamento de Biofísica e Fisiologia

10.010 Effects of prodigiosin and derivatives in melanoma lineages. Pontes CA1, Branco PC1, Jimenez PC2, Costa-Lotufo LV1 1ICB-USP – Farmacologia, 2Unifesp

10.011 Investigation of cytotoxic mechanisms of synthetic derivatives of seriniquinone in melanoma cell lines. Hirata AS1, Branco PC1, Santos EA2, Jimenez PC3, Fenical W4, Costa-Lotufo LV1 1USP – Farmacologia, 2USP – Biologia Celular e Molecular, 3Unifesp – Ciências do Mar, 4Scripps Institution of Oceanography

10.012 Versican: A differential marker and a potential pharmacological target for gestational trophoblastic diseases. Souza LPG1, Oliveira HGS1, Pires KSN1, Santos JC1, Gonçalves CM1, EMP Silva1, Botelho RM1, Silva ALM1, Pendelosky KPT2, Daher S2, Sun SY2, Borbely KSC1, AU Borbely1 1UFAL – Health and Biological Sciences, 2Unifesp – Obstetrics

10.013 Investigation of the effect of Synadenium grantii on the inhibition of breast cancer cell proliferation Oliveira JS, Martins MM, Montor WR FCMSCSP – Ciências Fisiológicas

10.014 Prodigiosin effects on melanoma cell lines: survivin as a possible target. Branco PC, Pontes CA, Bauermeister A, Alves-Fernandes DK, Hirata AS, Jimenez PC, Lopes NP, Engler SSM, Lotufo LVC ICB-USP

10.015 Spontaneously hypertensive rats were more resistant to the 4NQO-induced oral carcinogenesis than normotensive rats. Tjioe KC1,2, Lopes FYK1,2, Valente VB2, Soubhia AMP3, Oliveira SHP1, Bernabé DG2 1FOA-Unesp – Basic Sciences, 2FOA-Unesp – Pathology and Clinical Propaedeutics, 3FOA-Unesp – Pathology and Clinical Propaedeutics

11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Toxicology

11.001 Lipid core nanocapsules modulate quetiapine hippocampal exposure in a neurodevelopmental model of schizophrenia. Carreño F1, Helfer VE1, Staudt KJ1, Paese K1, Meyer FS1, Silva CM1, Herrmann AP2, Rates SMK1, Guterres SS1, Dalla Costa T1 1UFRGS, 2UFFS

11.002 The low contribution of urinary excretion in the elimination of daunorubicin and its metabolite daunorubicinol in patients with acute myeloid leucemia. Oliveira ML1, Nardotto GHB1, Rocha A1, Simoes BP2, Lanchote VL1 1FCFRP-USP – Análises Clínicas e Toxicológicas,

2FMRP-USP – Clínica Médica

11.003 Exposure to the electrophilic air pollutant 1,2-naphtoquinone and health effects in the vascular system: Role of transient receptor potential. Soares AG1, Florenzano J1, Rodrigues L1, Teixeira SA1, Muscará MN1, Brain SD2, Costa SK1 1ICB-USP – Pharmacology, 2King's College London – Cardiovascular

11.004 Comparative toxicological effects of the antiatherogenic drugs LASSBio-788 and simvastatin. Maia IC1, Motta NAV1, Ribas JAS1, Kümmerle AE2, Brito FCF1, Marostica E1 1UFF – Fisiologia e Farmacologia, 2UFRRJ – Química

11.005 Metformin pharmacokinetics and pharmacodynamics evaluation in diabetic rats induced by streptozotocin and nicotinamide. Braga A, Lima D, Barreto F, Dalla Costa T, Araujo BV UFRGS

11.006 Biodisponibility study of two propafenone formulations in healthy volunteers. Iwamoto RD, Moreno RA, de Nucci G Unicamp

11.007 Evaluation of the safety and wound healing activity of the aqueous extract of Sorocea guilleminiana Gaudich. Leaves. Figueiredo FF, Venturini CL, Pavan E, Oliveira DM, Paes RL, Almeida POA, Martins DTO UFMT – Basic Sciences in Health

11.008 Determination of glyphosate in urine samples derivatisation with 9-fluorenylmethyl chloroformate by liquid chromatography with fluorescence detection. Melo KG1, Rosa PCP1, de Nucci G1, Trape AZ2, Garlipp CR3 1FCM-Unicamp – Farmacologia, 2FCM-Unicamp – Farmacologia e Toxicologia, 3FCM-Unicamp – Patologia

11.009 Association of the ABCB1 c.3435C>T genotypes and required warfarin doses. Tavares LC1, Marcatto LR1, Cassaro-Strunz CM1, Scanavacca M1, Krieger JE1, Pereira AC1, Santos PCJL2 1FMUSP, 2Unifesp – Farmacologia


11.010 Molecular Mechanisms Associated with Palmitate Induced Atrophy in Cells C2C12. Paixão AO, Rodrigues AC ICB-USP – Farmacologia

11.011 Angiotensin converting enzyme inhibitors enhance the hypotensive effects of propofol by increasing nitric oxide production. Oliveira-Paula GH1, Pinheiro LC1, Ferreira GC1, Garcia W2, Lacchini R3, Garcia LV2, Tanos-Santos JE1 1FMRP-USP – Farmacologia, 2FMRP-USP – Anestesiologia, 3EERP-USP – Enfermagem Psiquiátrica e Ciências Humanas

11.012 Ceftriaxone population pharmacokinetics in adults and limited sampling strategy in paediatric patients. Neves DV1, Lanchote VL1, Oosterholt S2, Pasqua OD2 1FCFRP-USP – Análises Clinicas, Toxicológicas e Bromatológicas, 2University College London – Clinical Pharmacology & Therapeutics

11.013 Microsatellite polymorphism in the heme oxygenase-1 promoter is not associated with antihypertensive therapy response in preeclampsia. Sandrim VC1, Lacchini R2, Coeli-Lacchini FB3, Cavalli R4 1IBB-Unesp – Farmacologia, 2FMRP-USP – Enfermagem Psiquiátrica e Ciências Humanas, 3FMRP-USP – Medicina Interna, 4FMRP-USP – Ginecologia e Obstetrícia

11.014 Study of the oral acute toxicity of zinc oxide nanoparticles. Sousa RV1, Abreu CPV1, Oliveira CP, Andrade PVD, Gern JC, Wouters F, SIlva SR, Brandão HM – 1UFLA – Medicina Veterinária

11.015 Populational pharmacokinetic modeling of cefazolin prophylatic doses to morbidly obese patients undergoing bariatric surgery. Palma EC1, Meinhardt NG2, Heineck I1, Fischer MI3, Stein AT2, Araújo BV4, Dalla Costa T4 1UFRGS – Pharmaceutical Sciences, 2Hospital Nossa Senhora Conceição, 3UFRN – Pharmacy, 4UFRN – Pharmaceutical Sciences

11.016 Evaluation of the association between 3435 C>T ABCB1 gene polymorphism and response to clozapine treatment. Ghedini PC, Brito RB UFG – Farmacologia

11.017 Pharmacological inquiry of negative results associated with medications for hypertension and diabetes in primary care facilities in Manaus, AM. Pinto EO1, Cruz LO1, Albuquerque NR1, Correa JWN2 1UFAM – Enfermagem, 2UFAM – Pharmacology

11.018 Influence of cetirizine on gabapentin kinetic disposition and pharmacodynamics in patients with neuropathic pain. Costa ACC1, Yamamoto PA2, Benzi JRL1, Lauretti GR3, Moraes NV2 1FCFRP-USP, 2FCFar-Unesp-Araraquara, 3FMRP-USP

12. Drug Discovery and Development

12.001 Development and challenges of topical nanoparticulate carrier systems for hybrid (Corticoid) hydrogen sulfide (H2S) donos. Gomes GL, Rodrigues L, Cerqueira ARA, Teixeira SA, Muscará MN, Lopes LB, Costa SKP ICB-USP

12.002 Evaluation of the protective effect of carvacryl acetate in intestinal mucosite induced by antineoplasic irinotecan (CPT-11). Alvarenga EM1, Lopes ALF1, Sousa NA1, Araújo S1, Júnior JLP1, Iles B1, Pacífico DM2, Souza EP2, Souza EP2, Sousa DP3, Medeiros JVR1 1 Lafidg-UFPI – Pharmacology of Inflammation and Gastrointestinal Disorders, 2UFC – Morphofunctional Sciences, Department of Morphology, 3UFPB – Pharmaceutical Sciences

12.003 Inhibition of absorptive transporters in the skin by nanocarriers as a strategy for cutaneous localization of anticancer agents. Giacone DV1, Dartora VFC1, Costa SKP1, Lopes LB1 1ICB-USP – Farmacologia

12.004 Bioadhesive nanocoarriers for intraductal administration and localized breast cancer treatment: safety and synergistic effects of C6 ceramide and tributyrin. Migotto A, Carvalho VFM, Lotufo LVC, Silva FWM, Ishida K, Lopes LB USP – Farmacologia

12.005 Evaluation of the activity of a new molecule derived from isoniazid against Mycobacterium tuberculosis. Campos DL1, Maia PIS2, Souza PC1, Pavan FR1 1FCFar-Unesp-Araraquara, 2IQSC-USP

12.006 Oral clioquinol is effective in the treatment of toll-deficient drosophila flies infected with Candida albicans. Merkel S1, Pippi B2, Alves RJ3, Andrade SF4, Fuentefria AM2,4, Zanette RA1 1UFRGS – Farmacologia e Terapêutica, 2UFRGS – Microbiologia Agrícola e do Ambiente, 3UFMG – Farmácia, 4UFRGS – Ciências Farmacêuticas

12.007 Metal complex active against intracellular bacteria of tuberculosis: Tris(1,10-phenanthroline)iron(II). Solcia MC, Campos DL, Pavan FR FCFar-Unesp-Araraquara

12.008 Efficacy of a semi synthetic compound phenol derivative as anti-inflammatory agent: new small molecule cox inhibitor without gastric side effects. Nogueira KM

1, Souza LKM

1, Sousa FBM

1, Araújo S

1, Nicolau LAD

2, Lopes ALF

1,

Chaves LS1, Oliveira AP1, Araújo TSL1, Alencar MS1, Silva IS1, Medeiros JVR1 1UFPI, 2UFC

13. Systems Pharmacology

13.001 Is body weight gain under regulation of circadian melatonin? Cruz-Machado SS1, Pereira EP1, Oliveira AP2, Silva-Souza E1, Markus RP1 1IB-USP – Departamento de Fisiologia, 2UFPI – Biologia e Fisiologia

13.002 Early-life stress promotes alterations in intestinal permeability and hippocampal 5-HT 1A mRNA expression in juvenile rats. Bravo JA1, Astudillo-Guerrero C1, Rossi-Vargas G1, Escobar-Luna J1, Barrera-Bugueño C1, Gotteland M2, Julio-Pieper M

1

1Pontificia Universidad Católica De Valparaíso – NeuroGastroBioquímica,

2Universidad de Chile –

Nutrición


14. Pharmacology Education and Technology

14.001 Use of board game for studying clinical cases in pharmacology. Silva DG, Bacchi AD – UEL – Ciências Fisiológicas

15. Pharmacology: Other

15.001 Nanocarrier-mediated cutaneous co-localization of chemotherapeutic agents and efficacy in 3D models of skin câncer. Dartora VFC1, Lemos DP1, Zanoni TB2, Maria-Engler SS2, Costa-Lotufo LV1, Lopes LB1 1ICB-USP – Farmacologia, 2FCF-USP – Análises Clínicas e Toxicológicas

15.002 Systemic injection of biperiden reduces ethanol consumption in rats. Zaniboni CR1, Moreira JF1, Santos MG1, Leão RM2, Galduróz JCF3, Cruz FC1 1Unifesp-EPM – Farmacologia, 2UFBA – Farmacologia, 3Unifesp-EPM – Psicobiologia

15.003 Effect of fluoxetine on autonomic responses of chemoreflex and baroreflex in rats submitted to chronic stress. Firmino EMS, Kuntze LB, Lagatta DC, Resstel LBM FMRP-USP – Farmacologia

15.004 Raltitrexate: A promising alternative for the treatment of toxoplasmosis in immunosuppressed patients, Reis MP1, Pauli KB1, Lima DA1, Moraes ALS1, Lívero FAR1, Lourenço ELB1 1Unipar – Preclinical Investigation of Natural Products

15.005 Hibiscus acetosella (Welw) hydroalcoholic extract cytotoxicity to epithelial cell. Fontes VC, Castelo Branco SJS, Lima Neto LG, Zago PMW Universidade Ceuma

15.006 Cytotoxic effect of Chenopodium ambrosioides in epithelial cells Castelo Branco SJS, Fontes VC, Lima Neto LG, Gonçalves LM, Zago PMW Universidade Ceuma

15.007 Bioresponsive nanostructured systems for sustained drug release and treatment of alcoholism. Santos R1, Lopes LB1, Rae M1, Camarini R1, Stainer A2 1ICB-USP – Farmacologia, 2ICB-USP – Imunologia

15.008 Dietary fatty acids content modifies memory parameters in rats: Comparative study between Mediterranean- versus western-based diet. Haygert PF, Roversi K, Milanesi LH, Vey LT, Duarte MMF, Burguer ME UFSM – Farmacologia

15.009 Determination of manganese in blood using graphite furnace atomic absorption spectroscopy. Carrara MYW, Jacobucci SR, Trape AZ, Garlippi CR, Rosa PCP Unicamp – Farmacologia

15.010 Structure-activity relationship between cardenolides and bufadienolides for the inhibition of porcine kidney Na+K+-ATPase and the antagonistic effect of K+. Azalim PN1, Rendeiro MM1, Leitão SG2, Quintas LEM1, Noël F1 1UFRJ – Farmacologia Bioquímica e Molecular, 2UFRJ – Farmácia

15.011 Development and evaluation of the cytotoxic potential of topical nanocarriers co-encapsulating endoxifen and metformin for breast cancer chemoprevention Lemos DP1, Giacone DV1, Lotufo LV1,2, Lopes LB1,3 1ICB-USP – Farmacologia, 2UFC, 3Albany College of Pharmacy and Health Sciences

15.012 Development and validation of a stability indicating method to determination of Cloxazolam and its degradation products by HPLC-DAD. Resck RR, Rosa PCP FCM-Unicamp – Farmacologia

15.013 Evaluation of the antimicrobial activity of phenylacrylates series (AL) Schiavon MSC1, Andrade VS2, Araújo IDR3, Moura RO4, Nascimento DP4, Moura WCS4 1UFRN – Biofísica e Farmacologia, 2UFRN – Microbiologia e Parasitologia, 3UFRN – Biologia Parasitária, 4UFPB – Farmácia


Poster Session 2 – Oct 20 2017

01. Cellular and Molecular Pharmacology

01.024 Human organotypic skin explant for mycobacterium leprae artificial cultivation . Paula NA1,2, Leite MN2, Rosa PS3, Das PK, Frade MAC2 1FMRP-USP – Biologia Celular e Molecular, 2FMRP-USP – Clínica Médica, 3ILSL

01.025 Changes of cardiorenal Na+/K+-ATPase triggered by chronic ouabain administration in rats are pressure-dependent. Feijó PRO1, França-Neto A2, Rossoni LV2, Noël F1, Quintas LEM1 1ICB-UFRJ – Farmacologia Bioquímica e Molecular, 2ICB-USP – Farmacologia

01.026 Paracrine control of skeletal neuromuscular transmission by the extracellular cyclic AMP-adenosine pathway. Sanders-Silveira S, Duarte T, Pacini ES, Godinho RO Unifesp-EPM – Farmacologia

01.027 Integrative meta-analysis identifies candidate drug targets based in MicroRNA-regulated networks in cancer-cachexia. Freire PP1, Cury SS1, Oliveira G1, Moraes LN1, Moraes D1, Marques DVP1, Lopes LO1, Reis PP2, Dal-Pai-Silva M1, Carvalho RF1 1IBB-Unesp – Morfologia, 2FCMBB – Cirurgia e Ortopedia

01.028 Biochemical and pharmacological characterization of Angiotensin II AT1 receptors containing mutations associated. Simoes SC

1, Silva ALB

1, Parreiras-e-Silva LT

1, Costa-Neto CM

1 1FMRP-USP – Biochemistry and Immunology

02. Neuropharmacology

02.023 New piperazine derivate (LQFM183) improves cognitive dysfunction and oxidative stress in aluminium chloride-induced model in mice. Neri HFN1, Costa EA1, Santos FCA2, Menegatti R3, Ghedini PC1 1UFG – Farmacologia, 2UFG – Histologia, 3UFG – Faculdade de Farmácia

02.024 Evaluation of the influence of maternal voluntary physical exercise on synaptic plasticity and cognition in animals with PTEN deletion. Andreotti DZ, Cabral-Costa JV, Scavone C, Kawamoto EM ICB-USP

02.025 Sulfated polysaccharides from red seaweed Gracilaria cornea protects against neurodegenerative damage in 6-OHDA model in rats. Frota AF1, Soares VVM1, Sousa RM1, Nascimento HG1, Silva Júnior PN1, Aguiar LMV2, Benevides NMB1 1UFC – Bioquímica e Biologia Molecular, 2UFC-Sobral – Medicina

02.026 Taurine counteracts the neurotoxic effects of chronic hyperglycemia in diabetic rats. Bandiera S1, Caletti G1, Pulcinelli RR1, Hansen AW1, Steffens L2, Herrmann AP3, Moura DJ2, Barros TMH2, Gomez R1 1UFRGS – Farmacologia, 2UFCSPA – Farmacologia, 3UFFS – Patologia

02.027 A2A receptor facilitates neuromuscular transmission activating PKA, thereby increasing the high-affinity choline transporter rate. Castellão-Santana LM1, Abiko PY1, Ambiel CR2, Correia-de-Sa P3, Alves-Do-Prado W1 1UEM – Farmacologia e Terapêutica, 2UEM – Ciências Fisiológicas, 3Universidade do Porto – Ciências Biomédicas

02.028 Presynaptic adenosine (A2A) receptor reduces the neostigmine-induced fade by diminishing both desensitization of neuronal nicotinic receptor and inhibitory effect caused muscarinic (M2) receptor activations on motor nerve terminal , Andreo PHM1, Ambiel CR1, Castellão-Santana LM2, Correia-de-Sá P3, Alves-do-Prado W2 1UEM – Ciências Fisiológicas, 2UEM – Farmacologia e Terapêutica, 3Universidade do Porto

02.029 Effects of enrichment environment in female rats and its effects on choice between cocaine and saccharine in a CPP model. Heidrich N1, Almeida FB2, Fernandes PR2, Fonseca AR1, Costa L1, Silva FFS1, Freese L1, Barros HMT2,1 1UFCSPA – Neuropsicofarmacologia,

2UFCSPA – Ciências da Saúde

02.030 Anxiolytic-like effect of [BMZPdCl]2, an organometallic bromazepam-palladium(II) derivatives, in the mouse elevated plus maze. Santos-Neto JG1, Souza FMA2, Nicácio DCS2, Silva AHQ3, Maciel DM, Cavalcante GTS4, Souza GF2, Santos-Vieira MP2, Silva OBS2, Meneghetti MR3, Duzzioni M2 1UFAL, 2UFAL – Farmacologia, 3UFAL – Química, 4UFAL – Farmacologia

02.031 Na+,K+-ATPase and NMDA receptor-related alterations in cerebellum of Klotho hypomorfic mice – a genetic model of aging. Cararo-Lopes MM, Mello PS, Mazucanti CH, Sá Lima L, Andreotti DZ, Scavone C, Kawamoto EM ICB-USP – Farmacologia

02.032 The role of GCs signaling via GR in BLA on stress-induced late anxiety-like behavior in rats. Bueno-de-Camargo LM, Novaes LS, Munhoz CD ICB-USP – Farmacologia

02.033 Study of new multi-target acetylcholinesterase inhibitors of greater tolerability for treatment of Alzheimer's disease. Guimarães MJR1, Viegas CJ2, Castro NG1 1ICB-UFRJ, 2Unifal

02.034 Study of neuroprotective effect of arylnitrones in In vitro models of stroke. Boni MS, Castro NG ICB-UFRJ – Farmacologia e Química Medicinal

02.035 The Role of 5-HT2A receptors in the dorsal raphe nucleus in panic-like behaviours and antinociception evoked by chemical stimulation of the inferior Colliculus . Soares-Junior RS, Falconi-Sobrinho LL, Garcia TA, Coimbra NC FMRP-USP – Neurociências


02.036 N-type Ca2+ channels are affected by full-length mutant huntingtin expression in a mouse model of Huntington's disease. Santos RPM1, Silva FR2, Miranda AS, Olmo IG, Zamponi GW, Dobransky T, Cruz JS, Vieira LB1, Ribeiro MR 1UFMG – Farmacologia Básica e Clinica, 2UFMG – Bioquímica

02.037 Evaluation of cytokines in patients with temporal lobe epilepsy. Silva MCM, Martins FMA, Gonçalves AP, Teixeira AL, Vieira ELM, Vieira ELM, Oliveira ACP, Oliveira ACP – UFMG

02.038 Role of TLR2 in biochemical effects induced by intermittent fasting. Paixão AG, Vasconcelos AR, Scavone C, Kawamoto EM ICB-USP – Farmacologia

03. Psychopharmacology

03.017 Panic-attack like-defensive behaviour induced by Nitric Oxide donor microinjections into the anterior hypothalamus causes antinociception. Falconi-Sobrinho LL1, Anjos-Garcia T2, Coimbra NC2 1FMUSP – Neurociências, 2FMUSP – Farmacologia

03.018 Acute stress impairs the extinction of conditioned fear memory: participation of glucocorticoid receptors in the prefrontal cortex. Rosa J, Uliana DLM, Resstel LBM FMRP-USP – Farmacologia

03.019 Antidepressant-like effect induced by Cannabidiol (CBD) is dependent on serotonin levels. Sales AJ1, Guimarães FS1, Joca SRL2 1FMRP-USP – Farmacologia, 2FCFRP-USP

03.020 Cannabidiol reduces haloperidol-induced orofacial dyskinesia and neuroinflammation in mice. Sonego AB, Prado DS, Guimarães FS FMRP-USP – Farmacologia

03.021 Anxiolytic-like effect of 2,6-di-tert-butyl-4-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)phenol mediated by GABAergic and monoaminergic pathway in mice. Moreira LKS, Brito AF, Silva DM, Cardoso CS, Siqueira L, Menegatti R, Costa EA UFG

03.022 Chronic stressed mice treated with cannabidiol for 7 days shows attenuation in anxiogenic-like effect in the novelty suppressed feeding test. Detoni VL1, Scarante FF1, Aguiar RP2, Fusse EJ3, Guimarães FS1, Campos AC1 1FMRP-USP – Farmacologia, 2UEM – Farmacologia e Terapêutica, 3FMRP-USP – Neurociência e Ciência do Comportamento

03.023 Effects of acute and chronic administration of agomelatine on anxiety and panic behavior in rats submitted to elevated T Maze Gomes ACCN1, Medeiros AC, Bortolin RH2, Gavioli EC1, Soares-Rachetti VP1 1UFRN – Biofísica e Farmacologia, 2UFRN – Ciências Farmacêuticas

03.024 Environmental enrichment affects emotional behavior and pharmacological response to antidepressants in CF1 mice. Speck ML, Gomes AL, Stein DF, Rojas C, Rates SMK UFRGS – Ciências Farmacêuticas

03.025 Study of the effect of daidzin and a synthetical analogue – LQB 308 – in Caenorhabditis elegans and primary cerebellar culture. Silva CPM1, Stein DF1, Goethel G1, Costa P2, Garcia SC1, Rates SMK1 1UFRGS, 2UFRJ

03.026 The FAAH Inhibitor, URB597, modulates anxiety-like behavior in mice depending on previous stressful experience. Fusse EJ, Turcato F, Scarante FF, Marrubia MM, Aguiar RP, Detoni VL, Guimarães FS, Campos AC FMRP-USP

04. Inflammation and Immunopharmacology

04.037 Mast cells involvement in the inflammatory process and local renin angiotensin system components expression on gingival tissue of diabetic mice with periodontal disease. Queiroz DPS1,2, Brito VGB3,2, Pereira JP3, Beltran CT3,2, Vieira LV3,2, Lara VS4, Santos CF5, Oliveira SHP3 1Unesp-Araçatuba – Ciências Básicas, 2Multicenter Graduate Program in Physiological Sciences, 3FOA-Unesp – Ciências Básicas, 4FOB-USP – Estomatologia, 5FOB-USP – Ciências Biológicas

04.038 Cross-talk between protease activated receptor (PAR)2 and toll-like receptor (TLR)4 on phagocytosis of zymosan and inflammatory activity of murine peritoneal macrophages. Barra A, Klein A UFMG – Farmacologia

04.039 Beneficial effects of a H2S-releasing dexamethasone derivative on atopic dermatitis in mice, Coavoy-Sánchez SA1, Cerqueira ARA1, Teixeira SA1, Soares AG1, Santagada V2, Caliendo G2, Costa SKP1, Muscará MN1 1ICB-USP – Pharmacology, 2University of Naples – Pharmacy

04.040 Potential anti-inflammatory effect of LQFM-021 in carrageenan-induced inflammation: The role of nitric oxide. Florentino IF1, Silva DPB1, Silva DM1, Cardoso CS1, Moreira ALE2, Borges LB2, Soares CMA2, Carvalho PMG3, Lião LM4, Ghedini PC1, Menegatti R5, Costa EA1 1UFG – Farmacologia, 2UFG – Bioquímica, 3UFOB, 4UFG – Química, 5UFG

04.041 Early mice exposure to the ambient pollutant 1,2-napththoquinone impairs adhesion molecules expression in the airways. Feitosa KB1, Cunha AC1, Santos KT1, Favaro RR2, Santana FPR3, Prado CM4, Zorn TMT2, Muscará MN1, Costa SKP1 1ICB-USP – Farmacologia, 2ICB-USP – Biologia celular e Desenvolvimento, 3Unifesp-Diadema – Biociências, 4Unifesp – Biociências

04.042 Involvement of Adenosine A2A receptor in the lung fibrosis caused by silica particles in mice. Silva PMR1, Jannini-Sá YAP

1, Savio LEB

2, Coutinho-Silva R

2, Carregaro V

3, Alves-Filho JC

4, Martins MA

1

1Fiocruz – Inflamação,

2UFRJ –

Imunofisiologia, 3FMRP-USP Bioquímica e Imunologia, 4FMRP-USP – Farmacologia


04.043 N-acetylcysteine prevents the decreased carotid occlusion time in mice injected with lipopolysaccharide. Caloi CM1, Vicente C2, Pereira DS3, Werneck CC3, Naime ACA1, Marcondes S1 1Unicamp – Farmacologia, 2Unicamp – Biologia Estrutural e Funcional, 3Unicamp – Biologia Funcional e Molecular

04.044 Biocompatibility evaluation of polypyrrole polymer using zebrafish as a model organism. Costa KM1, Pereira TCB2, Valente CA3, Soares JC2, Cruz FF2, Basso NRS4, Bogo MR2 1PUCRS – Ciências da Saúde, 2PUCRS – Biologia Celular e Molecular, 3PUCRS, 4PUCRS – Química

04.045 Siglec-5 Activation by Alpha-1-Acid Glycoprotein (AGP) inhibits neutrophil actin polymerization. Lorenzini CB1, Cardoso F1, Colon D2, Cunha FQ2, Spiller F1 1UFSC – Farmacologia, 2FMRP-USP – Farmacologia

04.046 Hydrogen sulfide inhibits histopathologic changes in mouse model of asthma. Villela Filho GJM, Colombo FF, Araújo VC, Passador-Santos F, Renno AL, Ferreira HHA São Leopoldo Mandic Center

04.047 Regulatory T cells accumulate in the injured nerve and reduce neuropathic pain by suppression of TH1 cells. Davoli-Ferreira M, Lima KA, Fonseca MDM, Guimarães RM, Quadros AU, Cunha TM FMRP-USP

04.048 Antioxidant activity of Aedes aegypti’s saliva in murine model of sepsis. Monterio VVS1, Gomes RS1, Navegantes KC1, Reis JF1, Oliveira ALB1, Rodrigues DVS1, Romao PRT2, Monteiro MC1 1UFPA – Farmácia, 2UFCSPA – Biomedicina

04.049 Leukocyte recruitment in Zebrafish: a new tool for the study of inflammation and discovery of new drugs. Charlie-Silva I1, Prata MNL2, Brasil AF3, Melo DC4, Corrêa JD2, Belo MAA1, Belo MAA1, Manrinque W, Gomes JMM2, Ferraris F5, Conceição K6, Lopes-Ferreira M7, Klein A3, Peres AC2 1Unesp-Jaboticabal, 2ICB-UFMG, 3ICB-UFMG – Farmacologia e Fisiologia, 4UFMG, 5Fiocruz, 6Unifesp, 7IBu

04.050 Antiprectic effect of citral during LPS fever. Emílio-Silva MT, Mota CMD, Hiruma-Lima CA, Antunes-Rodrigues J, Cárnio EC, Branco LGS Unesp

04.051 Generation of PKM2 knockout HaCaT cell line by CRISPR/Cas-9 mediated genome editing. Públio GA1, Cecílio NT

1,

Vieira GV2, Veras PV

1, Cunha Fernando Q

1, Cunha TM

1, Sales KU

2, Alves-Filho JC

1

1FMRP-USP – Farmacologia,

2FMRP-

USP – Biologia Celular e Molecular

04.052 Comparison of immune-pineal axis activation in lethal and non-lethal LPS-induced endotoxemie Mori LT, Takiguchi RS, Markus RP, Fernandes PA IB-USP – Fisiologia

04.053 Suppression by gold nanoparticles of silica-induced lung fibrosis in mice. Ribeiro NBS1, Ciambarella BT, Arantes ACS, Serra MF, Azevedo R B, Fernandes AJM, Martins MA, Silva PMR Fiocruz – Farmacologia e Inflamação

04.054 In vitro evaluation of the anti-inflammatory activity of essential oil of Cyperus articulatus L. in macrophages. Ferreira JCC, Silva EBS, Almeida Junior JS, Barata LES, Moraes TMP, Pires-Moraes W UFOPA- Laboratório de Farmacologia Experimental

04.055 Effect of Tityus bahiensis e Tityus serrulatus crude venom on platelet aggregation of rats. Morau MV, Naime ACA, Bueno PI, Bonfitto PHL, Marcondes S FCM-Unicamp – Farmacologia

04.056 Evaluation of anti-inflammatory and antioxidant activities of ethyl p-coumarate in acute inflammatory models.

Gonçalves RLG1, Lima-Filho ACM1, Silva BG1, Rezende DC1, Silva IS2, Sousa FBM2, Sousa LKM2, Medeiros JVR2, Sousa DP3,

Oliveira FA1 1UFPI – Research Center on Medicinal Plants, 2UFPI – Experimental Physiopharmacology, 3UFPB – Pharmaceutical Sciences

04.057 Regulation of Th17 cell differentiation by pyruvate kinase M2 supports autoimmune-mediated neuroinflammation. Damasceno LEA, Prado DS, Fonseca MDM, Veras FP, Cunha FQ, Alves-Filho JCF FMRP-USP

04.058 Establishment of an experimental model of emphysema: Effect of the phosphodiesterase (PDE) 4 inhibitor cilomilast. Cunha LCL1, Souza ET2, Martins MA1, Silva PMR1 1Fiocruz, 2 Unime

05. Pain and Nociception Pharmacology

05.017 Involvement of cytokines in paclitaxel-induced acute pain syndrome in mice. Oliveira FFB1, Fonseca MDM2, Lopes AHP2, Cunha TM2, Vale ML1 1UFC – Fisiologia e Farmacologia, 2FMRP-USP – Farmacologia

05.018 Analgesic effects of intranasal ketamine in rats models of orofacial pain. Araya EI1, Claudino RF1, Nones CFM1, Chichorro JG1 1UFPR – Farmacologia

05.019 Acute treatment with adenosine receptor A3 agonist alters hiperalgesic response in rats with chronic inflammatory pain. Cioato SG2,1,3, Lopes B4,1,3, Salvi AA1,3, Medeiros LF5,1,3, Torres ILS4,2,5,1,3 1UFRGS – Farmacologia da Dor e Neuromodulação: Modelos Animais, 2UFRGS – Farmacologia e Terapêutica, 3Hospital de Clínicas de Porto Alegre – Experimentação Animal, 4UFRGS – Fisiologia, 5UFRGS – Medicina

05.020 HUF-101 prevents the development of mechanical allodynia induced by paclitaxel in mice. Silva NR1, Fonseca MDM

1, Mechoulam R

2, Cunha TM

1, Guimarães FS

1

1FMRP-USP – Pharmacology,

2Hebrew University of Jerusalem –

Medicinal Chemistry and Natural Products


05.021 Nicorandil inhibits mechanical allodynia in the model of neuropathic pain induced by paclitaxel by activating opioidergic and serotoninergic mechanisms. Morais MI1, Braga AV1, Rodrigues FF1, Melo ISF1, Fátima A2, Coelho MM1, Machado RR1 1UFMG – Ciências Farmacêuticas, 2UFMG – Química

05.022 Involvement of dorsal root ganglia NMDA receptors on acute pain in rats. Mendes DR1, Lemes JBP, Silva MV, Fagundes RGM, Lotufo CM UFU – Fisiologia

05.023 Antioxidant and antinociceptive effect of 2-PHE in the sciatic nerve partial ligation model França ARS1, Piauilino CA1, Lopes EM1, Gomes LS1, Sousa DP2, Almeida FRC1 1UFPI – Medicinal Plants, 2UFPB – Pharmaceutical Sciences

05.024 The role of CCR2+ and CX3CR1+ cells in genesis and maintenance of neuropathic pain Guimarães RM1, Ferreira MD1, Fonseca MDM2, Kusuda R2, Cunha TM 1FMRP-USP – Imunologia, 2FMRP-USP – Farmacologia

05.025 Hypernociceptive effect of the lectin isolated from Platypodium elegans Laranjeira EPP1, Almeida LM1, Silva IB2, Nascimento KS2, Cavada BS2, Assreuy AMS2, Pires AF1 1UECE, 2UFC

05.026 Anti-hyperalgesic action of N-type calcium channel blockers and TRPA1 antagonist in mice models of HIV-related pain. Lückemeyer DD, Prudente AS, Ferreira M A, Tonello R, Ferreira J UFSC – Farmacologia

05.027 Participation of TNF-α and astrocytes in Ehrlich tumor-induced pain in mice. Domiciano TP, Zarpelon AC, Ferrari LS, Campos CC, Fattori V, Borghi S, Filho JCA, Cunha FQ, Cunha TM, Verri WAV UEM, FMRP-USP

05.028 Infection by Plasmodium berghei strain ANKA prevents the development of inflammatory hyperalgesia, but not of mechanical and thermal, induced by chloroquine in mice. Aguida WR1, Neves AB2, Aguiar MFS2, Feitosa IB3, Teles CBG1, Dias QM1 1Fiocruz RO – Neuro e Imunofarmacologia, 2UNIR, 3IBCCF-UFRJ

05.029 Prophylactic endocannabinoid hydrolysis inhibition alleviates end stage osteoarthritis pain and neuropathy in mice. McDougall JJ, Muley M, Reid A, Krustev E Dalhousie University – Pharmacology

06. Cardiovascular and Renal Pharmacology

06.033 Plasticity of calcium handling proteins are different between male and female rats submitted to neonatal hyperleptinemia. Souza KP, Souza JRN, Alvim-Silva T, Marques EB, Scaramello CBV UFF – Farmacologia e Fisiologia

06.044 Action of tadalafil in the treatment of cardiac, urinary and erectile disorders in heart failure rats. Mora AG, Tartarotti SP, Andrade DR, Janussi SC, Gonçalves TT, Priviero F, Claudino MA USF – Ciências Básicas em Saúde

06.045 Hypercontractility state of the iliac arteries from middle-aged rats. Justo AFO, Oliveira MG, Alexandre EC, Calmasini FB, de Nucci G, Antunes E, Mónica FZ FCM-Unicamp – Farmacologia

06.046 Doxycycline reduces blood pressure and reestablishes the antioxidant capacity without changes in feto-placental restriction in hypertensive pregnant rats. Possomato-Vieira JS, Gonçalves-Rizzi VH, Dias-Junior Unesp – Farmacologia

06.047 Trans-resveratrol ameliorates nitric Oxide production in endothelial cells incubated with plasma from nonresponsive preeclamptic patients Caldeira-Dias M, Possomato-Vieira JS, Cavalli RC, Sandrim VC Unesp – Farmacologia

06.048 Diuretic herb Gomphrena celosioides Mart. (Amaranthaceae) promotes sustained arterial pressure reduction on renovascular hypertensive rats. Vasconcelos PCP, Leitão MM, Carneiro MTS, Tirloni CAS, Palozi R, Schaedler MI, Silva AO, Gasparotto Junior A, Kassuya CAL UFGD – Ciências da Saúde

06.049 IL-33/ST2 Signaling downregulates reactive oxygen species generation and improves PVAT anti-contractile effects in mice fed a high fat diet. Costa RM, Neves KB, Alves-Filho JCF, Tostes RC FMRP-USP – Farmacologia

06.050 Pregnancy reduces O-GlcNAc expression in blood vessels from normotensive and hypertensive rats. Troiano JA, Potje SR, Graton ME, Silva DA, Antoniali C FOA-Unesp – Ciências Básicas, 2FCFRP-USP

06.051 Involvement of NO/cGMP signaling pathway on the acute effect of estrone in rat thoracic aorta. Oliveira TS1, Oliveira LM1, Oliveira LP1, Costa RM2, Tostes RCA2, Costa EA1, Filgueira FP3, Ghedini PC1 1UFG – Farmacologia, 2FMRP-USP – Farmacologia, 3UFG – Ciências da Saúde

06.052 Vasorelaxant effects of the monoterpenes (+)-rose oxide, β-citronellol and geraniol in rat. aorta. Vasconcelos-Silva AA, Magalhães PJC UFC – Departamento de Fisiologia e Farmacologia

06.053 Radical scavenger activities and hypotensive effects of jabuticaba fruit (Myrciaria cauliflora) in hypertensive rats. Andrade DML, Souza CG, Marcelino RIA, Borges LL, Valadares MC, Conceiçao EC, Rocha ML UFG

06.054 Thromboxane-prostanoid receptors activation induces KATP channels dysfunction of concentration-dependent manner in rat aorta. Santos JD1, Paulo M2, Bendhack LM2 1FMRP-USP – Farmacologia, 2FCFRP-USP – Física e Química

06.055 Nitrate competes with nitrite for XOR and attenuates the fall in blood pressure induced by nitrite in hypertensive rats. Damacena-Angelis CD1, Pinheiro LC2, Portella RL2, Ferreira GC2, Oliveira-Paula GH2, Tanus-Santos JE2 1FCM-Unicamp,

2FMRP-USP


06.056 Quercetin decreases the activity of matrix metalloproteinase-2 and ameliorates vascular remodeling in renovascular hypertension Pereira SC, Parente JM, Belo VA, Mendes AS, Gonzaga NA, do Vale GT, Ceron CS, Tanus-Santos JE, Tirapelli CR, Castro MM USP

06.057 Reduction of cardiac and skeletal muscle dysfunction by activation of estrogen receptors in ovariectomized hypertensive rats. Silva AMS1, Silva JS1, Wang H2, Sun X2, Groban L2, Zapata-Sudo G1, Sudo RT1 1UFRJ – Desenvolvimento de Fármaco, 2Wake Forest School of Medicine – Anesthesiology

06.058 Effect of chronic treatment with apocynin on the vasoconstrictor response of angiotensin ii in spontaneously hypertensive rats. Graton ME1, Potje SR1, Troiano JA1, Ferreira BHSH1, Vale GT2, Tirapelli CR2, Nakamune AC1, Bendhack LM3, Antoniali C1 1FOA-Unesp – Ciências Básicas, 2EERP-USP, 3FCFRP-USP

06.059 Angiotensin II-induced contractile response is negatively modulated by the endothelial cells by a non COX-derived and a non-reactive oxygen species in rat aorta. Pelegrin JA1, Vercesi JA1, Bendhack LM1 1FCFRP-USP – Física e Química

06.060 S-Nitroso-N-acetylcysteine reduces aortic vasoconstriction induced by phenylephrine and calcium. Ferreira LAB, Portella RL, Tanus-Santos JE FMRP-USP

06.061 Endothelium removal does not change the NO donor RuBPY-induced relaxation in rat aorta. Romano JT1, Vercesi JA1, Bendhack LM1 1FCFRP-USP – Física e Química

06.062 Activation of G coupled estrogen receptor (GPER) improved cardiac and skeletal muscle dysfunction in male Zucker diabetic fat rats. Costa GC1, Silva AMS2, Silva JSS2, Sudo RT2, Sudo GZ2 1Laureate International Universities, 2UFRJ – Farmacologia e Química Medicinal

06.063 Evaluation of sexual dimorphism and cardiovascular disease related to perinatal overweight in adult rats. Araújo GA, Farias RS, Marques EB, Rocha N, Scaramello CBV UFF

06.064 Combined therapeutic effect of the angiotensin converting enzyme inhibitor with resveratrol against cardiac damage consequent in renovascular hypertension. Carmo MFA

1, Nowicki VF

1, Alves CAC

1, Rizzi E

1, Ramalho LNZ

2, Restini

CBA1 1UNAERP – Biotecnologia, 2FMRP-USP – Patologia

06.065 Primary cultured endothelial cells from veins are reactive to Angiotensin II. Assunção HCR, Trindade M, Bertolino J, Torres TC, Fernandes L Unifesp-Diadema – Ciências Farmacêuticas

06.066 Effect of PDE9 Inhibitor (BAY 73-6691) on the contractile response of cavernous smooth muscle of heart failure rats submitted to treatment with tadalafil. Janussi SC, Tartarotti SP, Mora AG, Andrade DR, Barbosa JWP, Priviero F, Claudino MA USF – Multidisciplinary Research

06.067 Novel inhibitor of MAPK decreases ventricular dysfunction induced by pulmonary hypertension in rats. Fernandes G1, Silva MMC1, Silva AMS1, Freitas RCN1, Marinez ST2, Alencar AKN1, Amaral M1, Lima LM1, Fraga CAM1, Barreiro EJ1, Sudo RT1, Zapata-Sudo G1 1UFRJ, 2UFF

06.068 Endotoxemia in rats chronically treated with Fluoxetine. Moreira CM, Linder AE UFSC – Farmacologia

06.069 Nitrite treatment with a non-antihypertensive effect improves cardiovascular responses to bradykinin in renovasclar hypertension. Blanco ALF1, Oliveira-Paula GH2, Angelis CD1, Portella RL2, Tanus-Santos JE2 1FCM-Unicamp – Farmacologia, 2FMRP-USP – Farmacologia

06.070 Impairment in vascular relaxation caused by treatment with paracetamol is improved after exercise training in rats. Ribeiro MTL, Ayres JC, Porto HKP, Rocha ML UFG – Farmácia

06.071 Oral and venous farnesol reduces blood pressure in rats. Nunes ASS1, Carvalho GD2, Mendes MB2, Ribeiro AMB2, Quintans-Junior LJ3, Oliveira AP4 1UFPI – Farmacologia, 2Renorbio – Biotecnologia, 3UFS – Fisiologia, 4UFPI – Biofísica e Fisiologia

06.072 Verapamil decreases matrix metalloproteinase-2 activity and renovascular hypertension-induced cardiac hypertrophy. Mendes AS, Neves EVN, Tanus-Santos JE, Castro MM FMRP-USP

06.073 Potent antiplatelet and anti-inflammatory effects of simvastatin in hypercholesterolemic rats: pivotal roles of cyclic nucleotides and p38 mitogen-activated protein kinase. Motta NAV

1, Lima GF

1, Lopes RO

1, Mendes ABA

1, Brito FCF

1

1UFF – Farmacologia e Fisiologia

06.074 Prolonged diuretic and saluretic effect of nothofagin in normotensive and hypertensive rats. Souza P, Mariano LNB, Boeing T, Almeida CLB, Silva LM, Cechinel-Filho V, Andrade SF Univali – -Ciências Farmacêuticas

06.075 Simvastatin improves endothelial function in hypercholesterolemic rats: role of endothelial nitric oxide synthase phosphorylation and NF-κB inhibition. Motta NAV1, Lima GF2, Lopes RO2, Mendes ABA1, Marques EB1, Scaramello CBV1, Brito FCF3 1UFF, 2UFF – Farmacologia Experimental, 3UFF – Fisiologia e Farmacologia

06.076 Antihypertensive effects of sodium nitrite and S-nitrosoglutathione are associated with tissue angiontensin converting enzyme inhibition. Pinheiro LC, Ferreira GC, Oliveira-Paula GH, Tanus-Santos JE FMRP-USP – Farmacologia

06.077 Nitrite decreases MMP-2 activity, oxidative stress and vascular remodeling independent of its antihypertensive effects in two-kidney, one-clip hypertension. Rizzi E1, Amaral J2, Guimaraes DA2, Conde-Tella SO2, Pinheiro LC2, Gerlach


RF3, Tanus-Santos JE2 1UNAERP – Biotecnologia, 2FMRP-USP – Farmacologia, 3FORP-USP – Morfologia, Estomatologia e Fisologia

06.078 Effect of Solanum sisymbriifolium LAM. (SALANACEAE) in L-Name (Nω-Nitro-L-Arginine methyl ester induced hypertension in rats: A preliminary study. Ibarrola DA, Campuzano A, Ovando F, Arrúa K, Rodas E, Heinichen O, Campuzano MA, Montalbetti Y, Hellion-Ibarrola MC 1Universidad Nacional de Asunción – Farmacologia

06.079 Protective effect of hydro-alcoholic extract of Baccharis crispa Spreng. (Jaguareté Ka´a, carqueja) (Bc) against gentamicin-induced nephrotoxicity in mice. Hellion-Ibarrola MC, Diarte EMG, Velázquez AM, Coronel C, Ferreira PA, Kennedy ML, Montalbetti Y, Ibarrola DA Universidad Nacional de Asunción – Farmacologia

07. Endocrine, Reproductive and Urinary Pharmacology

07.013 Tetrodotoxin-Insensitive Electrical Field Stimulation-Induced Contractions on Crotalus durissus terrificus Corpus Cavernosum. Campos R, Mónica FZ, Rodrigues RL, Rojas-Moscoso JA, Moreno RA, Cogo JC, Antunes E, de Nucci G Unicamp – Farmacologia

07.014 Menthol improves obesity-associated mouse bladder dysfunction independently of TRPM8 activation. Oliveira M, Nascimento D, Alexandre EC, Calmasini FB, Zapparoli A, Antunes E FCM-Unicamp – Farmacologia

07.015 Inhibition or deletion of toll like receptor 4 (TLR4) confers protection against cyclophosphamide-induced mouse cystitis. Oliveira MG1, Calmasini FB1, Alexandre EC1, Mónica FZ1, Soares AG2, Costa SKP2, Antunes E1 1FCM-Unicamp – Pharmacology, 2ICB-USP – Pharmacology

08. Respiratory and Gastrointestinal Pharmacology

08.010 Comparison of the mechanisms underlying the relaxation induced by two nitric oxide donors in airways from asthmatic rats. Castro PFS1, Batista AC2, Silva RS3, Rocha ML2 1UEG, 2UFG, 3FCFRP-USP

08.011 Gastrointestinal dysfunction associated with dystrophin deficiency in mdx mice and GABAergic neurotransmission. Frangiotti MIB1, Silva JDP1, Nogueira-Bechara FM1, Silva RV1, Lima-Landman MTR1, Lapa AJ1,2, Souccar C1 1Unifesp-EPM – Farmacologia, 2UEA – Medicina Experimental

08.012 Gastroprotective and healing effects of the dual endothelin receptor antagonist bosentan against chronic gastric ulcer in rats. Dal Lin FT, Werner MFP UFPR – Farmacologia

08.013 Relaxant mechanism of essential oil from Lippia origanoides on guinea pig airway smooth muscle. Menezes PMN1, Brito MC1, Paiva GO1, Ribeiro LAA1, Lucchese AM2, Silva FS1 1UNIVASF, 2UEFS

08.014 Cholinergic Transmission and Gastrointestinal Dysfunction in Dystrophic (mdx) Mice Ferraz MC1, Frangiotti MIB1, Pisano Dias ASES

1, Nogueira-Bechara FM

1, Silva JDP

1, Silva RV

1, Lima-Landman MTR

1, Lapa AJ

1,2, Souccar C

1

1Unifesp-

EPM – Farmacologia, 2UEA – Medicina Experimental

08.015 Geraniol, but not Citral, participates in the gastric healing activity of the essential oil of Cymbopogon citratus in mice. Somensi LB1, Venzon L2, Boeing T1, Mariano LNB1, Souza P1, Wagnet TM3, Andrade SF1, Nesello LAN2, Silva LM1 1Univali – Ciências Farmacêuticas, 2Univali – Nutrição, 3Univali – Farmácia

08.016 p-cymene presents low toxicity after repeated doses and gastroduodenal antiulcerogenic activity related to antioxidant and anti-inflammatory effects. Formiga RO1, Pessoa MMB1, Barros MEF1, Silva SL1, Guedes JM1, Alves EB1, Vasconcelos RC2, Rodrigues CRS1, Sobral MV1, Lima CMBL1, Araújo RF2, Araújo AA2, Batista LM1 1UFPB, 2UFRN

08.017 Gaseous mediators (H2S, NO and CO) and AMPK interactions is required to gastric protection in mice. Araújo S, Oliveira AP, Sousa FBM, Lima EBS, Araújo TSL, Souza LKM, Iles B, Nogueira KM, Lopes ALF, Pacheco G, Oliveira RCM, Medeiros JVR UFPI – Biofísica e Farmacologia

08.018 Physical exercise reverts decrease in the gastric emptying induced by renovascular hypertension model 2K1C in rats. Lima EBS1, Telles PVN2, Sousa JFR2, Lima LC2, Oliveira LCS3, Silva MTB2 1UFPI – Farmacologia, 2UFPI – Educação Física, 3UFPI – Nutrição e Alimentos

08.019 Lactobacillus reuteri DSM 17938 decrease biomarkers of oxidative stress and gastric damage induced by ethanol administration in mice: role of TRPV1/Substance P axis. Oliveira AP

1, Araújo S

1, Souza LKM

1, Sousa FBM

1, Araújo TSL

1,

Nogueira KM1, Pacífico DM2, Brito GAC2, Medeiros JVR1 1UFPI – Farmacologia da Inflamação e Desordens Gastrintestinais, 2UFC – Morfologia

08.020 EValuation of acute toxicity and gastroprotective activity of (-)-fenchone in animal models. Guedes JM1, Silva SL1, Formiga RO1, Barros MEFX1, Pessoa MMB1, Vasconcelos RC2, Araujo AA2, Barbosa JM1, Batista LM1 1UFPB, 2UFRN

08.021 Involvement of potassium channels, nitric oxide synthase and guanylate cyclase in the antispasmodic effect of Simaba ferruginea A.St.-Hil. on rat isolated ileum. Almendra RB1, Fonseca OC1, Oliveira JSSM2, Chaves MH2, Santos RF3, Oliveira AP3, Oliveira RCM3 1UFPI – Pharmacology, 2UFPI – Chemistry, 3UFPI – Medicinal Plants

08.022 Evaluation of antidiarrheal effect of ethanolic extract of Simaba ferruginea A.St.-Hil. (Simaroubaceae) leaves in mice. Negreiros PS1, Almendra RB1, Ferreira OC1, Costa DS1, Oliveira JSSM2, Chaves MH2, Santos RF3, Oliveira RCM3 1UFPI – Pharmacology, 2UFPI – Chemistry, 3UFPI – Medicinal Plants


08.023 Antispasmodic activity of JME-173, a non-anesthetic analogue of mexiletine, in the airway smooth muscle depends of the blockade of voltage-gated calcium channels. Carvalho KIM1, Joca HC2, Cruz JS2, Silva ET1, Costa JCS1, Faria RX, Martins MA1 1Fiocruz, 2UFMG

08.024 Pre-clinical evaluation of antiulcerogenic activity of geopropolis from Melipona fasciculata in mice. Brito H1, Pessoa DL, Sousa AK, Barbosa RA, Caldas GF, Borges ACR, Borges MO1 1UFMA – Ciências Biológicas e da Saúde

08.025 Gastroprotective effects of hydroethanolic extract of Cochlospermum regium (Mart & Schrank) Pilger against acute gastric ulcers in rodents. Arunachalam K, Pavan E, Oliveira DM, Figueiredo FF, Machado MTM, Martins DTO UFMT – Basic Sciences in Health

09. Natural Products and Toxinology

09.034 From popular use to preclinical validation: A study of the healing activity of hydroalcoholic extract from the leaves of Eugenia punicifolia (Myrtaceae) in rodents. Périco LL1, Rodrigues VP1, Ohara R1, Santos BB1, Santos RC2, Vilegas W3, Rocha LRM1, Santos C4, Hiruma-Lima CA1 1IBB-Unesp – Fisiologia, 2USF – Farmacologia e Gastrenterologia, 3Unesp-Litoral Paulista, 4FCLAr-Unesp

09.035 Vasorelaxant effect of neryl acetate in rat thoracic aorta. Carvalho EF, Gadelha KKL, Oliveira DMN, Magalhães PJC UFC – Fisiologia e Farmacologia

09.036 Biopolymer Extracted From Exudate of Anadenanthera colubrina var. cebil (Griseb.) Altschul (Angico Gum) displays antidiarrheal therapeutic potential in mice. Araújo TSL1,2, Nicolau LAD3,1, Sousa NA1,2, Souza LKM1,2, Araújo S1, Sousa FBM1,2, Oliveira AP1, Nogueira KM1, Iles B1, Pacheco G1, Medeiros JVR1,2 1UFPI – Farmacologia da Inflamação e Desordens Gastrintestinais, 2Renorbio, 3UFC – Fisiologia e Farmacologia

09.037 Antifungal activity and mechanism of action of monoterpene linalool on Candida albicans strains of pulmonary origin. Silva ACL

1, Silva DF

1, Diniz-Neto H

1, Sousa JP

2, Lima EO

1 1UFPB – Farmacologia e toxicologia de produtos naturais,

2UFPB – Análises Clínicas

09.038 Methyl cinnamate, a natural phenolic compound, inhibits elastase-induced emphysema in mice. Silva LMP1, Ferro JNS1, Souza TNC1, Melo LEJ1, Conserva LM2, Barreto E1 1 ICBS-UFAL, 2IQB-UFAL

09.039 Ultralow concentration piericidin A1 changes phenotype of tumor cells. Florêncio KGD1, Wilke DV1, Costa-Lotufo LV2, Pinto FCL3, Oliveira FAS1, Pessoa ODL3, Rocha DD1 1UFC – Fisiologia e Farmacologia, 2ICB-USP, 3UFC – Química Orgânica

09.040 Anti-inflammatory and antinociceptive activities of cashew gum (Anacardium occidentale) in mice. Silva DPB1, Lino RC1, Cardoso CS1, Florentino IF1, Pereira-Junior MA2, Fernandes KF2, Costa EA1 1UFG – Farmacologia, 2UFG – Bioquímica

09.041 Lipid-lowering and antiatherogenic effects of Echinodorus grandiflorus (Cham. & Schltdl.) Micheli. in rabbits . Gasparotto FM1, Lourenço ELB2, Gasparotto Junior A1, Kassuya CAL1 1UFGD – Ciências da Saúde, 2Unipar – Farmácia

09.042 Antinociceptive and anti-inflammatory effect of the dichloromethane extract from the roots of Arrabidaea brachypoda (DC.) bureau and its role on asic and TRPM8 receptors. Rodrigues VP1, Périco LL1, Ohara R1, Santos RC2, Vilegas W3, Rocha CQ4, Rocha LRM1, Hiruma-Lima CA1 1IBB-Unesp, 2USF, 3Unesp-Câmpus do Litoral Paulista, 4UFMA

09.043 Modulating activity of the alga Chlorella in impaired glucose tolerance and type-2 diabetic patients. Castro TCL, Martins F, Torello CO, Queiroz MLS FCM-Unicamp – Farmacologia

09.044 Anti-inflammatory potential of aqueous extract and polysaccharide fraction from Thuja occidentalis Linn. in reducion of COX-2, iNOS and pro-inflammatory cytokines in mice. Fonseca AMV1, Silva IS2, Nicolau LAD3, Sousa FBM4, Silva RO3, Oliveira AP5, Araújo S5, Nogueira KM5, Souza LKM4, Araújo TSL4, Alencar MS5, Costa ACB5, Pacheco G5, Medeiros JVR5 1IESVAP, 2ICB-UFMG, 3UFC, 4Renorbio, 5UFPI

09.045 Marine microorganisms from the north coast of São Paulo are a promising source of anticancer compounds . Rigato DB1, Domingos HV2, Chain BG1, Souza BV1, Falcão GC1, Branco P2, Costa-Lotufo LV2, Jimenez PC1 1Unifesp – Departamento de Ciências do Mar, 2Universidade de São Paulo – USP – Departamento de Farmacologia

09.046 Effect of the hexane fraction of Punica granatum leaves in the oxidative stress induced in septic mice Sousa NCF1, Simone AT2, Araújo MC1, Figueiredo IFS1, Pereira DMS1, Mendes SJF1, Silva BRS1, Silva LCN1, Muscará MN2, Fernandes ES1 1Ceuma, 2USP

09.047 Investigation of anticancer potential of Neoteredo Reynei’s microbiota through metagenomics and culturing approaches. Brito TL, Wilke DV, Silva AB, Pessoa ODL, Silva AT UFC – Farmacologia

09.048 Biochemical and biological characterization of Leptodeira annulata (Banded Cat-Eyed snake; Dipsadidae) venom. Torres-Bonilla KA, Panunto PC, Hyslop S Unicamp – Farmacologia

09.049 Antitumor potential of bacteria associated to Zoanthid Palythoa caribaeorum from Trindade Island, Brazil Ferreira KQ1, Oliveira FAS1, Pinto FCL2, Pessoa ODL2, Sahm BDB3, Costa-Lotufo LV3, Wilke DV1 1UFC – Farmacologia e Fisiologia, 2UFC – Química Organica, 3ICB-USP – Farmacologia


09.050 Antimalaric activity in vitro of essential oils of Piper marginatum Jacq. (Piperaceae). Moraes-Castilho J, Silva EBS, Cirino-Lopes JM, Silva NC, Pires-Moraes TM, Ferreira-Castro KC, Pires-Moraes W UFOPA – Farmacologia Experimental

09.051 Antihypertensive and cardioprotective effects of Cuphea carthagenensis (Jacq.) J. F. Macbr. in a renovascular hypertension model associated with ovariectomy. Schaedler MI1, Tirloni CS1, Palozi RAC1, Silva AO1, Vasconcelos PC1, Lívero FAR2, Araújo VO2,3, Gasparotto Junior A1 1UFGD – Toxicologia e Farmacologia Cardiovascular, 2Unipar – Farmacologia e Toxicologia de Produtos Naturais

09.052 Role of the NO-cGMP pathway on the sustained antihypertensive effects of Acanthospermum hispidum DC. on ovariectomized rats with renovascular hypertension. Palozi RAC, Schaedler MI, Tirloni CAS, Silva AO, Gasparotto Junior A UFGD – Ciências da Saúde

09.053 Cytotoxicity of BjcuL, a Galactose-binding Lectin from Bothrops jararacussu Snake Venom, in J774A.1 macrophages. Pereira BB, Panunto PC, Hyslop S Unicamp – Farmacologia

09.054 Beta-Cyclodextrin enhanced antioxidant effect of (-)-linalool, a monoterpene present in Rosewood essential oil, in gastric lesion models Silva FV1, Sousa SS2, Fernandes HB1, Oliveira IS1, Viana AFSC3, Araújo AAS4, Quintans-Júnior LJ5, Oliveira RCM1 1Renorbio-UFPI – Biotechnology, 2UFPI – Pharmacology, 3UFC – Pharmacology, 4UFS – Pharmacy, 5UFS – Neuroscience and Pharmacological Assays

09.055 Gastroprotective effect of sedum dendroideum leaves infusion on acute ethanol-induced gastric lesions in rats. Luz BB1, Maria-Ferreira D2, Dallazen JL1, Oliveira AF2, Cipriani TR2, Werner MF1 1UFPR – Farmacologia, 2UFPR – Bioquímica e Biologia Molecular

09.056 Evaluation of the acute toxicity and gastroprotective activity of hesperetin in animal models. Silva SL1, Guedes JM1, Formiga RO1, Pessoa MMB1, Barros MEFX1, Vasconcelos RC2, Araujo AA2, Batista LM1 1UFPB, 2UFRN

09.057 Rhamnogalacturonan for the management of pain in ulcerative colitis. Maria-Ferreira D1, Dallazen JL

1, Barbosa

BL1, Nascimento AM2, Cipriani TR2, Baggio CH3, Werner MFP1 1UFPR – Farmacologia, 2UFPR – Bioquímica, 3University of Calgary – Chronic Diseases

09.058 Toxicity induced by bee venom (Apis mellifera) antagonized by polyanion (Fucosylated chondroitin sulfate – fucCS). Cons BL1, Tavares-Henriques MS1, Monteiro-Machado M1, Strauch MA2, Teixeira-Cruz JM1, César MO1, Peçanha TSC1, Patrão-Neto FC1, Mourão PAS3, Melo PA1 1UFRJ – Farmacologia e Química Medicinal, 2IVB, 3HUCFF-UFRJ – Tecido Conjuntivo

09.059 Evaluation of the intestinal anti-inflammatory activity from green propolis extract in a model of colitis in mice induced by dextran sulfate sodium. Silva RCMVAF, Costa APM, Perondi G P, Bolda LNM, Somensi LB, Souza P, Andrade SF, Silva LM Univali – Ciências Farmacêuticas

09.060 Conservation among venoms PLA2 molecules as basis for development of pan-PLA2 antibodies. Strauch MA1,2, Corrêa-Netto C1, Araújo RT1, Brazil-Más L1, Monteiro-Machado M3, Leitão-Araújo M4, Foguel D5, César MO3, Calvete JJ6, Migowski ERC1,7, Melo PA3, Zingali RB5 1IVB, 2UFRJ, 3ICB-UFRJ, 4FZB-RS – Ofiologia, 5UFRJ – Bioquímica Médica, 6IBV-CSIC 7UFRJ – Puericultura e Pediatria

10. Cancer Pharmacology

10.016 Antitumor, hepatic and hematological effects of the mesoionic compound SIDNONE-1 in mice with Ehrlich tumor. Agnes JP

1,2, Corso C R

2, Adami ER

2, Echevarria A

3, Acco A

2

1UFSC – Farmacologia,

2UFPR – Farmacologia,

3UFRRJ –

Química

10.017 Polymeric nanocarrier systems containing lapachol derivatives: development and evaluation of anticancer activity Vieira JB1, Oliveira FC2, Nunes da Silva EJ3, Dias GG, Pessoa C1 1UFC – Fisiologia e Farmacologia, 2UFC, 3UFMG

10.018 Cytotoxic effect of a synthetic benzodiazine entitled PACP08A in non-small cell lung carcinoma cell line NCI-H460. Santos RS1, Maranhão SS, Lima DJB, Rocha GGG, Moraes OM1, Souza MVN2, Pessoa C2 1UFC – Fisiologia e Farmacologia, 2Fiocruz

10.019 The tumor suppressor, micro-RNA-137, inhibits malignant melanoma migration by targetting TBX3 Peres J1, Maliepaard EM1, Rambow F2, Larue L3, Prince S1 1University of Cape Town – Health Sciences, 2VIB-Campus Gasthuisberg – Molecular Cancer Biology, 3Institut Curie – Normal and Pathological Development of Melanocytes

10.020 Chuquiraga spinosa Less (Huamanpinta) ethanol extract of leaves Chemopreventive effect in cancer gastric NMU-induced rat. Arroyo J1, Rojas J1, Herrera O2, Chavez R3, Chumpitaz V4, Enciso E5, Tinco A6 1Universidad Nacional Mayor de San Marcos – Farmacologia, 2Universidad Nacional de Ica, 3Facultad de Medicina Universidad Nacional Mayor de San Marcos – Farmacologia, 4Facultad de Odontología Universidad Nacional Mayor de San Marcos – Farmacologia, 5Dirección de Farmacia y Bioquímica Universidad Nacional San Cristobal de Huamanga de Ayacucho – Farmacologia e Toxicologia, 6Dirección Facultad de Farmacia y Bioquímica de la Universidad Nacional San Cristobal de Huamanga de Ayacucho – Farmacologia e Toxicologia


10.021 Targeting Stathmin 1 and microtubule dynamics in acute lymphoblastic leukemia. Machado-Neto JA, Rodrigues Alves APN, Fernandes JC, Coelho-Silva JL, Scopim-Ribeiro R, Fenerich BA, Silva FB, Simões BP, Rego EM, Traina F FMRP-USP

11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Toxicology

11.019 Study of the oral acute toxicity of titanium dioxide nanoparticle. Abreu CPV1, Brandão HM, Oliveira CP, Wouters F, Pereira MM, SIlva SR, Sousa RV1 1UFLA – Medicina Veterinária

11.020 Chronic treatment with paracetamol impairs vascular relaxation in rats. Porto HKP, Rocha ML UFG – Ciências Farmacêuticas

11.021 PK-PD modeling of triazoles against Cryptoccocus neoformans using time-kill curves and simulation. Alves IA1, Staudt KJ1, Kuhn K2, Dalla Costa T1, Araújo BV1 1UFRGS, 2URI-Santo Angelo

11.022 Markers of sildenafil responsiveness in the treatment of erectile dysfunction: asymmetric dimethylarginine related genes. Milanez-Azevedo AM1, Viana-Figaro F2, Belo VA3, Molina CAF4, Andrade MF5, Muniz JJ6, Tanus-Santos JE1, Tucci Jr S4, Lacchini R2 1FMRP-USP – Farmacologia, 2 EERP-USP – Enfermagem Psiquiátrica e Ciências Humanas, 3UFMG – Instituto de Ciências Biológicas, 4FMRP-USP – Cirurgia e Anatomia, 5FMRP-USP – Cirurgia, Ortopedia e Traumatologia, 6Univas

11.023 Estimation of In vivo hepatic extraction ratio of doxorubicin in breast cancer patients. Pippa LF1, Rocha A1, Andrade JM2, Lanchote VL1 1FCFRP-USP, 2FMRP-USP

11.024 Effects of the CYP2D6 and CYP3A4/5 genetic polymorphisms on the population pharmacokinetics of tamoxifen and its main metabolites in breast cancer patients. Ximenez JPB1, D'Agate S2, Pereira MPM1, Andrade JM1, Suarez-Kurtz G3, Della Pasqua O2, Lanchote VL1 1USP, 2University College London, 3INCa

12. Drug Discovery and Development

12.009 Novel long-acting amylin agonist suppresses food intake and Improves GLP-1 effect in vivo Nascimento CVMF1, Lima LMTR2 1Biozeus Biopharmaceutical S.A., 2UFRJ – Farmácia

12.010 Layered Double Hydroxides with Intercalated Mefenamic Acid: antinociceptive study and gastroprotective effect Marcelino BR1, Castro AS1, Aviz BNL1, Freitas JJS1, Anicete-Santos M2, Lima AB1 1UEPA, 2UFPA

12.011 New QSAR method based on the molinspiration computer platform for discovering new drugs. Antunes JE1, Fernandes GS2, Pereira MBM3 1UFJF – Farmácia, 2UFJF – Acadêmico, 3UFJF – Ciências Básicas em Saúde

14. Pharmacology Education and Technology

14.002 Historical aspects of pharmacology according to bibliographic reference of pharmacy School Pharmacy Museum (MPh/UFOP) Santos WP1, Grabe-Guimarães A2, Borges I3 1UFOP – Acadêmico, 2UFOP – Farmácia, 3UFOP – Museologia





Index of Authors

A

Abdalla HB 05.003, 05.004 Abiko PY 02.027 Abildgaard A 02.009 Abreu CPV 11.014, 11.019 Abreu VS 09.006 Acco A 10.016 Adami ER 10.016 Agnes JP 10.016 Aguiar DC 05.002 Aguiar LCT 05.012 Aguiar LMV 02.025 Aguiar MFR 09.011 Aguiar MFS 05.028 Aguiar MG 10.002 Aguiar RP 03.007, 03.022, 03.026 Aguida WR 05.028 Akamine EH 06.002 Alberti TB 02.017 Albuquerque JSS 09.033 Albuquerque NR 11.017 Albuquerque TB 04.017 Alcântara IS 04.023 Alcântara TC 06.014 Alencar AKN 06.004, 06.067 Alencar MS 09.044, 12.008 Alencar POC 08.007 Alexandre EC 06.045, 07.011, 07.014, 07.015 Alexandre TL 04.004 Almeida AFS 09.003 Almeida AJPO 06.017, 06.018 Almeida CLB 06.074 Almeida DL 06.030 Almeida FB 02.029, 03.008 Almeida FRC 05.012, 05.023 Almeida Junior JS 04.054 Almeida LC 09.016 Almeida LM 05.025 Almeida MP 04.024 Almeida POA 11.007 Almeida PRC 10.006 Almeida RF 02.019 Almeida RN 05.011 Almendra RB 08.008, 08.021, 08.022 Alvarenga EM 12.002 Alvarez ARP 04.005 Alves APNN 10.003 Alves CAC 06.064 Alves EB 08.016 Alves IA 11.021 Alves LF 06.014 Alves M 04.006 Alves RJ 12.006 Alves-do-Prado W 02.027, 02.028 Alves-Fernandes DK 10.014

Alves-Filho JC 04.005, 04.006, 04.014, 04.025, 04.026, 04.042, 04.051

Alves-Filho JCF 04.012, 04.057, 06.049 Alvez-Filho J 10.001 Alvim-Silva T 06.025, 06.033 Amaral J 06.077 Amaral M 06.067 Ambiel CR 02.027, 02.028 Amorim YM 09.032 Andrade DM 09.027 Andrade DML 06.053 Andrade DR 06.044, 06.066 Andrade IR 01.022 Andrade JM 11.023, 11.024 Andrade KQ 04.003, 04.018 Andrade MF 11.022 Andrade PVD 11.014 Andrade SF 02.010, 06.074, 08.006, 08.009,

08.015, 09.001, 09.059, 12.006 Andrade VS 15.013 André DM 04.013 André E 05.005 Andreo PHM 02.028 Andreotti DZ 02.021, 02.024, 02.031 Angelis CD 06.069 Anicete-Santos M 12.010 Anjos-Garcia T 03.003, 03.017 Anjos-Valotta EA 04.007 Antero LS 03.012 Antoniali C 01.018, 06.027, 06.050, 06.058 Antoniazzi CTD 03.001 Antunes E 04.013, 04.016, 06.045, 07.004,

07.009, 07.011, 07.013, 07.014, 07.015

Antunes JE 12.011 Antunes-Rodrigues J 04.050 Aquino FLT 09.026 Aquino PEA 04.019 Aquino RAN 02.010 Aragão KS 10.006 Aragão Neto HC 05.011 Arantes AC 04.030 Arantes ACS 04.004, 04.020, 04.053 Arantes G 01.021 Araujo AA 08.020, 09.056 Araújo AA 08.016 Araújo AAS 09.054 Araujo BV 11.005 Araújo BV 11.015, 11.021 Araújo G 06.024 Araújo GA 06.026, 06.063 Araújo IDR 15.013 Araújo JSC 06.001, 06.008 Araújo LEPF 08.008 Araújo MC 04.001, 09.046 Araujo MGF 09.032


Araújo N 06.009 Araújo NF 06.005, 06.010 Araújo ORP 04.003 Araújo RF 08.016 Araújo RT 09.060 Araújo S 01.002, 08.005, 08.017, 08.019,

09.036, 09.044, 12.002, 12.008 Araújo TSL 01.002, 08.005, 08.017, 08.019,

09.005, 09.036, 09.044, 12.008 Araújo VC 04.046 Araújo VO 09.051 Araya EI 05.018 Arriaga AMC 05.008 Arroyo J 09.031, 10.020 Arrúa K 06.078 Arunachalam K 08.025 Assereuy AMS 05.025 Assreuy J 04.036, 06.003, 06.006, 06.035 Assunção HCR 06.065 Astudillo-Guerrero C 13.002 AU Borbely 10.012 Autran LJ 06.019, 06.034 Avellar MCW 01.010, 01.021, 07.007, 07.010,

07.012 Aviz BNL 12.010 Ayres JC 06.070 Azalim PN 15.010 Azevedo MLSG 04.003 Azevedo R B 04.053

B

Bacchi AD 14.001 Baggio CH 09.057 Bandiera S 02.012, 02.013, 02.019, 02.026 Barata LES 04.054 Barbosa ALR 09.018 Barbosa BL 09.057 Barbosa GH 01.012 Barbosa JM 08.020 Barbosa JWP 06.066 Barbosa RA 08.024 Barbosa WLR 02.017 Barcelos LS 04.031 Barja-Fidalgo C 01.001, 01.005, 01.022 Barp CG 06.006 Barra A 04.038 Barreiro E 06.024 Barreiro EJ 05.007, 06.008, 06.067 Barreiro EJL 06.001, 08.004 Barrera-Bugueño C 13.002 Barreto AEA 01.017, 04.028 Barreto E 01.011, 04.020, 09.026, 09.038 Barreto F 11.005 Barros BC 07.001 Barros FCN 08.007 Barros HMT 02.029, 03.008, 03.011 Barros MA 09.027 Barros MEF 08.016 Barros MEFX 08.020, 09.056 Barros RBM 06.025

Barros TMH 02.026 Barros-Filho MC 10.002 Basso NRS 04.044 Bastos PR 04.033 Batista AC 08.010 Batista JA 09.018 Batista LM 08.016, 08.020, 09.056 Batista NY 09.007, 09.017 Batista-Lima FJ 08.002 Bauermeister A 09.004, 09.016, 10.014 Beber AP 08.009 Becker LK 06.031 Beleza MLML 08.006 Bellaver B 02.013 Belo MAA 04.049, 04.049 Belo VA 06.056, 11.022 Beltran CT 01.017, 04.028, 04.037 Bendhack LM 01.018, 01.019, 06.016, 06.054,

06.058, 06.059, 06.061 Benevides NMB 02.025, 04.015 Benham A 07.012 Bento S 04.030 Benzi JRL 11.018 Bernabé DG 10.015 Bernardi A 04.010 Bertolino J 06.065 Bertollotto G 07.011 Bezerra MM 05.008 Bianchi PC 02.001, 03.015, 03.016 Bingana RD 08.007 Biojone C 02.003, 02.009 Blanco ALF 06.069 Bobermin L 02.012 Boeing T 06.074, 08.009, 08.015, 09.001 Bogo MR 04.044 Bolda LNM 09.059 Bonaventura D 06.005, 06.009, 06.010 Bonfante R 05.003, 05.004 Bonfitto PHL 04.016, 04.055 Boni MS 02.034 Bonilla-Becerra SM 07.004 Borbely AU 07.005 Borbely KSC 07.005, 10.012 Borges ACR 08.024 Borges I 14.002 Borges LB 04.040 Borges LL 06.053 Borges MO 08.024 Borges PA 09.030 Borges-Assis AB 02.006, 02.007 Borghi S 05.027 Bortolin RH 03.023 Bortolini MC 01.020 Botelho RM 07.005, 10.012 Bouskela E 01.022 Bouvier M 01.020 Braga A 11.005 Braga AV 05.021 Braga RM 05.011


Braga VA 09.015 Brain SD 11.003 Branco LGS 04.050 Branco P 09.022, 09.045 Branco PC 01.012, 10.010, 10.011, 10.014 Brandão HM 11.014, 11.019 Brasil AF 04.049 Bravo JA 13.002 Bravo TP 09.006 Brazão SC 06.036 Brazil-Más L 09.060 Brentani H 01.013 Brito AF 03.021 Brito F 06.024 Brito FC 09.018, 09.019 Brito FCF 06.019, 06.034, 06.036, 06.073,

06.075, 11.004 Brito GAC 08.019 Brito H 08.024 Brito LM 10.005 Brito MC 08.013 Brito MD 01.016 Brito RB 06.028, 06.029, 06.029, 11.016 Brito TL 09.047 Brito VGB 01.017, 04.028, 04.037 Britto Junior J 09.020 Bruffato JPT 02.006 Bruno AS 06.030 Buch HS 01.021 Bueno PI 04.016, 04.055 Bueno-de-Camargo LM 02.032 Burger ME 03.001 Burguer ME 15.008 Buriche ALR 07.006

C

Cabral-Costa JV 02.016, 02.024 Caceres RA 01.020 Caldas GF 08.024 Caldeira-Dias M 01.004, 06.047 Caletti G 02.026 Caliari MV 04.031 Caliendo G 04.039 Calil-Elias S 09.006, 09.008, 09.030 Calixto MC 04.013 Calmasini FB 06.045, 07.004, 07.014, 07.015 Caloi CM 04.043 Calvete JJ 09.060 Camandola S 02.005 Camara AC 07.008 Camarini R 15.007 Campos A 08.006 Campos AC 03.007, 03.022, 03.026 Campos CC 05.027 Campos DL 12.005, 12.007 Campos HA 06.028, 06.029 Campos HM 06.028, 06.029 Campos R 07.013 Campos-Mota GP 06.010 Campuzano A 06.078

Campuzano MA 06.078 Candido K 09.007 Capettini L 06.009 Capettini LSA 06.010 Cararo-Lopes MM 02.031 Cardillo GM 01.013 Cardoso AR 02.011 Cardoso CS 03.021, 04.040, 05.016, 09.040 Cardoso F 04.045 Cardoso PF 09.008 Carlos D 06.013 Carmo JOS 01.011, 07.005 Carmo MFA 06.064 Carneiro FS 07.002 Carneiro MTS 06.048 Cárnio EC 04.050 Carrara MYW 15.009 Carregaro V 04.042 Carreño F 11.001 Carvalho CC 06.039 Carvalho EF 09.035 Carvalho F 03.009 Carvalho GD 06.071 Carvalho KIM 08.023 Carvalho MAJ 04.019 Carvalho MHC 06.002 Carvalho MTL 07.001 Carvalho PMG 04.040 Carvalho RF 01.027 Carvalho VF 07.006 Carvalho VFM 12.004 Casarotto PC 02.003, 02.009 Cassaro-Strunz CM 11.009 Cassola AC 09.025 Castellão-Santana LM 02.027, 02.028 Castelo Branco SJS 15.005, 15.006 Castelo-Branco MTL 10.008 Castilho RO 06.038 Castor RGM 06.030 Castrén E 02.003 Castro AS 12.010 Castro LGZ 04.015 Castro MM 06.012, 06.056, 06.072 Castro MVEA 06.017, 06.018 Castro NG 02.011, 02.033, 02.034 Castro PFS 08.010 Castro QJT 06.031 Castro TCL 09.002, 09.043 Cau SBA 06.030 Cavada BS 05.025 Cavalcante AACM 10.009 Cavalcante FA 07.001, 08.001, 08.004 Cavalcante GTS 02.015, 02.018, 02.020, 02.030 Cavalcante TMB 04.019 Cavalli R 11.013 Cavalli RC 06.047 Cechinel-Filho V 06.074, 08.006, 09.001 Cecilio N 04.006 Cecílio NT 04.051


Cenci L 03.009 Ceravolo GS 06.002, 06.032 Ceron CS 06.056 Cerqueira ARA 04.011, 04.039, 09.025, 12.001 César MO 09.058, 09.060 Chain BG 09.022, 09.045 Chan BY 06.012 Chapman V 05.001 Charão CCT 04.036 Charlie-Silva I 04.049 Charo IF 04.035 Chaves HV 05.008 Chaves LS 08.005, 09.012, 12.008 Chaves MH 08.021, 08.022 Chavez R 10.020 Chichorro JG 05.018 Chies AB 06.011, 06.043 Chimini JS 06.007, 06.020, 06.040 Chumpitaz V 10.020 Ciambarella BT 04.053 Cioato SG 05.019 Cipriani TR 09.055, 09.057 Cirino-Lopes JM 09.050 Cirpriani TR 05.013 Citó AMGL 08.008 Claudino MA 06.044, 06.066 Claudino RF 05.018 Clemente-Napimoga JT 05.003, 05.004 Coavoy-Sánchez SA 04.039 Coelho MM 05.021 Coelho-Silva JL 10.021 Coeli-Lacchini FB 11.013 Cogo JC 07.013 Coimbra NC 02.035, 03.003, 03.017 Colombo FF 04.046 Colon D 01.006, 04.045 Colón DF 10.001 Conceiçao EC 06.053 Conceição K 04.049 Conde-Tella SO 06.077 Cons BL 09.028, 09.058 Conserva LM 09.026, 09.038 Cordeiro RSB 04.007, 04.020 Coronel C 06.079 Correa AMC 04.021 Correa FM 02.002 Corrêa JD 04.049 Correa JWN 09.007, 09.017, 11.017 Corrêa-Netto C 09.060 Correia ACC 01.011 Correia-de-Sa P 02.027 Correia-de-Sá P 02.028 Corso C R 10.016 Côrtes SF 06.038 Cortez IL 03.006 Costa AC 08.001, 08.004 Costa ACB 09.044 Costa ACC 11.018 Costa APM 09.059

Costa DS 08.008, 08.022 Costa EA 02.023, 03.021, 04.040, 05.016,

06.051, 09.040 Costa GC 06.062 Costa JCS 08.023 Costa KM 04.044 Costa L 02.029, 04.006, 04.026 Costa LB 03.008 Costa MP 10.009 Costa P 03.025 Costa RM 06.049, 06.051 Costa RO 04.019 Costa SK 04.011, 11.003 Costa SKP 04.039, 04.041, 05.006, 06.015,

07.015, 09.025, 12.001, 12.003 Costa-Júnior JS 08.008 Costa-Lotufo LV 01.012, 09.004, 09.016, 09.022,

09.023, 09.024, 09.039, 09.045, 09.049, 10.010, 10.011, 15.001

Costa-Neto CM 01.020, 01.028 Cotias AC 04.007, 04.020 Coura CO 04.015 Coutinho D 04.030 Coutinho DS 04.010 Coutinho-Silva R 04.018, 04.042 Couto GC 04.007 Crestani CC 03.013 Cruz F 03.016 Cruz FC 02.001, 03.013, 03.015, 15.002 Cruz FF 04.044 Cruz JS 02.036, 08.023 Cruz LO 11.017 Cruz-Machado SS 04.033, 04.034, 13.001 Cunha AC 04.041 Cunha F 04.026 Cunha Fernando Q 04.051 Cunha FQ 01.006, 04.006, 04.012, 04.014,

04.025, 04.045, 04.057, 05.001, 05.027, 10.001

Cunha LCL 04.058 Cunha MPSS 10.002 Cunha T 04.026 Cunha TM 01.006, 04.001, 04.006, 04.012,

04.014, 04.022, 04.025, 04.047, 04.051, 05.001, 05.017, 05.020, 05.024, 05.027, 10.001

Cunha VMN 06.004 Cury SS 01.027

D

D'Agate S 11.024 Daher S 10.012 Dal Lin FT 08.012 Daleprane JB 04.007 Dalla Costa T 11.001, 11.005, 11.015, 11.021 Dallazen JL 05.013, 09.055, 09.057 Dal-Pai-Silva M 01.027 Dal-Secco D 04.035 Damacena-Angelis C 06.041 Damacena-Angelis CD 06.055


Damasceno LEA 04.014, 04.057 Damazo AS 04.032 Damico MV 04.009, 04.027 Dantas BPV 06.017, 06.018 D'Aquino MS 02.022 Dartora VFC 12.003, 15.001 Das PK 01.024 Davoli-Ferreira M 04.047 de Nucci G 06.045, 07.013, 11.006, 11.008 Del Bel EA 02.004 Del Bianco B 09.023 Delgobbo MS 06.001 Della Pasqua O 11.024 Detoni VL 03.007, 03.022, 03.026 Diarte EMG 06.079 Dias DF 04.021 Dias GG 10.017 Dias QM 05.028, 09.011 Dias-Batista JB 02.015, 02.018, 02.020 Dias-Junior 06.046 Dias-Junior CA 06.007, 06.020, 06.040 Diniz CRAFD 03.012 Diniz-Neto H 09.037 Do Val DR 05.008 do Vale GT 06.056 Dobransky T 02.036 Domiciano TP 05.027 Domingos HV 09.022, 09.045 Domingos LB 03.010 Domingues LM 04.022 Domingues NLC 04.017 Dourado TMH 09.033 Driemeier D 03.009 Duarte DA 01.020 Duarte FS 02.018, 02.020 Duarte IDG 05.002, 09.003 Duarte LC 04.017 Duarte LP 09.029 Duarte MMF 15.008 Duarte T 01.026 Duarte-Souza PC 03.007 Dutra RC 02.017 Duzzioni M 02.015, 02.018, 02.020, 02.030

E

Eccard B 06.001, 06.008 Echem C 06.002 Echevarria A 10.016 Echeverry MB 02.008 Elfving B 02.009 Emílio-Silva MT 04.050 EMP Silva 10.012 Enciso E 10.020 Engi SA 03.013, 03.015 Engler SSM 10.014 Escobar-Luna J 13.002 Espinoza-Pardo GV 01.020

F

Facine LM 06.009

Facundo AV 09.011 Fagundes RGM 05.022 Fahning BM 06.016 Fais RS 07.002 Falcão AL 10.002 Falcão GC 09.045 Falconi-Sobrinho LL 02.035, 03.003, 03.017 Faria RX 08.023 Farias R 06.024 Farias RS 06.026, 06.063 Fassini A 02.002 Fatima A 02.010 Fátima A 05.021 Fattori V 05.027 Favaro RR 04.041 Feijó PRO 01.025 Feitosa IB 05.028, 09.011 Feitosa KB 04.041 Fenerich BA 10.021 Fenical W 10.011 Fernandes AJM 04.053 Fernandes C 10.002, 10.003, 10.006 Fernandes EC 09.002 Fernandes ES 04.001, 09.046 Fernandes G 06.067 Fernandes GS 12.011 Fernandes HB 09.054 Fernandes ILM 06.037 Fernandes JC 10.021 Fernandes KF 09.040 Fernandes L 06.065 Fernandes LMP 02.014 Fernandes MNM 04.023 Fernandes PA 04.052, 10.007 Fernandes PR 02.029, 03.008, 03.011 Fernandes R 06.014 Fernandes SG 07.012 Fernandes-Santos C 06.021, 06.025 Ferrari LS 05.027 Ferraris F 04.049 Ferraz MC 08.014 Ferreira AJ 06.030 Ferreira AM 04.029 Ferreira AVM 06.010 Ferreira BHSH 06.027, 06.058 Ferreira DPPF 10.002 Ferreira ES 07.001 Ferreira GC 06.041, 06.042, 06.055, 06.076,

11.011 Ferreira HHA 04.046 Ferreira J 04.029, 05.005, 05.010, 05.014,

05.026 Ferreira JCC 04.054 Ferreira JRO 10.009 Ferreira KQ 09.049 Ferreira LA 04.032, 09.014 Ferreira LAB 06.060 Ferreira LGA 07.010 Ferreira M A 05.026


Ferreira MA 05.014 Ferreira MD 05.001, 05.024 Ferreira MJP 09.024 Ferreira MP 09.023 Ferreira NS 06.013, 07.002 Ferreira OC 08.022 Ferreira PA 06.079 Ferreira PMP 10.009 Ferreira RCM 05.002 Ferreira RG 04.005, 04.012, 04.014 Ferreira SRD 08.004 Ferreira TPT 04.004, 04.021, 04.030 Ferreira ZS 04.033 Ferreira-Castro KC 09.050 Ferrero MR 04.030 Ferro JNS 01.011, 09.026, 09.038 Figueiredo FF 08.025, 11.007 Figueiredo IFS 09.046 Filgueira FP 06.028, 06.029, 06.051 Filho JCA 05.027 Filho MDS 09.005 Finkler AD 01.020 Firmino EMS 15.003 Fischer MI 11.015 Florêncio KGD 09.039 Florentino IF 04.040, 05.016, 09.040 Florenzano J 11.003 Foguel D 09.060 Fonseca AMV 09.044 Fonseca AR 02.029, 03.008 Fonsêca DV 05.011 Fonseca FCS 04.008 Fonseca MD 01.006 Fonseca MDM 04.047, 04.057, 05.017, 05.020,

05.024 Fonseca MMD 05.001 Fonseca OC 08.008, 08.021 Fonteles MMF 04.019 Fontella FU 02.019 Fontes VC 15.005, 15.006 Fontes-Júnior EA 09.013, 09.027 Forlenza OV 01.013 Formiga RO 08.016, 08.020, 09.056 Fortes-Dias CL 04.009, 04.027 Frade MAC 01.024 Fraga AG 06.004 Fraga CAM 05.007, 06.067 França ARS 05.023 França KC 02.008 França-Neto A 01.025 Francischi JN 04.008, 04.024 Frangiotti MIB 08.011, 08.014 Freese L 02.029, 03.008 Freire PP 01.027 Freitas ALP 08.007, 09.005 Freitas BR 09.013 Freitas GA 01.010 Freitas JA 10.006 Freitas JJS 12.010

Freitas KM 04.031 Freitas RCN 06.067 Freitas VM 07.005 Frony AC 01.001, 01.005 Frota AF 02.025, 04.015 Fuentefria AM 12.006 Fukada SY 01.023 Furtado FF 05.004 Furtado LC 09.024 Fusse EJ 03.007, 03.022, 03.026

G

Gadelha KKL 09.035 Galduróz JCF 15.002 Gama LF 09.006 Garcia CC 04.030 Garcia LV 11.011 Garcia SC 03.025 Garcia TA 02.035, 09.006, 09.008 Garcia W 11.011 Garlipp CR 11.008 Garlippi CR 15.009 Garofalo CB 02.013, 02.019 Gasparotto FM 09.041 Gasparotto Junior A 06.048, 09.009, 09.041, 09.051,

09.052 Gattaz WF 01.013 Gavioli EC 03.023 Gerardin CCD 06.032 Gerardin DCC 06.002 Gerlach RF 06.077 Gern JC 11.014 Ghedini PC 02.023, 04.040, 06.028, 06.029,

06.051, 11.016 Giacomelli SR 03.009 Giacone DV 12.003, 15.011 Gil ES 09.020 Giusti-Paiva A 09.029 Gobira PH 03.014 Godinho RO 01.026, 08.003 Godoy TM 10.008 Goethel G 03.025 Gomes ACCN 03.023 Gomes AL 03.024 Gomes FIF 05.008 Gomes FR 04.033 Gomes FV 03.002 Gomes GL 12.001 Gomes GP 06.032 Gomes JMM 04.049 Gomes LS 05.023 Gomes RS 04.048 Gomez R 02.012, 02.013, 02.019, 02.026 Gonçalves AE 02.010, 02.022 Gonçalves AP 02.037 Gonçalves CM 07.005, 10.012 Gonçalves ECD 02.017 Gonçalves G 01.020 Gonçalves LM 15.006 Gonçalves MC 05.005, 05.014


Gonçalves PFR 02.011 Gonçalves RLG 04.056 Gonçalves RM 10.004 Gonçalves TT 06.044 Gonçalves-Rizzi VH 06.007, 06.046 Gonzaga NA 06.056 Gotteland M 13.002 Goulart MOF 04.003 Grabe-Guimarães A 14.002 Graça ACS 09.007, 09.017 Grando J 06.035 Grando MD 01.018, 01.019 Graton ME 06.027, 06.050, 06.058 Groban L 06.057 Guatimosin S 06.014 Guedes JM 08.016, 08.020, 09.056 Guedes RC 01.003 Guimarães AG 06.031 Guimaraes DA 06.077 Guimaraes FS 03.002 Guimarães FS 02.002, 02.004, 03.004, 03.006,

03.007, 03.019, 03.020, 03.022, 03.026, 05.020

Guimarães FV 04.004 Guimarães MJR 02.033 Guimarães RM 04.047, 05.024 Guimarães-Bastos D 01.005 Gurgel DC 10.006 Guterres SS 04.010, 11.001 Gutierrez J 03.009

H

Hansen AW 02.012, 02.013, 02.019, 02.026 Hartmann A 02.002 Haygert PF 15.008 Heidrich N 02.029, 03.008 Heineck I 11.015 Heinichen O 06.078 Helfer VE 11.001 Hellion-Ibarrola MC 06.078, 06.079 Herrera O 10.020 Herrmann AP 02.026, 11.001 Hickmann J 04.020 Hidalgo MS 09.012 Higashi CM 06.002 Hinton BT 07.010 Hirata AS 10.011, 10.014 Hiruma-Lima CA 04.050, 09.021, 09.034, 09.042 Holtermann AR 03.009 Hott SC 03.010 Hyslop S 09.010, 09.048, 09.053

I

Ibarrola DA 06.078, 06.079 Iles B 08.005, 08.017, 09.036, 12.002 Interaminense LFL 07.001 Ishida K 12.004 Issy AC 02.004 Iwamoto RD 11.006

J

Jacobucci SR 15.009 Jannini-Sá YAP 04.042 Janussi SC 06.044, 06.066 Jenne CN 04.035 Jesus FN 06.015 Jimenez PC 09.004, 09.022, 09.045, 10.010,

10.011, 10.014 Joca HC 08.023 Joca SRL 02.003, 02.009, 03.012, 03.014,

03.019 Julio-Pieper M 13.002 Júnior JLP 12.002 Júnior SNS 09.008 Justo AFO 06.045

K

Kassuya CAL 05.015, 06.048, 09.041 Kawamoto E 02.016 Kawamoto EM 02.005, 02.021, 02.024, 02.031,

02.038 Kennedy ML 06.079 Kerr DS 01.013 Kiguti LRA 01.004 Kimani S 09.004 Kinker GS 10.007 Kinoshita PF 02.021 Klein A 04.005, 04.038, 04.049, 09.029 Kocan M 01.004 Kolaczkowska E 04.035 Krieger JE 11.009 Krueger CMA 09.001 Krustev E 05.029 Kuasne H 10.002 Kubes P 04.035 Kuhn K 11.021 Kümmerle AE 06.024, 11.004 Kuntze LB 15.003 Kushima H 07.007, 07.008 Kusuda R 05.024

L

Lacchini R 11.011, 11.013, 11.022 Lagatta DC 02.006, 15.003 Lanchote VL 11.002, 11.012, 11.023, 11.024 Lanzetti M 01.014, 04.020 Lapa AJ 08.011, 08.014 Lara V 04.028 Lara VS 04.037 Laranjeira EPP 05.025 Larue L 10.019 Lastra CA 09.012 Lauretti GR 11.018 Leal LKAM 01.003 Leão LM 05.016 Leao RM 02.001, 15.002 Leão RM 03.015, 03.016 Leitão MM 05.015, 06.048 Leitão SG 15.010 Leitão-Araújo M 09.060


Leite CAVG 10.001 Leite JA 02.021 Leite JRSA 01.003 Leite KCS 09.020 Leite LCTF 05.012 Leite MN 01.024 Lemes JBP 05.022 Lemos DP 15.001, 15.011 Lemos VS 04.005, 06.014, 06.038 Leodido ACM 09.005 Lião LM 04.040 Lim L 01.004 Lima AB 12.010 Lima CMBL 08.016 Lima D 04.006, 04.026, 11.005 Lima DA 15.004 Lima DF 01.003 Lima DJB 10.018 Lima EBS 08.017, 08.018 Lima EO 09.037 Lima ES 09.007 Lima FO 06.017, 06.018 Lima GF 06.019, 06.034, 06.036, 06.073,

06.075 Lima IBC 08.008 Lima KA 04.019, 04.047 Lima LC 08.018 Lima LM 06.001, 06.008, 06.067 Lima LMTR 12.009 Lima MPD 05.012 Lima Neto LG 15.005, 15.006 Lima OCO 04.005 Lima TCM 02.018, 02.020 Lima-Filho ACM 04.056 Lima-Junior RCP 10.001, 10.002 Lima-Júnior RCP 10.003, 10.006 Lima-Landman MTR 08.011, 08.014 Linares CEB 03.009 Linder AE 06.068 Lino RC 09.040 Lisboa SF 02.002, 03.004 Lívero FAR 09.051, 15.004 Longo D 01.020 Lopes AH 04.022 Lopes AHP 01.006, 05.017 Lopes ALF 08.017, 12.002, 12.008 Lopes B 05.019 Lopes EM 05.012, 05.023 Lopes FYK 10.015 Lopes KS 09.013, 09.027 Lopes LB 12.001, 12.003, 12.004, 15.001,

15.007, 15.011 Lopes LO 01.027 Lopes MTP 04.031 Lopes NP 09.004, 10.014 Lopes PD 06.030 Lopes RO 06.036, 06.073, 06.075 Lopes-Ferreira M 04.049 Lorenzini CB 04.045

Lotufo CM 05.022 Lotufo LV 15.011 Lotufo LVC 10.014, 12.004 Lourenço ELB 09.041, 15.004 Lucchese AM 08.013 Lucetti LT 10.002 Lucion AB 01.020 Lückemeyer DD 04.029, 05.014, 05.026 Luiz JPM 04.012, 10.001 Luz BB 05.013, 09.055 Luz DA 02.014

M

Macedo CG 05.003, 05.004 Macedo FS 06.021, 06.025 Macedo Junior SJ 05.014 Macedo Juniro SJ 04.029 Machado CP 03.009 Machado IN 01.021 Machado KN 10.009 Machado MTM 08.025 Machado RR 05.021 Machado TB 09.008 Machado-Neto JA 10.021 Maciel DM 02.015, 02.020, 02.030 Maciel IS 02.003 Magalhães DA 09.018 Magalhães NS 07.006 Magalhães PJC 06.052, 09.035 Maia CDSF 02.014 Maia IC 11.004 Maia PIS 12.005 Maia R 06.024 Maldonado GP 09.023 Maliepaard EM 10.019 Manrinque W 04.049 Mansour CA 06.024 Maranhão SS 10.018 Marcatto LR 11.009 Marcelino BR 12.010 Marcelino RIA 06.053 Marcondes S 04.016, 04.043, 04.055 Maria-Engler SS 15.001 Maria-Ferreira D 05.013, 09.055, 09.057 Mariano LNB 02.010, 06.074, 08.006, 08.009,

08.015, 09.001 Marie SKN 10.007 Marinez ST 06.067 Marinho CRF 04.001 Mariot M 08.006 Markus RP 04.033, 04.034, 04.052, 10.007,

13.001 Marostica E 11.004 Marques AAM 09.009 Marques DVP 01.027 Marques E 06.024 Marques EB 06.021, 06.023, 06.026, 06.033,

06.037, 06.063, 06.075 Marques VDB 06.032 Marrubia MM 03.026


Martinez MLC 09.012 Martins AOBPB 04.023 Martins ASP 04.003 Martins DTO 04.032, 08.025, 09.014, 11.007 Martins F 09.002, 09.043 Martins FMA 02.037 Martins M A 04.020 Martins MA 04.004, 04.007, 04.010, 04.021,

04.030, 04.042, 04.053, 04.058, 07.006, 08.023

Martins MM 10.013 Martins PMRS 04.021 Matheus E 01.022 Matildes BLG 09.029 Matos NA 04.005, 09.029 Mattos MS 04.005 Mattson MP 02.005 Mazucanti C 02.016 Mazucanti CH 02.005, 02.031 McDougall JJ 05.029 Mechoulam R 03.006, 05.020 Medeiros AC 03.023 Medeiros IA 06.017, 06.018 Medeiros JVR 01.002, 04.056, 08.002, 08.005,

08.017, 08.019, 09.005, 09.012, 09.036, 09.044, 12.002, 12.008

Medeiros LF 05.019 Meinhardt NG 11.015 Mello JBH 10.002 Mello MMB 06.012 Mello NP 02.016 Mello PS 02.031 Melo AS 02.014 Melo AT 10.006 Melo B 04.006, 04.025, 04.026 Melo DC 04.049 Melo ISF 05.021 Melo KG 11.008 Melo LEJ 09.038 Melo P 04.006 Melo PA 04.002, 09.028, 09.030, 09.058,

09.060 Mendes ABA 06.073, 06.075 Mendes AS 06.056, 06.072 Mendes DR 05.022 Mendes LVP 06.004 Mendes MB 06.071 Mendes RA 02.015, 02.018, 02.020 Mendes SJF 09.046 Mendez-Otero R 06.004 Mendonca M 01.007 Menegatti M 05.016 Menegatti R 02.023, 03.021, 04.040 Meneghetti MR 02.030 Menezes IRA 04.023 Menezes PMN 08.013 Merkel S 12.006 Mestriner F 07.002 Meyer FS 11.001

Migotto A 12.004 Migowski ERC 09.060 Milanesi LH 15.008 Milanez-Azevedo AM 11.022 Minshall RD 01.019 Miranda AS 02.036 Miranda C 06.009 Miyajima F 04.032, 09.014 Moita LA 09.018, 09.019 Molina CAF 11.022 Mónica F Z 07.011 Mónica FZ 06.045, 07.009, 07.013, 07.015 Montagnoli TL 06.004 Montalbetti Y 06.078, 06.079 Monteiro MC 04.048 Monteiro MML 01.014 Monteiro-Machado M 04.002, 09.028, 09.058, 09.060 Monteiro-Neto V 04.001 Monterio VVS 04.048 Montes GC 05.007, 05.009, 06.004 Montor WR 10.013 Mora AG 06.044, 06.066 Moraes ALS 15.004 Moraes D 01.027 Moraes JA 01.001, 01.005, 01.022, 04.002 Moraes LAB 09.016 Moraes LN 01.027 Moraes NV 11.018 Moraes OM 10.005, 10.018 Moraes TMP 04.054 Moraes-Castilho J 09.050 Morais MI 05.021 Morau MV 04.055 Moreira ALE 04.040 Moreira CM 06.068 Moreira EG 06.002 Moreira EM 06.032 Moreira FA 05.002 Moreira J 02.001 Moreira JF 15.002 Moreira LKS 03.021 Moreira LL 08.004 Moreira R 01.003 Moreira RLR 08.007 Moreira V 04.009, 04.027 Moreno RA 07.013, 11.006 Moreno SE 04.017 Mori LT 04.052 Mota CMD 04.050 Mota G 06.009 Mota J 05.015 Mota JMSC 10.001 Motta N 06.024 Motta NAV 06.019, 06.034, 06.036, 06.073,

06.075, 11.004 Moura AF 10.005 Moura DJ 02.026 Moura FA 04.003 Moura FK 06.032


Moura RO 15.013 Moura WCS 15.013 Mourão PAS 09.058 Mueller A 07.007 Mueller AM 01.009 Muley M 05.029 Müller HK 02.009 Munhoz CD 02.032 Muniz HA 10.002 Muniz JJ 11.022 Murillo O 04.001 Muscará MN 04.001, 04.011, 04.039, 04.041,

05.006, 06.015, 09.025, 09.046, 11.003, 12.001

Muxel SM 10.007

N

Naime ACA 04.016, 04.043, 04.055 Nakamune AC 06.058 Nakaya H 04.006, 04.026 Napimoga HN 05.003 Nardotto GHB 11.002 Nascimento AM 05.013, 09.057, 10.009 Nascimento AS 09.008 Nascimento CVMF 12.009 Nascimento D 07.014 Nascimento DP 15.013 Nascimento DRB 04.012 Nascimento HG 02.025 Nascimento JHM 06.025 Nascimento KS 05.025 Nascimento TB 07.002 Navegantes KC 04.048 Negreiros PS 08.008, 08.022 Neri HFN 02.023 Neri HFS 06.028, 06.029 Nesello LAN 08.006, 08.015 Neto FPS 06.014 Netto GPL 09.029 Neves AB 05.028, 09.011 Neves DV 11.012 Neves EVN 06.072 Neves G 02.011 Neves KB 06.049 Nicácio DCS 02.018, 02.030 Nicácio DCSP 02.015, 02.020 Nicolau LAD 01.002, 08.002, 08.007, 09.036,

09.044, 12.008 Nicoletti AS 07.009 Nietiedt NA 02.013, 02.019 Nikolaev A 04.006 Nin MS 03.008 Nobre LMS 10.002, 10.003 Nobre-e-Souza MA 08.002 Nóbrega N 06.005, 06.009, 06.010 Noël F 01.025, 15.010 Nogueira HN 06.031 Nogueira KM 08.005, 08.017, 08.019, 09.005,

09.036, 09.044, 12.008 Nogueira TA 09.030

Nogueira-Bechara FM 08.011, 08.014 Nones CFM 05.018 Norbiato TS 04.006, 04.025 Norões MM 05.005 Noronha TM 09.003 Novaes LS 02.032 Novi RBSD 06.032 Nowicki VF 06.064 Nunes ASS 06.071 Nunes da Silva EJ 10.017 Nunes IKC 08.004

O

Oba-Shinjo SM 10.007 Ohara R 09.021, 09.034, 09.042 Oliveira ACP 02.037, 02.037 Oliveira ACT 09.011 Oliveira AF 09.055 Oliveira ALB 04.048 Oliveira AP 06.071, 08.005, 08.017, 08.019,

08.021, 09.036, 09.044, 12.008, 13.001

Oliveira CC 09.003 Oliveira CP 11.014, 11.019 Oliveira DF 06.025 Oliveira DM 08.025, 11.007 Oliveira DMN 09.035 Oliveira EB 01.020 Oliveira FA 04.056 Oliveira FAS 09.039, 09.049 Oliveira FC 10.017 Oliveira FFB 05.017, 10.001 Oliveira FL 04.002, 09.008, 09.030 Oliveira G 01.027 Oliveira GA 08.001 Oliveira GAL 09.012 Oliveira HGS 07.005, 10.012 Oliveira IS 09.054 Oliveira JP 09.013, 09.027 Oliveira JRJM 05.005 Oliveira JS 09.018, 09.019, 10.013 Oliveira JSSM 08.021, 08.022 Oliveira KC 09.006 Oliveira LCS 08.018 Oliveira LES 09.018, 09.019 Oliveira LM 06.051 Oliveira LP 06.051 Oliveira M 07.014 Oliveira MF 05.006 Oliveira MG 06.045, 07.015 Oliveira ML 11.002 Oliveira MRC 04.023 Oliveira MTP 04.010 Oliveira NVM 09.018, 09.019 Oliveira PB 06.043 Oliveira PR 06.043 Oliveira RCM 08.008, 08.017, 08.021, 08.022,

09.054 Oliveira RG 04.032, 09.014 Oliveira S 09.015


Oliveira SHP 01.017, 04.028, 04.037, 10.015 Oliveira TM 08.002 Oliveira TS 06.028, 06.029, 06.051 Oliveira VR 06.022 Oliveira-Carneiro PE 03.016 Oliveira-Paula GH 06.039, 06.041, 06.055, 06.069,

06.076, 11.011 Oliveira-Tintino CDM 04.023 Oliveria MG 07.004 Olmo IG 02.036 Oosterholt S 11.012 Orellana AM 02.021 Ortiz J 09.031 Ostrowski LH 10.007 Ovando F 06.078

P

Pacheco G 08.017, 09.012, 09.036, 09.044 Pacífico DM 08.019, 12.002 Pacini ES 01.026, 08.003 Paes RL 11.007 Paese K 11.001 Paiva GO 08.013 Paiva IKD 10.003 Paixão AG 02.038 Paixão AO 01.007, 11.010 Paixão-Côrtes VR 01.020 Palma EC 11.015 Palombo P 02.001, 03.015, 03.016 Palomino M 09.031 Palozi R 06.048 Palozi RAC 09.009, 09.051, 09.052 Panunto PC 09.048, 09.053 Pão CRR 04.007 Paré P 01.020 Paredes A 09.031 Parente JM 06.012, 06.056 Parreiras-e-Silva LT 01.020, 01.028 Pasqua OD 11.012 Passador-Santos F 04.046 Passaglia RT 06.013 Patrão-Neto FC 04.002, 09.028, 09.030, 09.058 Patrocinio MS 04.028 Paula C Jimenez 01.012 Paula LF 02.012, 02.013, 02.019 Paula NA 01.024 Paula PL 06.038 Paula VJR 01.013 Pauli KB 15.004 Paulo M 01.019, 06.054 Pavan E 04.032, 08.025, 11.007 Pavan FR 12.005, 12.007 Peçanha TSC 09.058 Pedrazzi JFC 02.004 Pedro S 06.024 Peixoto EPM 04.001 Peixoto FN 09.032 Pelegrin JA 06.059 Pelegrino MT 06.039 Pelosi GG 06.002

Pendelosky KPT 10.012 Pereira AC 11.009 Pereira BB 09.053 Pereira C 06.013 Pereira DMS 04.001, 09.046 Pereira DS 04.043 Pereira EP 13.001 Pereira IS 08.007 Pereira JA 10.001 Pereira JP 04.037 Pereira LM 01.014 Pereira MA 10.006 Pereira MBM 12.011 Pereira MM 11.019 Pereira MPM 11.024 Pereira SC 06.056 Pereira TCB 04.044 Pereira VBM 10.003 Pereira VS 02.009 Pereira-Junior MA 09.040 Peres AC 04.049 Peres J 10.019 Peres RS 04.012 Perez AC 09.003 Périco LL 09.021, 09.034, 09.042 Perondi G P 09.059 Pessoa C 10.017, 10.018 Pessoa DL 08.024 Pessoa EV 09.007, 09.017 Pessoa LD 08.001 Pessoa MMB 08.016, 08.020, 09.056 Pessoa OC 10.005 Pessoa ODL 09.024, 09.039, 09.047, 09.049 Pessoa RT 04.023 Petri B 04.035 Piauilino CA 05.012, 05.023 Picinin R 06.032 Pimentel A S 04.020 Pimentel-Coelho PM 06.004 Pinge FP 06.032 Pinge-Filho P 06.002 Pinheiro BG 02.014, 09.027 Pinheiro CCS 09.017 Pinheiro LC 06.039, 06.041, 06.042, 06.055,

06.076, 06.077, 11.011 Pinna G 01.010 Pinto EO 11.017 Pinto FCH 09.032 Pinto FCL 09.024, 09.039, 09.049 Pippa LF 11.023 Pippi B 12.006 Pires AF 05.025 Pires KSN 07.005, 10.012 Pires LMN 09.032 Pires-Moraes TM 09.050 Pires-Moraes W 04.054, 09.050 Pisano Dias ASES 08.014 Pita LM 06.043 Planeta CS 03.013, 03.015, 03.016


Planets CS 02.001 Pohlmann AR 04.010 Polho GB 01.013 Pontes CA 10.010, 10.014 Portella RL 06.041, 06.055, 06.060, 06.069 Porto GP 03.005 Porto HKP 06.070, 11.020 Possomato-Vieira JS 06.007, 06.020, 06.040, 06.047 Possomato-VieiraJS 06.046 Potje SR 01.018, 06.027, 06.050, 06.058 Prado CM 04.041 Prado D 04.006, 04.026 Prado DS 03.020, 04.014, 04.057 Prata MNL 04.049 Prieto SG 02.008 Prince S 09.004, 10.019 Priviero F 06.044, 06.066 Protasio F 04.026 Prudente AS 04.029, 05.014, 05.026 Publio G 04.006 Públio GA 04.051 Pulcinelli RR 02.012, 02.013, 02.019, 02.026 Pupo AS 01.004, 01.009, 01.015

Q

Quadros AU 04.047, 05.001 Queiroz BFG 04.024 Queiroz DP 01.017, 04.028 Queiroz DPS 04.037 Queiroz LY 09.013 Queiroz MLS 09.002, 09.043 Quetz JS 10.002 Quincozes-Santos A 02.012, 02.013 Quintans-Junior LJ 06.071 Quintans-Júnior LJ 09.054 Quintas LEM 01.025, 10.008, 15.010 Quinteros DA 02.012, 02.013

R

Rae M 15.007 Ramalho LNZ 06.064 Rambow F 10.019 Ramires MS 06.001 Ramos D 03.005 Ransohoff RM 04.035 Raposo NRB 02.017 Rates SMK 03.024, 03.025, 11.001 Rego EM 10.021 Reid A 05.029 Reina E 06.008 Reis D 06.005, 06.009, 06.010 Reis JF 04.048 Reis MP 15.004 Reis PP 01.027 Rendeiro MM 15.010 Renno AL 04.046 Renovato-Martins M 01.001, 01.022 Resck RR 15.012 Resstel LBM 02.002, 02.006, 02.007, 03.010,

03.012, 03.018, 15.003

Restel LBM 03.004 Restini CBA 06.064 Rezende B 05.007 Ribas JAS 11.004 Ribeiro AMB 06.071 Ribeiro CM 07.007, 07.010 Ribeiro DE 02.009 Ribeiro LAA 08.013 Ribeiro MF 09.006, 09.008 Ribeiro MR 02.036 Ribeiro MTL 06.070 Ribeiro NBS 04.053 Ribeiro RA 10.002 Ribeiro TP 06.017, 06.018 Rigato DB 09.022, 09.045 Rizzi E 06.064, 06.077 Rocha A 11.002, 11.023 Rocha CQ 09.042 Rocha DD 09.039 Rocha GGG 10.005, 10.018 Rocha KC 01.008 Rocha LK 04.005 Rocha LRM 09.021, 09.034, 09.042 Rocha ML 06.053, 06.070, 08.010, 09.020,

11.020 Rocha N 06.063 Rocha NN 06.021, 06.023 Rocha TM 01.003 Rocha-Neto LM 05.003, 05.004 Rodas E 06.078 Rodrigues A C 11.010 Rodrigues AC 01.007, 01.008, 07.003 Rodrigues Alves APN 10.021 Rodrigues CRS 08.016 Rodrigues DVS 04.048 Rodrigues FF 05.021 Rodrigues L 04.011, 09.025, 11.003, 12.001 Rodrigues LC 09.015 Rodrigues NS 03.002, 03.006 Rodrigues RL 07.013 Rodrigues VG 09.029 Rodrigues VP 09.021, 09.034, 09.042 Rogatto SR 10.002 Rohde BZ 03.005 Rojas C 03.024 Rojas J 09.031, 10.020 Rojas-Moscoso JA 07.004, 07.013 Romano JT 06.061 Romao PRT 04.048 Romero MGMC 06.030 Romero TRL 05.002, 09.003 Roncalho AL 02.009 Rosa J 03.018 Rosa PCP 11.008, 15.009, 15.012 Rosa PS 01.024 Rosales TO 06.003 Rosenstock TR 01.016 Rosillo MAR 09.012 Rossi-Vargas G 13.002


Rossoni LV 01.025 Rovaris D 01.020 Roversi K 15.008 Roversi Kr 03.001 Russo RC 04.005 Ryffel B 04.014, 04.025

S

Sá Lima L 02.031 Sá LL 02.021 Sá YAPJ 04.021 Sagar DR 05.001 Sahm BDB 09.004, 09.049 Sakamoto RY 09.032 Saldanha-Gama R 01.005 Sales AJ 02.003, 03.019 Sales KU 04.006, 04.051 Sales TM 08.002 Sales TMAL 08.007 Salvi AA 05.019 Salzano FM 01.020 Sanches-Lopes JM 06.042 Sanders-Silveira S 01.026 Sandrim V 01.004 Sandrim VC 06.047, 11.013 Sandy MV 05.006 Santagada V 04.039 Santana AP 08.002 Santana FPR 04.041 Santana PHDS 09.028 Santana RO 10.002 Santos AA 08.002, 08.007 Santos AJA 09.032 Santos BAC 01.008 Santos BB 09.021, 09.034 Santos C 09.034 Santos CC 10.005 Santos CF 04.028, 04.037 Santos EA 09.016, 10.011 Santos FCA 02.023 Santos JA 05.015 Santos JC 07.005, 10.012 Santos JD 06.054 Santos KF 03.009 Santos KT 04.041 Santos LC 09.021 Santos MG 15.002 Santos PCJL 02.001, 11.009 Santos PF 06.017, 06.018 Santos R 15.007 Santos RC 09.021, 09.034, 09.042 Santos RF 08.008, 08.021, 08.022 Santos RPM 02.036 Santos RR 09.013 Santos RS 05.008, 10.005, 10.018 Santos SHS 09.003 Santos TMA 08.008 Santos WP 14.002 Santos-Neto JG 02.015, 02.018, 02.020, 02.030 Santos-Silva ML 06.007, 06.020, 06.040

Santos-Vieira MP 02.030 Santuchi MC 06.014 Sá-Nunes A 09.025 Saraiva A 04.025 Saraiva ALL 01.006 Sarmento DM 09.033 Sarmento DV 09.015 Sartoretto SM 06.002 Savio LEB 04.042 Scanavacca M 11.009 Scaramello C 06.024 Scaramello CBV 06.021, 06.023, 06.025, 06.026,

06.033, 06.037, 06.063, 06.075 Scarante FF 03.007, 03.022, 03.026 Scavone C 01.010, 02.005, 02.016, 02.021,

02.024, 02.031, 02.038 Schadler MI 09.009 Schaedler MI 06.048, 09.051, 09.052 Schezaro-Ramos R 09.010 Schiavon MSC 15.013 Schimidt T 04.011 Schlickmann F 09.001 Schüller R 04.006 Schulz R 06.012 Scomparin DS 03.007 Scopim-Ribeiro R 10.021 Scopinho A 02.002 Seabra AB 06.039 Seemann H 06.014 Serra M F 04.020 Serra MF 04.007, 04.021, 04.053 Sifrim D 08.002, 08.007 Silote GP 03.014 Silva AAS 01.009, 07.007 Silva AB 09.047 Silva ACL 09.037 Silva AHQ 02.030 Silva ALB 01.028 silva ALM 07.005, 10.012 Silva AMS 06.004, 06.057, 06.062, 06.067 Silva AO 06.048, 09.009, 09.051, 09.052 Silva AT 09.047 Silva BA 07.001, 08.001, 08.004 Silva BAF 04.023 Silva BG 04.056 Silva BRS 09.046 Silva CC 01.022 Silva CCS 02.014 Silva CFB 05.009 Silva CLM 01.014, 04.018 Silva CM 11.001 Silva CMS 10.001, 10.002, 10.003 Silva CPM 03.025 Silva CR 05.010, 10.001 Silva CSMR 01.012 Silva CYY 09.013, 09.027 Silva DA 06.050, 08.002 Silva DF 09.037 Silva DG 14.001


Silva DM 03.021, 04.040, 05.016 Silva DPB 04.040, 05.016, 09.040 Silva EBS 04.054, 09.050 Silva EJR 01.009, 07.007, 07.008 Silva EL 09.032 Silva EMP 07.005 Silva ET 08.023 Silva FB 10.021 Silva FFS 02.029, 03.008 Silva FR 02.036 Silva FS 08.013 Silva FV 09.054 Silva FWL 10.003 Silva FWM 12.004 Silva GBA 06.022 Silva GGO 04.017 Silva IB 05.025 Silva IS 01.002, 04.056, 09.044, 12.008 Silva J 09.023 Silva JDP 08.011, 08.014 Silva JF 04.005 Silva JN 10.009 Silva JS 06.057 Silva JSS 06.062 Silva Júnior PN 02.025 Silva KP 01.004 Silva LCN 09.046 Silva LM 02.010, 06.074, 08.006, 08.009,

08.015, 09.001, 09.059 Silva LMP 09.038 Silva MAP 02.009 Silva Martins PMR 04.010 Silva MCC 08.001, 08.004 Silva MCM 02.037 Silva MFS 10.005 Silva MGV 01.003 Silva MMC 06.067 Silva MN 09.013, 09.027 Silva MTB 08.018 Silva MV 05.022 Silva NC 09.050 Silva NR 03.002, 03.006, 05.020 Silva OBS 02.030 Silva PMR 04.004, 04.007, 04.020, 04.042,

04.053, 04.058, 07.006 Silva RCMVAF 09.059 Silva RL 01.006, 04.022, 10.001, 10.003 Silva RM 06.023 Silva RO 01.002, 08.007, 09.044 Silva RS 08.010 Silva RV 08.011, 08.014 Silva SC 09.032 Silva SL 08.016, 08.020, 09.056 SIlva SR 11.014, 11.019 Silva SSC 06.031 Silva SV 01.022, 07.005 Silva TF 06.001 Silva-Neto JA 06.022 Silva-Souza E 04.034, 13.001

Silveira ALM 06.010 Silveira ER 04.019 Silveira SS 08.003 Simoes BP 11.002 Simões BP 10.021 Simoes SC 01.028 Simone AT 09.046 Simplicio JAP 06.005 Siqueira L 03.021 Soares AG 04.011, 04.039, 07.015, 11.003 Soares CMA 04.040 Soares JC 04.044 Soares VVM 02.025, 04.015 Soares-Junior RS 02.035 Soares-Rachetti VP 03.023 Sobral MV 08.016 Sobrinho AP 09.008 Solanha RL 02.022 Solcia MC 12.007 Somensi LB 08.009, 08.015, 09.059 Sonego AB 03.002, 03.020 Soubhia AMP 10.015 Souccar C 08.011, 08.014 Sousa AA 06.022 Sousa AK 08.024 Sousa DP 04.056, 05.012, 05.023, 12.002 Sousa E 01.007, 07.003 Sousa FBM 01.002, 04.056, 08.005, 08.017,

08.019, 09.005, 09.012, 09.036, 09.044, 12.008

Sousa IJO 10.009 Sousa JAC 01.003 Sousa JFR 08.018 Sousa JP 09.037 Sousa LKM 04.056 Sousa MCL 04.028 Sousa NA 01.002, 08.005, 09.005, 09.036,

12.002 Sousa NCF 09.046 Sousa RM 02.025 Sousa RV 11.014, 11.019 Sousa SG 09.018 Sousa SS 09.054 Souza AAP 01.022 Souza AG 04.019 Souza AM 09.008 Souza BS 09.018, 09.019 Souza BV 09.022, 09.045 Souza C 04.006, 04.026 Souza CG 06.053 Souza CMV 09.006, 09.008 Souza DS 06.022 Souza EP 12.002, 12.002 Souza ET 04.010, 04.058 Souza FM 01.002 Souza FMA 02.015, 02.018, 02.020, 02.030 Souza GF 02.030 Souza GG 09.029 Souza ILL 07.001


Souza JRN 06.033 Souza KP 06.021, 06.033 Souza LB 03.005 Souza LKM 01.002, 08.005, 08.017, 08.019,

09.005, 09.036, 09.044, 12.008 Souza LM 05.013 Souza LPG 07.005, 10.012 Souza MAN 08.007 Souza MHLP 01.002, 08.007, 10.002 Souza MHP 08.002 Souza MM 02.010, 02.022 Souza MVN 10.018 Souza Neta OAC 09.015, 09.033 Souza P 06.074, 08.006, 08.009, 08.015,

09.001, 09.059 Souza PC 12.005 Souza PHFS 09.013 Souza RM 04.015 Souza TNC 09.038 Souza-Junior FJC 09.027 Spadacci-Morena DD 04.009, 04.027 Speck ML 03.024 Spiller F 04.045 Stainer A 15.007 Stanquini LA 02.009 Staudt KJ 11.001, 11.021 Steffens L 02.026 Steimbach VMB 09.001 Stein AC 03.009 Stein AT 11.015 Stein DF 03.009, 03.024, 03.025 Strauch MA 09.028, 09.030, 09.058, 09.060 Suarez-Kurtz G 11.024 Sudo GZ 06.062 Sudo RT 05.007, 05.009, 06.001, 06.004,

06.008, 06.057, 06.062, 06.067 Summers RJ 01.004 Sun SY 10.012 Sun X 06.057

T

Takahashi JA 09.029 Takiguchi RS 04.052 Taniguchi ÉY 09.025 Tanos-Santos JE 11.011 Tanus-Santos JE 06.039, 06.041, 06.042, 06.055,

06.056, 06.060, 06.069, 06.072, 06.076, 06.077, 11.022

Tartarotti SP 06.044, 06.066 Tavares EBG 04.013 Tavares JC 04.005 Tavares LC 11.009 Tavares-Henriques MS 09.058 Teixeira AL 02.037 Teixeira LRM 09.003 Teixeira RGS 09.006, 09.008 Teixeira SA 04.001, 04.011, 04.039, 05.006,

06.015, 09.025, 11.003, 12.001 Teixeira-Cruz JM 09.058 Teles CBG 05.028

Telles PVN 08.018 Terzian ALB 03.010 Tinco A 10.020 Tirapelli CR 06.005, 06.056, 06.058 Tirloni CAS 06.048, 09.009, 09.052 Tirloni CS 09.051 Tjioe KC 10.015 Tobar N 07.004 Toledo JH 09.002 Toledo MF 06.004 Tomaz MA 04.002 Tomazetto TA 09.009 Tonello R 05.026 Torello CO 09.002, 09.043 Torres CV 02.008 Torres ILS 05.019 Torres J 04.030 Torres TC 06.065 Torres-Bonilla KA 09.048 Tostes RC 06.049, 07.002 Tostes RCA 06.051 Tozzato GPZ 06.011 Trachez MM 06.001, 06.008 Traina F 10.021 Trape AZ 11.008, 15.009 Travassos RA 09.015, 09.033 Trindade M 06.065 Troiano JA 06.027, 06.050, 06.058 Tucci Jr S 11.022 Turcato F 03.026 Turchetti-Maia RMM 04.008

U

Uliana DLM 02.006, 02.007, 03.004, 03.018 Umpierrez LS 03.011

V

Valadares MC 06.053 Vale GT 06.058 Vale ML 05.017, 08.002 Valença SS 01.014 Valente CA 04.044 Valente VB 10.015 Vargas-Pinilla P 01.020 Vasconcelos AR 02.038 Vasconcelos CML 06.022 Vasconcelos JP 05.016 Vasconcelos LHC 08.001 Vasconcelos PC 09.051 Vasconcelos PCP 06.048 Vasconcelos RC 08.016, 08.020, 09.056 Vasconcelos U 09.015 Vasconcelos WP 06.038 Vasconcelos-Silva AA 06.052 Velasco-Alzate K 09.023 Velázquez AM 06.079 Veloso CC 09.029 Venturini CL 11.007 Venzon L 08.015 Veras FP 04.006, 04.012, 04.025, 04.057


Veras PV 04.051 Vercesi JA 01.019, 06.059, 06.061 Verri WAV 05.027 Vey LT 15.008 Viacava PR 04.012, 10.001 Viana AFSC 09.054 Viana GSB 04.019 Viana-Figaro F 11.022 Vicente C 04.043 Viegas CJ 02.033 Vieira ELM 02.037, 02.037 Vieira GV 04.051 Vieira JB 10.017 Vieira JLF 02.017 Vieira LB 02.036 Vieira LV 04.028, 04.037 Vieira TN 05.010 Viel TA 01.021 Vila-Verde C 03.004 Vilegas W 09.021, 09.034, 09.042 Villegas I 09.012 Villela Filho GJM 04.046 Vitorino CA 04.012

W

Wagnet TM 08.015 Waisman A 04.006 Wandekin RR 01.015 Wanderley CWS 10.001 Wang H 06.057 Watai P 06.031 Wegener G 02.009 Werneck CC 04.043 Werner MF 05.013, 09.055

Werner MFP 08.012, 09.057 Whiteman M 04.011 Wilches-Buitrago L 01.023 Wilke DV 09.024, 09.039, 09.047, 09.049 Wong CHY 04.035 Wong DVT 10.002, 10.006 Wouters F 11.014, 11.019

D

X

Ximenes VF 06.027 Ximenez JPB 11.024

Y

Yamamoto PA 11.018

Z

Zago PMW 15.005, 15.006 Zamboni SD 01.006 Zamponi GW 02.036 Zanette RA 12.006 Zaniboni CR 02.001, 15.002 Zanluqui GN 06.032 Zanoni TB 15.001 Zanotto CZ 06.013 Zanotto-Filho A 10.004 Zapata-Sudo G 05.007, 05.009, 06.001, 06.004,

06.008, 06.057, 06.067 Zapparoli A 07.014 Zarpelon AC 05.027 Zingali RB 09.060 Zorn TMT 04.041 Zuntini ACS 04.009, 04.027







Date post:	19-Aug-2020
Category:	Documents
Upload:	others
View:	1 times
Download:	0 times

PROGRAM - Sbfte€¦ · Maria Christina W. de Avellar (Unifesp-EPM, Coordinator) Letícia V. Costa...

Documents